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Abstract 
 
MicroRNAs are now recognized as key players in the regulation of proteins and any abnormality 
in their function is a cause for pathway instability, leading to pathological conditions. Numerous 
reports from a variety of pathologies provide new data about microRNAs function, their targets 
and their potential as biomarkers and possible ways to control microRNAs’ expression for 
potential therapeutic purpose.  
A number of reports also connect microRNAs with pathological conditions in the kidney and 
point to the use of microRNAs as biomarkers for diagnosis and prognosis of kidney disease in 
blood, serum, tissue and urine samples. In this thesis, we researched: 
1) A possible role of the microRNAs in the progression of adult chronic kidney disease (CKD), a 
disease representing a global burden with the tendency to rise worldwide. Progression of CKD is 
still very hard to detect non-invasively with the currently used clinical tools (eGFR and 
albuminuria). In our work we studied alterations of the level of the microRNAs in human urine 
samples of patients with fast or slow progression of CKD, in order to identify new potential 
biomarkers for non-invasive progression of CKD.  Using Next Generation Sequencing, we 
analyzed urinary microRNA modifications in urine samples of 70 patients with established CKD 
and correlated their expression profiles to disease progression. This lead to the identification of 
25 urinary microRNAs significantly associated to CKD progression (adjusted pvalue<0.05). 
Among those, four microRNAs (hsa-miR-34c-5p, hsa-miR-410-3p, hsa-miR-301b-3p, and hsa-
miR-145-5p) were selected for validation in an independent cohort of 52 patients with CKD. 
Increased urinary abundance of hsa-miR-145-5p was confirmed to be associated to progression of 
CKD. In vitro exploration of the effects of hsa-miR-145-5p inhibition in human kidney cells 
showed that the microRNA seemed to be involved in necrotic processes. In conclusion we have 
identified hsa-miR-145-5p as potential urinary microRNA marker of CKD progression.  
2) The identification of microRNAs associated to obstructive nephropathy, a frequently 
encountered disease in children that can lead, in severe cases, to end stage renal disease (ESRD). 
In this study we used a comprehensive system biology analysis in which we combined micro- and 
mRNA data from human and animal obstructive nephropathy to obtain information on possible 
mechanisms involved in this disease. In particular, we have studied in parallel the urinary 
miRNome of infants with ureteropelvic junction (UPJ) obstruction and the kidney tissue 
miRNome and transcriptome of the corresponding neonatal partial unilateral ureteral obstruction 
(UUO) mouse model. Several hundreds of microRNAs and mRNAs displayed changed 
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abundance during disease. Combination of microRNAs in both species and associated mRNAs let 
to the prioritization of 5 microRNAs and 35 mRNAs associated to disease. In vitro and in vivo 
validation identified consistent dysregulation of let-7a-5p and miR-29-3p and new potential 
targets, E3 ubiquitin-protein ligase (DTX4) and neuron navigator 1 (NAV1). Our study is the first 
to correlate a mouse model of neonatal partial UUO with human UPJ obstruction in a 
comprehensive systems biology analysis. Our data revealed let-7a and miR-29b as molecules 
potentially involved in the development of fibrosis in UPJ obstruction via the control of DTX4 in 
both man and mice that would not be identified otherwise.  
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Résumé 
 
A l’heure actuelle, les microARNs sont reconnus comme des régulateurs essentiels de 
l’expression des protéines. Des anomalies dans leur fonction sont associées au développement de 
nombreuses pathologies. Ainsi, de nombreuses études s’intéressent au potentiel des microARNs 
en tant que biomarqueurs ou cibles thérapeutiques dans une grande variété de pathologies.  
De plus, un certain nombre de recherches font le lien entre microARNs et pathologies rénales et 
soulignent l’intérêt des microARNs en tant que biomarqueurs pour améliorer le diagnostic et le 
pronostic des maladies rénales en utilisant des échantillons sanguins, sériques, de tissus et d'urine.  
Dans le cadre de  cette thèse, nous avons étudié : 
1) L’association des microARNs urinaires avec l’évolution de la maladie rénale chronique (MRC) 
chez l’adulte. La prévalence de la MRC est actuellement estimée à 5-10% de la population et est 
en constante augmentation. La détection précoce et l’identification de patients ayant une MRC 
progressant rapidement vers l’insuffisance rénale sont la clé pour une meilleure prise en charge de 
ces patients. Actuellement les outils non-invasifs comme l’albuminurie ou l’estimation du débit 
de filtration glomérulaire manquent de précision. Dans notre travail, nous avons tenté d'identifier 
les modifications urinaires des microRNAs afin d’identifier de nouveaux biomarqueurs non-
invasifs associés à la progression de la MRC.  
Nous avons analysé les modifications des microARNs urinaires par séquençage à haut débit dans 
des échantillons d'urine de 70 patients atteints de MRC et corrélé leurs profils d'expression à la 
progression de la maladie. Cela a amené à l'identification de 25 microARNs urinaires (pvalue 
ajustée <0.05) potentiellement associés à la progression de la MRC. Parmi ceux-là, quatre 
microARNs (hsa-miR-34c-5p, hsa-miR-410-3p, hsa-miR-301b-3p, and hsa-miR-145-5p) ont été 
sélectionnés pour être validés dans une cohorte indépendante de 52 patients atteints de MRC. 
L’augmentation de l’abondance urinaire de hsa-miR-145-5p a été confirmée comme étant 
associée à la progression de la MRC. Des analyses in vitro de l’effet de l’inhibition de hsa-miR-
145-5p dans les cellules rénales ont mis en évidence que ce microARN semblait être impliqué 
dans le processus de nécrose. En conclusion, cette étude nous a permis d’identifier hsa-miR-145-
5p comme marqueur potentiel de la progression de la MRC. 
2) La présence de microARNs urinaires associés à la néphropathie obstructive, une maladie 
fréquemment rencontrée chez les enfants qui peut conduire, dans les cas graves, à l’insuffisance 
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rénale précoce. Dans cette étude, nous avons utilisé la biologie des systèmes et avons combiné 
des données microARN et ARNm de néphropathie obstructive humaine et animale pour obtenir 
des informations sur les mécanismes possibles impliqués dans cette maladie. En particulier, nous 
avons étudié simultanément  le miRNome urinaire de nourrissons présentant une obstruction de la 
jonction pyélo-urétérale et le miRNome et le transcriptome tissulaire rénal chez la souris dans le 
modèle animal d’obstruction urétérale unilatéral (OUU) partiel et néonatal. Plusieurs centaines de 
microARNs et d’ARNms étant modifiés, la combinaison des microARNs des deux espèces avec 
les ARNms cibles associés a permis de sélectionner les 5 microARNs et 35 ARNms les plus 
fortement associés à la néphropathie obstructive. Une validation in vitro et in vivo a mis en avant 
que let-7a-5p et miR-29-3p ainsi que deux nouvelles cibles potentielles, l’E3 ubiquitin-protein 
ligase (DTX4) et neuron navigator 1 (NAV1) étaient dérégulées au cours de cette pathologie. 
Cette étude est la première à corréler le modèle animal d’OUU partiel et néonatal avec 
l’obstruction pyélo-urétérale chez l’Homme dans une analyse intégrée de biologie des systèmes. 
Nos résultats ont révélé let-7a et miR-29b en tant que molécules potentiellement impliquées dans 
le développement de la fibrose dans la néphropathie obstructive via le contrôle de DTX4 chez 
l'homme et la souris, ce qui n’aurait pas été identifiable autrement. 
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1. miRNAs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parts of this chapter were published as: Papadopoulos et al., Expert Rev Mol Diagn. 2015  
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MiRNAs are short (18-23 nucleotides in length), non-coding, endogenous, single-
stranded RNA molecules involved in post-transcriptional regulation of gene expression. 
Discovered 2 decades ago, these small RNA molecules are one of the “hottest” trends in 
biological research.  
 
1.1 A little bit of history 
 
The discovery of the first miRNA took place in 1993. In that year, the two teams of 
Ambros and Ruvkun independently published complementary studies on a gene, called lin-4 in 
Caenorhabditis elegans (Lee et al., 1993, Wightman et al., 1993). Both teams identified that the 
lin-4 gene produces a small transcript that does not encode a protein but has complementary 
sequence with the 3’-UTR region of lin-14 gene and negatively regulates the level of the LIN-14 
protein involved in the development of C. Elegans (Lee et al., 1993, Wightman et al., 1993). 
These two groups had identified the first miRNA! Seven years had to pass until the identification 
of a second miRNA, let-7 (Reinhart et al., 2000).  
In 2006, the Nobel Prize in Physiology or Medicine was jointly given to Fire and Mello 
for their research in 1998 on the discovery of the silencing mechanism of mRNA expression by 
small interfering RNA molecules, now known as the action mechanism of miRNAs. Since 2001, 
miRNAs or miRNAs have been shown to be involved in a variety of physiological functions and 
diseases and forced the scientific interest and research to evolve accordingly towards detecting 
and identifying these small molecules (Almeida et al., 2011). The continuously increasing 
number of reports on miRNAs, starting from some hundreds per year until 2007 and reaching a 
total of approximately 9000/year in 2015 (PubMed search for “miRNAs” and “miRNA”), 
demonstrates the growing interest for these small molecules in physiology and disease.  
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Figure 1: The number of total publications/year on miRNAs has been continuously increasing over the 
years.    
 
This increase is also the result of the more extensive use of Next Generation Sequencing 
(NGS) technologies in combination with simplified extraction, quantification and expression 
analysis methods of miRNAs (see chapter “Research methods” on page 18). Improved 
bioinformatics tools have also contributed to the number of newly identified miRNAs 
(Friedlander et al., 2014). Today, the number of miRNA entries in miRBase (the first and 
largest database of miRNAs) in the last update of June 2014 (version 21.0) reached 28645 
miRNA entries when considering all species, and 2588 entries for human miRNAs only  
(Kozomara and Griffiths-Jones, 2014) .  
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1.2 Biogenesis and function 
 
The biogenesis of a miRNA is initiated with the generation of a so-called primary 
miRNA (pri-miRNA) in the nucleus, which is reformed to the precursor miRNA (pre-miRNA) 
before it leaves the nucleus (Bartel, 2004). Then, after some other maturation steps the pre-
miRNA is being transformed to the mature miRNA ready to perform its biological function: bind 
to the mRNA - target and suppress its expression (Hammond, 2015). The whole process of 
miRNA biogenesis and the function mechanism has been extensively studied and are summarized 
in Figure 2 (Hammond, 2015, Winter et al., 2009, Meister, 2013, Macfarlane and Murphy, 
2010, Lewkowicz et al., 2015, Ha and Kim, 2014, Eulalio et al., 2009).  
.  
 
Figure 2: miRNA biogenesis and function. A1) Canonical pathway: miRNA is transcribed in a primary 
form (pri-miRNA with a hairpin loop) with the help of Polymerase II or III and various transcription factors 
and then spliced by the Drosha/DGCR8 complex to form the precursor miRNA (pre-miRNA). A2) Non 
canonical pathway: a “mirtron” is generated from mRNA after splicing in a complex called spliceosome. 
Next, the mirtron reforms to the shape of a pre-miRNA. B) The pre-miRNA is transferred from the nucleus 
to the cytoplasm with the help of Exportin-5 in a Ran-GTP dependent manner. C) In the cytoplasm the 
protein DICER together with TRBP cleaves the pre-miRNA hairpin loop and releases the two strands. One 
strand will serve as the mature miRNA (18 - 22 nt length), while the other, in most cases, will be degraded. 
D) The mature miRNA then binds to a protein complex including AGO2, forming the so called RISC 
complex. AGO2 then leads the miRNA to the mRNA target: E) if the miRNA sequence is completely 
complementary to the 3’-UTR of the mRNA, it binds and AGO2 cleaves the mRNA, completely stopping 
the translation of the protein. F) if the miRNA sequence is partially complementary with the mRNA’s 3’-
UTR, GW182 is recruited in the RISC complex to aid with the connection and inhibit translation.  
Abbreviations: DGCR8 (DiGeorge Syndrome Critical Region 8), TRBP (HIV-1 transactivating response 
(TAR) RNA-binding protein), PACT (Protein Kinase R-activating protein), FXR1 (fragile X mental 
retardation-related protein 1), AGO2 (Argonaute 2), RISC (RNA-induced silencing complex). The picture 
was designed using Servier Medical Art http://smart.servier.fr/servier-medical-art  
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1.3 miRNAs in physiology 
 
MiRNAs play a significant role during organ development. It has been reported by Tang 
et al. that 54 miRNAs are expressed in higher levels in human foetal organs compared to adult 
matched organs (Tang et al., 2011). Furthermore, the importance of the miRNAs in keeping the 
homeostasis on the human body is reflected by the fact that any dysregulation in their expression 
leads to pathological conditions. The most characteristic example of that derives from mouse 
models deficient for Dicer and Drosha, two proteins with key roles in miRNA biogenesis. In 
particular, it has been shown that in knockout mice for these molecules leads to undeveloped 
organs and/or lethality (Bernstein et al., 2003, Wang et al., 2007, Park et al., 2010). 
More experiments in animal models have supported the concept that miRNAs are 
involved in numerous cellular events during animal development by controlling key processes 
including cell fate determination, proliferation and cell death (Stefani and Slack, 2008). For 
example, let-7 (the second ever discovered miRNA) is a well-studied miRNA that has been found 
to control cell proliferation via regulation of apoptosis and has been linked to different forms of 
cancer due to its dysregulation (Sun et al., 2016). MiR-203 is responsible for skin differentiation 
by repressing p63 in stratified epithelial cells and miR-196 is involved in the development of hind 
limb (Hornstein et al., 2005, Chen et al., 2016). Other examples of miRNAs involved in 
physiological processes include miR-124, a miRNA expressed specifically and abundantly in the 
mouse brain and helping to maintain the neuronal cellular identity (Sempere et al., 2004), miR-
134, an important actor for synaptic development and plasticity (Schratt et al., 2006), miR-1, for 
its role in controlling the development of skeletal and heart muscle (Zhao et al., 2005) and miR-
181 and miR-155 in lymphocyte development (Li et al., 2007, Metzler et al., 2004). Finally, 
miRNAs are also involved in immune response, insulin secretion, neurotransmitter synthesis and 
viral replication (Wijesekara et al., 2012, Greco and Rameshwar, 2007, Gantier et al., 2007, 
Kim et al., 2016).  
  
1.4 Annotation 
 
The nomenclature of miRNAs is complex. In 2003 Ambros et al. proposed guidelines for 
newly identified miRNA annotation (Ambros et al., 2003). These rules were applied later to 
miRBase and are followed until today for every new miRNA identified. The rules are 
summarized in Figure 3 (Griffiths-Jones, 2004). 
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Figure 3: Examples of the 
miRNA annotation. A) mir and 
miR: a small (r) represents the pre-
miRNA while the (R) represents the 
mature miRNA, e.g. mir-16 is the 
precursor miRNA-16 and miR-15 
the mature miRNA. Recent studies 
however suggested that not in all 
cases the mature miRNA is released 
from the same arm (Guo et al., 
2015) and as a result the suffix -5p 
or -3p is added to define from 
which arm of the pre-miRNA the 
mature miRNA is originating. B) 
The three letters in front of the miR 
represents the species in which a 
particular miRNA is observed; e.g. 
hsa (homo-sapiens), mmu (mus 
musculus). The numbers to register 
the miRNAs are ascending. The 
same miRNA in different species 
receives the same number to 
preserve homology among the 
database, e.g. hsa-miR-16-5p 
(human) is the ortholog of mmu-
miR-16-5p (mouse). Different 
numbers are given when a miRNA 
has significant sequence 
differences. The accession number 
of each miRNA is the only unique 
identifier. Lin-4 and let-7 (lethal-7) 
are an exception for historical 
reasons. C) Sequences with one or 2 
different nucleotides are assigned with the same number but an additional letter to distinguish; e.g. hsa-miR-15a and hsa-miR-15b. D) If the same miRNA is 
found in different loci of a chromosome, the difference is indicated from the pre-miRNA level, a number is added to distinguish those; e.g. hsa-mir-16-1 and hsa-
mir-16-2. E) If the miRNAs share the same sequence over a stretch of 2-8 nucleic acids, they are derived from the same precursor and belong to the same cluster 
generating a miRNA family; e.g. the mir-15 family consists of miR-15a and miR-15b sequences, as well as miR-16-1, miR-16-2, miR-195 and miR-497. 
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1.5 Location  
 
1.5.1 Tissue distribution 
 
Numerous reports, using a variety of molecular biology methods and in-silico analysis, 
provide information about the expression levels of miRNAs in different tissues (Liang et al., 
2007, Tang et al., 2011, Sood et al., 2006). This analysis led to the suggestion that miRNAs 
distribute unequally in tissue and that some miRNAs can be listed as “tissue specific” and can be 
used as identifiers for these tissues. For example, miR-122a is specific for the liver, miR-1 and 
miR-133a for the heart and skeletal muscle, miR-9 for the brain (Sood et al., 2006), and miR-192 
and miR-194 for gastrointestinal organs and kidney (Liang et al., 2007). 
 
1.5.2 Bodyfluids 
 
In 2009 Hanson et al. evaluated for the first time miRNA expression in five dried body fluids 
including blood, saliva, semen, vaginal secretions and menstrual blood (Hanson et al., 2009). 
They, in addition with others, were able to identify a number of miRNAs, which could be used to 
distinguish between different fluid samples. These miRNAs were (Zubakov et al., 2010, Nakai 
et al., 2010, Isakova et al., 2011, Shinkai et al., 2008): 
- miR-16, miR-20a, miR-126, miR-451 and miR-486  for blood 
- miR-10b, miR-135a, miR-135b, miR-888, miR-891a and miR-943 for semen 
- miR-138-2, miR-200c, miR-203, miR-205, miR-583 and miR-658 for saliva 
- miR-124a, miR-372, miR-617 and miR819a for vaginal secretions 
- miR-185, miR-214 and miR-412 (in combination with miR-451) for menstrual blood.  
Further studies by Weber et al. showed that miRNAs can be found in at least twelve different 
body fluids including milk, colostrum, saliva, seminal fluid, tears, urine, amniotic fluid, bronchial 
lavage, cerebrospinal fluid, plasma, pleural fluid, and peritoneal fluid (Weber et al., 2010).  
But how do these miRNAs end up in body fluids? MiRNAs are secreted from the cells in 
which they are produced and packed in microparticles such as microvesicles, exosomes or 
apoptotic bodies and are also attached to RNA-binding proteins or lipoprotein complexes 
explaining their presence in body fluids (Figure 4) (Beltrami et al., 2012). Of note, except of 
being the means of transport, miRNA carriers and binding proteins, also act as “bodyguards” of 
miRNAs by protecting them from RNAse activity.  
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Figure 4: miRNA transporting 
molecules. A) During biogenesis or 
even after fulfilling their biological 
function, miRNAs can be 
incorporated into exosomes or 
bound to lipoproteins (e.g. HDL) or 
RNA-binding proteins (e.g. AGO2). 
Release of the encapsulated or 
bound miRNAs can occur via B) 
exocytosis or C) during cell lysis 
and apoptosis. Encapsulation or 
binding to these proteins most likely 
protects the miRNAs from 
degradation in the hostile biofluid 
environment.  
 
 
 
 Exosomes are the best-studied miRNA-vehicles. These vacuoles transfer cellular 
components between cells and promote cell-to-cell communication and interactions (Camussi et 
al., 2010, Ramachandran and Palanisamy, 2012). Studies have shown the existence of 
exosomal transfer of functional mRNAs and miRNAs from one cell to another. One of the 
strongest arguments for the existence of this phenomenon is the study of Valadi et al. in which 
human mast cells were incubated with exosomes secreted by mouse mast cells for 24h. After the 
incubation, 92 mouse proteins were detected in the human cells showing that the exosomes 
carried mouse “functional” mRNAs into the human cells leading to the production of mouse 
proteins in the human cells (Valadi et al., 2007). Studies reported that exosomal miRNAs are 
intact and protected from degradation rather than cell-free miRNAs which are more likely to be 
degraded by RNAses (Cheng et al., 2014b) (Cheng et al., 2014a). 
Moreover, RNA-binding protein AGO2 (Figure 4) was shown to be involved in miRNA 
transport in the circulation, which potentially leads to the transport of a functional miRNA-
induced silencing complex (Arroyo et al., 2011). Another RNA-binding protein with a similar 
action as AGO2 is nucleophosmin 1, which was found to carry miRNA in serum in humans and is 
possibly involved in cell-to-cell communication (Wang et al., 2010b). HDL lipoproteins, 
surprisingly, were found to have a role in the transport of miRNAs in a similar way as RNA-
binding proteins (Vickers et al., 2011). Finally, circulating apoptotic cells seem to contribute to 
miRNAs transport as well. MiRNAs are released in the circulation after apoptosis bound to the 
previously mentioned RNA-binding proteins and can be absorbed by other cells and perform their 
function (Turchinovich et al., 2011, Mlcochova et al., 2014). 
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1.5.3 miRNAs in urine 
 
Urinary miRNAs are attached to RNA-binding proteins or contained in exosomes 
(Lorenzen and Thum, 2012, Cheng et al., 2014b). One point that needs to be highlighted is that 
miRNAs in urine are less abundant than in plasma or serum and this is most likely due to higher 
RNase activity in urine (Cheng et al., 2014b). The origin of urinary miRNAs is still not fully 
elucidated. Urinary miRNAs are likely to be shedded from cells all along the urinary pathway 
(Fang et al., 2013a, Mlcochova et al., 2014), but could also potentially be filtered from the 
plasma, making the urinary pool of miRNAs potentially suitable for detection and monitoring of 
both renal and non-renal diseases. Although the exosome size (30 – 100 nm) is at the limit value 
for glomerular filtration (fenestrations’ diameter is 60 - 80nm (Satchell, 2013, Haraldsson et al., 
2008)), a recent study has shown that exosomes can cross other physiological barriers, such as the 
brain blood barrier despite their large size (Alvarez-Erviti et al., 2011). 
The role of urinary miRNAs is still unknown. Either urinary miRNAs can be considered 
as waste or/and miRNAs could use urine as a vehicle to move through the urinary tract and 
function in areas downstream from their site of production. Further research to answer these 
questions is needed.   
 
1.6 Stability 
 
Due to their small size and the protective mechanisms described above, miRNAs are 
quite stable (Koberle et al., 2013, Gupta et al., 2010).   
For research purposes, it is possible to extract miRNAs from biological samples stored at 
least up to one year under laboratory conditions (relatively constant humidity and ambient 
temperature, no UV exposure and dust free). MiRNAs extracted from such samples show no 
signs of degradation (Zubakov et al., 2010). Plasma and serum miRNAs are stable for 24h at 
room temperature and resist to 8 cycles of freezing/thawing (Mitchell et al., 2008). Further 
stability studies showed that plasma miRNAs extracted from exosomes are more stable compared 
to free plasma miRNAs when storing the samples at 4
o
C, -20
o
C and -80
o
C for 2 weeks, 2 months, 
3 years and 5 years (Ge et al., 2014) (Figure 5).  
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Figure 5: Stability of plasma exosomal and free miRNAs. Four abundant plasma miRNAs extracted 
from plasma exosomes (EX) and free plasma miRNAs (P).  Exosomal plasma miRNAs are more stable 
compared to free plasma miRNAs (Ge et al., 2014).  
 
 
 
Urinary exosomes can also preserve miRNAs under different storage conditions as shown 
by Yun et al. In their study miR-200c extracted from urinary exosomes showed significant 
stability under different storage conditions and after multiple freeze-thawn circles (Yun et al., 
2012) (Figure 6).  
 
 
 
Figure 6: Stability of 
urinary exosomal miRNA 
(hsa-miR-200c). A) Analysis 
of miR-200c quantities in 
exosomes isolated from the 
same volume of pooled urine 
was 1) directly stored at -
80℃ for 1 week or 2) stored 
at 4℃ for 24h, followed by 
storage at -80℃ for 1 week. 
B) Quantity of miR-200c 
after 5 and 1 Freeze-thaw 
cycles. (Yun et al., 2012) 
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Similar observations hold for formalin fixed paraffin embedded (FFPE) tissue samples. 
MiRNAs were found to be more stable compared to mRNA housekeeping genes under different 
tissue sample storage conditions and treatment, suggesting that miRNAs are more suitable than 
mRNAs as potential biomarkers (Peiro-Chova et al., 2013) (Figure 7).  
 
 
 
 
 
Figure 7: Diagram showing the stability of 3 miRNAs (hsa-miR-21, hsa-miR-125b and hsa-miR-191) and 
two commonly used mRNA housekeeping genes (GAPDH and HPRT1) in breast tissue samples under 
different conditions (fresh frozen, FFPE, thawed and FFPE thawed samples). Samples were paired. 
miRNAs of the same sample under these different conditions displayed a much more stable expression 
pattern than the housekeeping mRNA genes, GAPDH and HPRT1. Interestingly RNU6B, RNA often used 
for normalization of miRNAs, also displayed high variability compared to the miRNAs (Peiro-Chova et 
al., 2013). 
 
 
 
The stability of free (non exosome encapsulated) urinary miRNAs has also been studied. 
One of the first studies that included the investigation of the stability of free miRNAs in urine 
was from Yun et al. They tested whether free miRNAs in urine can be used as prognostic and/or 
diagnostic biomarkers for bladder cancer. They showed that after 7 freeze-thaw cycles or after 
FFPE samples Fresh frozen samples Thawed  samples FFPE Thawed samples 
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storing urine at room temperature for 3 days, hsa-miR-145 and hsa-miR-200a showed only 
minimal signs of degradation (Figure 8) (Yun et al., 2012).  
 
 
 
Figure 8:  Free urinary hsa-miR-145 and hsa-miR-200a showing significant stability after A) 7 freeze and 
thaw cycles and B) over a period of 3 days in room temperature. (Yun et al., 2012)   
 
Other studies demonstrated successfully the stability of urinary miRNAs after up to 10 
freeze/thaw cycles, different storage temperatures between 4
o
C and -80°C for short and long 
periods of time (between 5 days to 2 years) (Mall et al., 2013, Lv et al., 2013a).  
This apparent stability of urinary miRNAs opens the window for multiple applications of 
miRNAs in research and in clinical practice.   
 Overall, the stability of miRNAs and their presence in nearly all tissues and body-fluids 
has placed miRNAs in the center of attention. Circulating miRNAs have become the study 
material of choice as possible biomarkers of disease.  
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1.7 Research methods 
 
As discussed above high quality miRNAs can be extracted from a wide range of cells and 
tissue samples, such as cell lines and fresh or formalin-fixed paraffin-embedded (FFPE) tissue 
samples as well as any kind of body fluid (plasma, serum, urine etc.). Even if it was estimated 
that the miRNA fraction is about ~0.01% of the total RNA mass, the technological progress, 
together with the aforementioned stability of the miRNAs, yields in general enough miRNA 
material and of high quality for downstream studies (RT-qPCR, microarrays, next generation 
sequencing (NGS) etc.) (Dong et al., 2013).  
 
1.7.1 miRNA detection techniques 
 
The techniques that are being used in miRNA expression analysis are similar to the 
techniques used in gene expression analysis with some modifications to adjust to the size and 
quantity of the miRNAs. Table 1 summarizes the features of the most important and popular 
detection techniques which will be briefly discussed below.  
Northern Blot analysis was the first technique used to study the miRNAs, but the gold 
standard technology now in miRNA research is RT-qPCR. On the other hand, microarrays and 
Next Generation Sequencing (NGS) significantly boosted miRNA research, making it possible to 
detect and analyze multiple miRNAs in one sample simultaneously. New technologies have also 
been developed for miRNA detection that can potentially complement the “traditional” 
techniques. Such techniques are called biosensor techniques (BT). The difference between the use 
of BTs and the aforementioned technologies is the rapid and highly sensitive results from 
complex samples such as blood and urine, through the use of  selective molecular probes, 
avoiding any need for polymerase-based amplification steps (Johnson and Mutharasan, 2014).  
All technologies have their advantages and disadvantages and a user must take under 
consideration all parameters before choosing the most suitable one. Sensitivity, cost, time to 
results, data processing are some of the most important parameters to consider. Even though NGS 
is winning the race of the most robust method for detection and discovery of new miRNAs, 
validation of findings with other technologies is currently mandatory.  
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Table 1: miRNA detection methods.  
Method Principle Advantage Disadvantage Variants References 
Northern blot 
Visualisation of the 
miRNA by 
electrophoresis with 
32
P-labeled DNA 
probes 
-Quantitative 
detection of mature 
miRNA, primary 
miRNA and 
precursor miRNA 
and miRNA 
complexes with 
Drosha, DICER and 
RISC 
-Low sensitivity, 
-Low throughput, 
-Need of high RNA 
input 
-(DIG)-labeled oligonucleotide 
probes with LNA, 
-EDC-mediated cross-linking, 
-LED, 
-DSLE 
(Lee et al., 1993, Ebhardt 
et al., 2010, Starega-
Roslan et al., 2011, 
Koscianska et al., 2011, 
Johnson and 
Mutharasan, 2014, Pall et 
al., 2007, Kim et al., 2010) 
RT-qPCR 
The extracted 
miRNAs are 
converted to the 
complementary 
DNAs generating 
cDNA followed by 
PCR amplification 
with specific primers 
to target the miRNA 
of interest 
-Sensitivity, 
-Specificity 
-Reproducibility, 
-Low cost, 
-Simplicity, 
-Fast 
-Lack of standardized 
normalization 
molecules, 
-Depends on purity and 
quality of RNA input, 
-Demanding design of 
the primers to deal with 
the small miRNA size 
-miRNA specific or universal 
primers, 
-TaqMan probe or Sybr Green 
(Mirco et al., 2013, Dong 
et al., 2013, Hunt et al., 
2015, Baker, 2010) 
 
Microarrays 
Hybridization of the 
target miRNAs to the 
complementary fixed 
probes and detection 
via fluorescence 
-Parallel analysis of 
hundred miRNAs in a 
single sample, 
-Easy, 
straightforward and 
automated analysis, 
-Short turn-around 
time, 
-Suitable for 
comparison between 
two conditions 
-Prefixed probes 
- Not possible to detect 
new molecules, 
-Hybridization bias, 
-Semi-quantitative 
method, 
-Limited dynamic 
range 
-΄5 hairpin, 
-SHUT, 
-Label-free PAZ-dsRBD method, 
-LASH 
(Dong et al., 2013, Hunt 
et al., 2015, Pritchard et 
al., 2012, Chugh and 
Dittmer, 2012) 
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Method Principle Advantage Disadvantage Variants References 
Next generation 
sequencing 
(NGS) 
Massively parallel 
sequencing of 
millions of fragments 
of DNA from a single 
sample 
-Suitable for 
detection of new 
molecules and 
miRNA 
heterogeneity 
-Increased dynamic 
range and sensitivity 
-Size of data files, 
-Complex data 
analysis, 
-Long time, 
-Costly 
-Semiconductor sequencing (Life 
Technologies -Ion Torrent), 
-Pyrosequencing (Roche - 454), 
-Sequencing by ligation (Life 
Technologies - SOLiD), 
-Reversible terminator - sequence 
by synthesis (Illumina - Solexa), 
-Single-molecule real-time DNA 
sequencing by synthesis (Pacific 
biosciences 
- PacBio) 
(Hunt et al., 2015, 
Pritchard et al., 2012, 
Metzker, 2010) 
 
Biosensor 
Techniques 
A biorecognition 
element (a DNA 
probe complementary 
to the miRNA of 
interest) is in direct 
contact with a 
transduction element 
-High sensitivity, 
-Very fast, 
-Label-free protocols 
-Hybridization bias, 
-Not useful for 
multiplexing, 
-Mass transfer 
challenge, 
-Reliability of 
measurements 
 
-Electrochemical 
-Electromechanical, 
-Optical-based 
(Johnson and 
Mutharasan, 2014, 
Thevenot et al., 2001, 
Hamidi-Asl et al., 2013, 
Johnson and 
Mutharasan, 2012)  
 
NanoString 
nCounter 
Molecular "barcodes" 
and microscopic 
imaging are used to 
detect and count up to 
several hundred 
unique transcripts in 
one hybridization rea
ction 
-Multiplex detection, 
-Direct digital 
detection, 
-No need for 
amplification, 
-High specificity 
-Semi-quantitative, 
-Not suitable for 
detection of new 
molecules, 
limited dissemination 
of the instrument, 
-Need for increased 
open-source software 
tools for data analysis. 
none (Geiss et al., 2008) 
 
Abbreviations: DIG = digoxigenin, LNA = locked nucleic acids, EDC = 1-ethyl-3-(3-dimethylaminopropyl) Carbodiimide, LED = LNA modified probes, EDC 
crosslinking and DIG-labeled), DSLE = DIG-labeled, splinted-ligation and EDC cross-linking method, RT-qPCR = reverse transcription - quantitative 
polymerase chain reaction, SHUT = stacking-hybridized universal tag, PAZ = Piwi/Argonaute/Zwille, RBD = RNA binding protein, LASH ligase-assisted 
sandwich hybridization 
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1.7.2 Data processing and molecular integration 
 
The difficulty in correlating miRNA expression with mRNA targets for clinical 
applications is the fact that miRNAs in physiological and pathological conditions control more 
than one mRNA (tens, even hundreds) and that one mRNA can be controlled by more than one 
miRNA (Rossi and Calin, 2013). The major issue in miRNA studies is to identify the targets of 
the miRNAs and narrow the options to the most important and relevant to the specific case.  
Because the in vitro and in vivo discovery of the real-life targets of miRNAs is a 
challenging - and time-consuming procedure, web-tools have been designed to tackle this 
problem and produce lists of the possible targets. The first bioinformatic approach on this subject 
was developed by Lai in 2002 (Lai, 2002). Lai compared the sequence of a subset of miRNAs to 
the K box and Brd box motifs that were previously shown to mediate negative post-
transcriptional regulation. In this study, it was determined that a region of 8 nucleotides in the 
beginning of a miRNA displays a perfect complementarity to the motifs, suggesting that this 
sequence is responsible for the post-transcriptional regulation mediated by miRNAs. This 8 
nucleotide sequences is now known as the seed of a miRNA and is the main area responsible for 
miRNA function. Nowadays the algorithms in the available web-tools that predict possible 
miRNA targets focus their search on four basic parameters: 
1. Seed matching: as mentioned above, the seed matching refers to the complementarity of 
the first 2-8 nucleotides of a miRNA in the 5’-end to the 3’-UTR of the mRNA target. It 
is the basic parameter that most (if not all) tools take under consideration. But perfect 
complementary is not always observed. The main types of seed matching include the 
6mer (complementary for 6 nucleotides), 7mer (complementary for 7 nucleotides) and 
8mer (perfect complementary) (Peterson et al., 2014).  
2. Conservation: the maintenance of the seed region of a miRNA among species enforces 
the proof of its existence and reduces the number of false positive predictions (Ritchie et 
al., 2013). 
3. Thermodynamic stability – site accessibility: the free energy (Gibbs energy, ΔG) is a 
measure of the stability of a system. Highly negative ΔG values characterize very stable 
RNA complexes. By predicting the ΔG between a miRNA and its candidate target it is 
possible to predict the stability of the duplex and conclude if this complex can form (the 
higher the ΔG the more stable the complex and more possible the binding of miRNA-
mRNA) (Peterson et al., 2014). Also, the energy needed for the unfolding of the 
secondary structure of the mRNA allowing the accessibility to the miRNA (Long et al., 
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2007) can be an additional parameter to consider. Less energy needed to unfold the 
mRNA, the more possible the target site to be accessible (Peterson et al., 2014). 
4. Multiple target sites in the 3’-UTR of the mRNA: studies have shown that in the 3-UTR 
of a mRNA there can be multiple target sites for one miRNA (Ritchie et al., 2009). The 
different algorithms allow analysis of mRNAs and can predict different possible binding 
cites for the one miRNA and, thus, increasing the possibility that this miRNA can bind 
and regulate the mRNA. 
Many web-tools are available, each with a different algorithm for calculating the predicted 
targets of miRNAs (Peterson et al., 2014). Complementary to the prediction databases are the 
databases which contain information on experimentally validated miRNA targets. These 
databases contain information extracted from citations where a well-documented interaction of a 
miRNA:mRNA target using dedicated methods (see paragraph below “In vitro target validation” 
on page 25) (Lee et al., 2015). A list of prediction and validation databases is shown in table 2 
and 3  
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Table 2: Available web-tools for miRNA target prediction. 
Web-tool Name Organisms Calculation Features 
miRanda All 
Seed match, conservation, and 
Thermodynamic stability 
miRanda-mirSVR 
Humans, rats, mice, flies, 
and worms 
 
Seed match, conservation, 
Thermodynamic stability, site 
accessibility 
TargetScan 
Mammals, flies, and 
worms 
Seed match and conservation 
 
DIANA-microT-CDS 
Humans, mice, flies, and 
worms 
 
Seed match, conservation, 
Thermodynamic stability, site 
accessibility, Multiple target 
sites 
 
MirTarget2 or miRDB 
Humans, mice, rats, 
dogs, and chickens 
Seed match, conservation, 
Thermodynamic stability, site 
accessibility 
RNA22-GUI 
Humans, mice, flies, and 
worms 
Seed match and 
Thermodynamic stability 
TargetMiner 
Any 
 
Seed match, conservation, 
Thermodynamic stability, site 
accessibility, Multiple target 
sites 
PITA 
Humans, mice, flies, and 
worms 
Seed match, conservation, 
Thermodynamic stability, site 
accessibility and Multiple 
target sites 
RNAhybrid Any 
Seed match, Thermodynamic 
stability, Multiple target sites 
miRGate Human, mice, rats 
Seed match, conservation, 
Thermodynamic stability, site 
accessibility, Multiple target 
sites 
miRWalk 2.0 
Human, mice, rats and 
all transcripts and 
mitochondrial genomes 
Seed match and conservationn 
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Table 3: Available web-tools for miRNA target validation. 
Web-tool Name Description  Species included 
mirRecords 
Contains manually curated 
experimental evidence for 2705 records of 
interactions between 
644 miRNAs and 1901 target genes 
9 species including 
human 
StarBase 
Large-scale CLIP-Seq data originating from 
HITS-CLIP, PAR-CLIP, iCLIP and 
CLASH  on more than 6000 samples 
14 cancer types (human, 
mouse, C. elegans) 
DIANA – TarBase 
High quality manually curated experimentally 
validated miRNA:gene interactions, enhanced 
with detailed meta-data. 
24 species including 
human 
miRTarBase 
Data for experimental miRNA – target 
interactions collected from literature from 
reporter assays, western blot, northern blot, 
RT-qPCR, microarrays, SILAC, NGS 
18 species including 
human 
miRWalk 2.0 
Experimentally verified miRNA interaction 
information associated with genes, pathways, 
organs, diseases, cell lines, OMIM disorders 
and literature on miRNAs. Around 668.000 
interactions 
15 species including 
human 
PhenomiR 2.0 
Manually curated database with information 
about differentially regulated miRNA 
expression in diseases and other biological 
processes. 
Human and mice 
miR2Disease Base  
A manually curated database that provides a 
comprehensive resource of miRNA 
deregulation in various human diseases. Hosts 
349 miRNAs related to 163 diseases. 
Human  
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1.7.3 In vitro target validation  
 
Currently, in vitro studies are the gold standard for validating predicted miRNA targets. 
The goal is to monitor any changes of the target gene’s expression in response to loss or gain of 
function of a specific miRNA .This is achieved mainly through artificial manipulation of the 
miRNA concentration with either the use of double stranded miRNA mimics or miRNA 
inhibitors (antagomirs). MiRNA mimics are artificial, chemically modified miRNA-like small 
RNAs with the ability to mimic the function of a miRNA guide strand while bypassing the 
maturation steps of Drosha and DICER and causing a rapid decrease in the expression of the 
potential target mRNA (Sokilde et al., 2015). On the other hand, antagomirs act by binding to 
mature miRNAs, blocking their activity, hence leading to the increased expression of the mRNA 
target. Figure 9 summarizes the actions of antagomirs and miRNA mimics.  
 
Figure 9: Antagomirs and 
miRNA mimics. Antagomir 
function: with the addition of 
the antagomirs the action of 
the miRNAs is inhibited.  
Antagomirs bind in a 
complementary manner to the 
miRNAs blocking their 
action leading to the normal 
translation of the targeted 
mRNA. miRNA mimics: the 
addition of miRNA mimics is 
leading to additional 
inhibition of translation of the 
mRNA - targets molecules.   
 
 
Quantitative analysis of miRNAs and mRNAs with microarrays or NGS after treating 
cells with miRNA mimics/inhibitors can provide a panel of the affected mRNAs and thus 
possible direct targets (Tarang and Weston, 2014). Quantitative proteomic analysis as a high 
throughput method has also been used to observe the alterations in the level of proteins that are 
considered possible miRNA targets.  
Other popular techniques are the cross-linking immunoprecipitation (CLIP-based) 
approaches which allow to study the interaction of miRNA-mRNA-AGO protein and, thus, to 
verify the effect of over or under expression of the miRNAs on their targets with or without the 
use of inhibitors (Wen et al., 2011). One of the first methods described based on this concept 
used co-immunoprecipitation of tagged-AGO protein (the main protein of the RISC complex that 
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connects to the miRNA-mRNA duplex) with the miRNAs and mRNAs (Karginov et al., 2007, 
Easow et al., 2007, Hendrickson et al., 2008). Two techniques from this category have helped 
significantly in the identification of the genuine miRNA targets (Haecker and Renne, 2014): 
High-throughput sequencing of RNA isolated by cross-linking and immunoprecipitation (HITS-
CLIP) and photoactivable-ribonucleoside-enhanced cross linking and immunoprecipitation (PAR-
CLIP). HITS-CLIP uses UV light to cross-link –freeze- the RISC complex including miRNA-
mRNA-AGO2, followed by immunoprecipitation, and sequencing of isolated miRNA and mRNA 
(Licatalosi et al., 2008). PAR-CLIP is a modification of HITS-CLIP where displays more 
efficient cross-linking and RNA recovery. However, this approach uses live cells that need to be 
supplemented with the nucleoside analog 4-Thiouridine (4SU) that is incorporated into nascent 
mRNAs, thus it cannot be applied to tissue samples (Hafner et al., 2010). Both techniques have 
helped significantly in the identification of the genuine miRNA targets (Haecker and Renne, 
2014). (Danan et al., 2016).  
 However, one of the gold standard target validation method is based on reporter assays. 
In brief, the potential miRNA target site is cloned and added to the open reading frame of a 
reporter gene, e.g. luciferase of Renilla or firefly. The recombinant plasmid is transfected into 
mammalian cells together with a mimic miRNA. Cells are incubated for 24-48 hours and then the 
luciferase activity or fluorescence intensity is measured. If the target site of the mRNA is a valid 
target for the miRNA under study reduced signal intensity compared to control plasmid 
(transfected with reporter vectors without the UTR sequence, or with a UTR cloned in the 
antisense orientation) will be observed (Ritchie et al., 2013).  
 A list with the different in vitro miRNA target validation methods is available in Table 4.  
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Table 4: miRNA target validation methods. For the validation phase, miRNA antagomirs or mimics are delivered to an in vitro or in vivo experimental system 
to reduce or increase the levels of the miRNAs of interest respectively, following by measuring the levels of the predicted mRNA targets or the protein level 
originating by the mRNA target.   
 
Method / 
molecule 
Full name Principle Can be used for... Reference 
HITS-CLIP 
High-throughput sequencing 
of RNA isolated by 
crosslinking and  
immunoprecipitation 
UV light to cross-link –freeze- the RISC complex 
including miRNA-mRNA-AGO2, followed by 
immunoprecipitation, and sequencing of isolated 
miRNA and mRNA 
In vitro – miRNAs and 
their target mRNAs 
(Licatalosi et 
al., 2008) 
 
PAR-CLIP 
Photoactivable-
ribonucleoside-enhanced 
cross linking and 
immunoprecipitation 
Similar to HITS-CLIP. Difference: Cells are first 
supplemented with the nucleoside analog 4-
Thiouridine (4SU) that is incorporated into 
nascent mRNAs. 
In vitro – miRNAs and 
their target mRNAs 
(Hafner et al., 
2010) 
SILAC Stable-isotope labeling with 
amino acids in culture 
Relative protein abundance is measured by mass 
spectrometry of samples labelled with different 
isotopes 
In vitro – the level of the 
protein originating from 
the mRNA target 
(Ong et al., 
2002) 
2D-DIGE Two dimensional gel 
electrophoresis 
Electrophoresis on a single gel of two samples 
labelled with different fluorescent dyes, 
separating the proteins by iso-electric focusing 
and SDS–PAGE and then identification by mass 
spectrometry 
In vitro – the level of the 
protein originating from 
the mRNA target 
(Zhu et al., 
2007) 
RT-qPCR 
Reverse transcription 
quantitative polymerase 
chain reaction 
Investigate the level of the miRNA or mRNA of 
interest with TaqMan or Sybr green probes 
In vitro – the level of the 
miRNAs and mRNAs 
(Tarang and 
Weston, 2014) 
Western blot 
 
Electrophoresis to separate proteins followed by 
staining with antibodies specific to the target 
protein. 
In vitro – the level of the 
proteins predicted to be 
affected by miRNA 
deregulation 
(Tarang and 
Weston, 2014) 
 
IHC 
Immunohistochemistry 
In situ hybridization with LNA probes 
complementary against the miRNA of interest 
and/or immunohistochemical detection of specific 
proteins 
In tissue samples – detect 
the level of miRNAs and 
proteins of interest 
 
(Tarang and 
Weston, 2014) 
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Method / 
molecule 
Full name Principle Can be used for... Reference 
Microarrays 
 
Hybridization of a panel of miRNAs or genes to 
the complementary fixed probes and detection via 
fluorescence 
In all samples examine 
the expression profile of 
miRNAs and/or mRNAs 
(Tarang and 
Weston, 2014) 
RNA 
Sequencing  
Massive parallel sequencing of millions of 
fragments of DNA from a single sample 
In all samples examine 
the expression profile of 
miRNAs and/or mRNAs 
(Tarang and 
Weston, 2014) 
Luciferase assay  
A luciferase reporter contains the 3΄-UTR target 
sites of a mRNA target which the miRNA mimics 
of the miRNA of interest should target and reduce 
the fluorescence signal 
In vitro – validation of 
the miRNA target 
(Ritchie et al., 
2013) 
GFP reporter Green fluorescent protein 
A GFP reporter is encoded with multiple 3΄-UTR 
target site of a miRNA and with the presence of 
the miRNA the expression level of the GFP is 
lower compared to the absence 
In vitro and in vivo - 
validation of miRNA 
target 
(Ritchie et al., 
2013) 
Biotin-tagged 
miRNA 
 
Biotinylated synthetic miRNA is transfected into 
cells followed by purification of miRNA:mRNA 
complexes connected to the seed sequence with 
streptavidin-agarose beads 
In vitro - capture of 
miRNA targets 
(Orom and 
Lund, 2007, 
Hsu et al., 
2009) 
 
PARE 
Parallel analysis of RNA 
ends 
Genome-wide identification of the miRNA-
induced cleavage products 
In vitro and in vivo - 
capture the miRNA-
mediated cleavage 
products 
(German et al., 
2008, Addo-
Quaye et al., 
2008) 
 
RLM-RACE 
RNA ligase mediated-5΄ 
rapid amplification of 
cDNA ends 
The 5΄ phosphate of the cleaved, uncapped poly-
A RNAs an RNA adapter is ligated followed by 
reverse transcription. Then the cDNAs are 
amplified with the adapter and the gene-specific 
primers to be cloned and sequenced 
In vitro and in vivo - 
capture the miRNA-
mediated cleavage 
products 
(Llave et al., 
2002, Thomson 
et al., 2011) 
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Method / 
molecule 
Full name Principle Can be used for... Reference 
LAMP 
Labeled miRNA pull-down 
assay system 
The pre-miRNA is labeled with digoxigenin 
(DIG), mixed with cell extracts, and 
immunoprecipitated by anti-DIG antiserum 
In vitro - identification of 
the target gene of known 
miRNAs 
(Hsu and Tsai, 
2011) 
Reverse 
transcription of 
targets 
 
Use of the sequence of the miRNA to generate 
primers via reverse transcription matching the 
mRNA targets followed by PCR 
In vitro - capture miRNA 
target genes 
(Ritchie et al., 
2013) 
Polysome 
profiling 
 
Cyclohexamide is used to trap elongating 
ribosomes followed by pull-down of the enclosed 
mRNA 
In vitro - detection of the 
effect of deregulation of 
a miRNA to the 
transcriptome 
(Ritchie et al., 
2013) 
Ribosome 
profiling 
 
Cyclohexamide is used to trap elongating 
ribosomes, cells are lysed and the mRNA 
enclosed to the monosomes is sequenced 
In vitro - detection of the 
effect of deregulation of 
a miRNA to the 
transcriptome 
(Ritchie et al., 
2013) 
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1.7.4 Mimicking or blocking miRNA in vivo  
 
The results from the in vitro experiments can be transferred to in vivo research with the 
hope to reproduce a similar outcome. The basic approach is similar in vitro and in vivo; deliver a 
synthetic miRNA mimic or inhibitor of a miRNA of interest and then observe the effects on the 
condition due to the miRNA abundance change or at the protein level with emphasis on the 
predicted and in vitro validated targets. A further step is the observation of any side effects, 
alterations in neighboring molecular pathways and pathologies and effects on the phenotype. The 
ultimate goal is to identify a possible therapeutic effect of a miRNA that can pass the clinical 
trials and enter the clinical practice.   
Until now the main focus has been on improving the stability of the molecules interfering 
with miRNA in vivo, since unprotected oligonucleotides can easily be degraded by RNAses in the 
blood. As a consequence the design of carriers has become essential in order to transfer and 
deliver the miRNA mimic or antagomir to the desired target while minimizing degradation. These 
carriers such as nanoparticules, lipid bilayers of viruses (e.g. adeno/lentiviruses) need to have 
particular features. They need to be large enough to avoid renal and hepatic filtration but also 
small enough to allow passage through the tissue and cellular barriers and release efficiently their 
load. Moreover carriers must not activate the immune system and should not be toxic for the 
organism. Finally, all possible side-effects from the delivery systems and off-target effects must 
be detected and examined, as, for example, designing an antagomir to inhibit a miRNA of interest 
and not another with similar sequence. (Zhang et al., 2013, Chen et al., 2015b, Orom and 
Lund, 2007).  
Table 5 summarizes the in vivo delivery systems developed so far. 
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Table 5: miRNA in vivo delivery systems 
 
Method / 
molecule 
Principle 
Can be used for... 
Reference 
Direct injection of 
ant-miRs or 
miRNA mimics 
Direct injection of antagomirs and miRNA 
mimics into animal model 
In vitro - in vivo antagomir or miRNA 
mimic system and detection/observation of 
the expression level of the possible targets 
and/or physiology 
(Orom and Lund, 2007) 
miRNA sponges 
or decoys 
Single piece of RNA containing multiple 
seed regions complementary to the miRNA 
family of interest. By delivering this system 
into cells, the miRNAs bind strongly to the 
RNA sequence resulting in silencing the 
miRNA activity 
In vitro - in vivo antagomir or miRNA 
mimic system and detection/observation of 
the expression level of the possible targets 
and/or physiology 
(Elmen et al., 2008a, 
Ebert et al., 2007) 
(Horie et al., 2009) 
Modified viruses 
Lentivirus, adenovirus and adeno-
associated virus are modified accordingly 
to transfer and deliver miRNA regulators in 
a model system 
In vitro - in vivo antagomir or miRNA 
mimic system and detection/observation of 
the expression level of the possible targets 
and/or physiology 
(Chistiakov et al., 2012, 
Chen et al., 2015b) 
 
Exosomes 
Microvesicles that naturally transfer 
miRNAs and can be used to deliver 
modified miRNA regulators 
In vitro - in vivo antagomir or miRNA 
mimic system and detection/observation of 
the expression level of the possible targets 
and/or physiology 
(Zhang et al., 2010) 
Liposomes 
(DOTMA, SLNs, 
MaxSuppressor In 
Vivo RNA-
LANCEr II, LPH, 
scFv, iNOPs) 
Lipid bilayers (cationic or neutral) with an 
internal aqueous phase to load and carry the 
desired molecules 
In vitro - in vivo antagomir or miRNA 
mimic system and detection/observation of 
the expression level of the possible targets 
and/or physiology 
(Wu et al., 2011, Hsu et 
al., 2013, Liu et al., 
2015, Wiggins et al., 
2010) 
 
(Trang et al., 2011, 
Chen et al., 2010) 
(Su et al., 2011) 
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Method / 
molecule 
Principle 
Can be used for... 
Reference 
PLGA 
(poly(lactide-co-
glycolic acid) 
PLGA polymers are transformed into 
microparticles or nanoparticles enclosing 
biological molecules that can release via 
endolysosomal escape after entering the 
cell 
In vitro - in vivo antagomir or miRNA 
mimic system and detection/observation of 
the expression level of the possible targets 
and/or physiology 
(Kulkarni et al., 1971, 
Chen et al., 2015b, 
Zhang et al., 2013) 
(Panyam and 
Labhasetwar, 2003, 
Blum and Saltzman, 
2008) 
 
PEI 
(polyethylenimine) 
Cargo release follows the so-called “proton 
sponge effect”; once the polymer interacts 
with the surface of the cell, endocytosis 
takes place. The PEI causes endosome 
swelling by influx of protons and water 
(proton sponge effect) which leads to 
endosome destabilization and the release of 
the miRNA 
In vitro - in vivo antagomir or miRNA 
mimic system and detection/observation of 
the expression level of the possible targets 
and/or physiology 
(Zhang et al., 2013, 
Boussif et al., 1995) 
 
Inorganic 
nanoparticles  
(Gold 
nanoparticles, 
disialoganglioside 
antibody) 
(AUNP-S-PEG, 
GD2) 
Inorganic nanoparticles are bound and 
deliver miRNA regulators  
In vitro - in vivo antagomir or miRNA 
mimic system and detection/observation of 
the expression level of the possible targets 
and/or physiology 
(Chen et al., 2015b, 
Zhang et al., 2013) 
(Ghosh et al., 2013) 
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1.8. miRNAs as potential therapeutic agents and biomarkers: lessons learned so far 
 
1.8.1. Therapeutic potential 
 
The most extensively studied miRNA to be potentially introduced in clinical practice is 
miRNA-122, an abundant liver-specific miRNA with a key role in liver function (fatty acid and 
cholesterol metabolism) and hepatitis C (HCV) progression (Takata et al., 2013). Elmen et al. 
showed that reduction of miRNA-122 with LNA-ant-mi-R122 (antagomir for miRNA-122) led to 
reduction of cholesterol levels in plasma of mice and non-human primates (Elmen et al., 2008b, 
Elmen et al., 2008a). Lanford et al. showed that suppression of HCV viremia by an antagomir for 
miR-122 in chimpanzees lead to improvement HCV-liver pathology (Lanford et al., 2010). In 
these three studies lasting from 3 weeks to 3 months, no short-term toxicity was observed, 
opening the way for use of the miRNA-122 antagomir as a drug in liver disease. Indeed, these 
preclinical results led to the development of miravirsen, the first antagomir drug candidate against 
HCV by Santaris Pharma A/S (Janssen et al., 2013). Miravirsen binds to the stem-loop structure 
of pri- and pre-miR-122 with nanomolar affinity, and inhibits both Dicer- and Drosha-mediated 
processing of miR-122 precursors and has entered Phase II trials, after displaying no side effects 
on healthy volunteers (Gebert et al., 2014).  
Another therapeutic miRNA candidate that is now in Phase I trials is the liposome-
formulated mimic miRNA-34, or MRX34 as it is named by the developing company MiRNA 
Therapeutics. The miRNA-34 family is found to be decreased in many cancer types. It was 
observed that the miRNA-34 family can regulate the p53 pathway by direct inhibition of many 
oncogenes including Myc, c-Met, BCL-2, CDK4 and CDK6. Treatment with miR-34 mimics 
reduced tumor-size or -growth in many cancer model systems (He et al., 2007, Li et al., 2015a, 
Liu et al., 2011, Roy et al., 2012). MRX34 could become one of the first mimic miRNA systems 
to restore the level of a miRNA and show significant anti-tumor activity 
(http://www.mirnatherapeutics.com/pipeline/mirna-pipeline.html).  
Another company, Miragen therapeutics, has initiated several preclinical studies for 
blocking a number of miRNAs. MiR-155 is studied in hematological malignancies and 
amyotrophic lateral sclerosis and miR-29 in cutaneous and pulmonary fibrosis. Antagomirs 
against miR-155 and miR-29 have passed the pre-clinical study stage and are now entering 
clinical trials. Moreover, Miragen therapeutics is performing preclinical studies in heart failure 
targeting miR-208 and miR-15 and in peripheral artery disease targeting miR-92 
(http://miragentherapeutics.com/pipeline/).  
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Finally, Regulus Therapeutics has initiated their ant-miR programs for blocking of miR-
122 in HCV and miR-10b in glioblastoma. In addition, in non-human primates, tests with an ant-
miR-33a/b showed positive results against atherosclerosis. In collaboration with Sanofi, Regulus 
is developing an ant-miR-221 against hepatocellular carcinoma and an ant-miR-21 for kidney 
fibrosis, the leading complication in kidney disease, and with AstraZeneca an ant-miR-103/107 
for the treatment of non alcoholic steatohepatitis (NASH) in patients with type 2 diabetes/pre-
diabetes (http://www.regulusrx.com/therapeutic-areas). 
Figure 10 summarizes the aforementioned studies. 
 
 
Figure 10: miRNAs being considered for clinical use by Industry and their progression in (pre)clinical 
trials.  
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1.8.2. miRNAs as potential biomarkers 
 
Another application is the use of miRNAs as potential diagnostic and prognostic 
biomarkers. A search in PubMed with the words “miRNA” AND “Biomarker” returns more than 
5000 publications, the majority related to cancer. However, as in miRNAs in therapy, further 
validation of these miRNAs as potential biomarkers of disease is necessary before a potential 
clinical application. As such, almost all reports provide strong indications of the possible use of 
the miRNAs as diagnostic and/or prognostic biomarkers. Below are discussed some key studies 
on the subject with emphasis on human studies.  
 
1.8.2.1 Tissue miRNAs - cancer  
 
In 2002, the first miRNAs characterized as being downregulated in patients with B-cell 
chronic lymphocytic leukemia were miR-15a and miR-16-1 (Calin et al., 2002), a year after the 
discovery of the second miRNA, let-7. Later on, the miR-17-92 cluster was identified to be 
upregulated in many kinds of cancers (mostly in lymphoma and leukemia) and associated with 
upregulation of the oncogene c-Myc, providing a first well characterized cancer associated 
miRNA cluster and introducing a new class of miRNAs, the oncomiRs (He et al., 2005, Dews et 
al., 2006, Lu et al., 2007). Additional miRNAs including miR-21 (Medina et al., 2010), miR-34 
family (Bommer et al., 2007, He et al., 2007) and let-7 (Johnson et al., 2005, Esquela-
Kerscher et al., 2008) are by now accepted as cancer associated miRNAs.  
The first key report that opened the road for considering the miRNAs as possible 
biomarkers came from the laboratory of Todd Golub covering 217 mammalian miRNAs and 
several hundred samples, including clinical samples, common cancer cell lines and mouse 
tumors. The authors demonstrated that miRNA profiles could distinguish a tumor’s 
developmental origin and that miRNAs are generally downregulated in cancers (129 out of 217 
miRNAs). In addition, they noticed that poorly differentiated tumors displayed lower miRNA 
expression compared to tumors with a higher differentiation (Lu et al., 2005). The latter was 
confirmed by Kumar et al. by performing experiments of conditional knockout mice for Dicer 
crossed with a K-Ras driven lung cancer model and demonstrating that a global reduction of 
miRNA biogenesis leads to reduced survival in affected mice and therefore may play tumor 
suppressive properties (Kumar et al., 2009).  
As the years were passing technology evolved allowing more routine screening of 
miRNAs profiles in disease.  Specific miRNA signatures allowed the definition of subtypes of 
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cancers, such as the use of a panel of 133 miRNAs from breast tumor samples to distinct between 
basal and luminal breast cancers (Blenkiron et al., 2007). In their review Omar Faruq and 
Andrea Vecchione discuss extensively the variety of miRNA signatures to define tumor 
subgroups (Faruq and Vecchione, 2015). Table 6 summarizes the most important miRNAs 
signatures in cancer.  
miRNAs were also reported to have potential clinical prognostic value. The first report on 
that subject came from Takamizawa et al. showing that decrease of let-7a was correlated with 
poor survival in lung cancer patients (Takamizawa et al., 2004) and a year later another 
important report mentions a panel of 13 miRNAs as prognostic biomarkers in chronic 
lymphocytic leukemia (CLL) (Calin et al., 2005). Of all miRNAs, miR-21 (increased in cancer) 
and let-7 (decreased in cancer) were the most common miRNAs associated with patient outcome 
(Hayes et al., 2014). The oncogenic miR-21 is overexpressed in many cancers, including breast 
cancer, glioblastoma, hepatocellular carcinoma, lung cancer, stomach cancer, colorectal cancer, 
and prostate cancer (Pan et al., 2010). The mechanistic function of miR-21 is to create a pro-
tumorigenic environment by targeting numerous tumor suppressor genes with roles in apoptosis, 
invasion, and proliferation, and thus is considered as number one novel molecular target for 
cancer therapy (Pan et al., 2010). 
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Table 6: miRNAs that can differentiate tumor subgroups. Table adjusted from (Faruq and Vecchione, 2015) 
 
Cancer Specific miRNA Sources Expression Significance 
Breast 
cancer 
miR-342 Tissue Up Luminal B-like breast  tumors  vs. healthy controls 
miR-18a, miR-135b, miR-93, miR-155 Different Up/Down Basal-like vs. healthy controls 
miR-145, miR-99a, miR-100, miR-130 Different Up/Down Normal-like vs. healthy controls 
Renal cell 
carcinoma 
miR-195, miR-15b, miR-99a, miR-191 Tissue Up ccRCC vs. other subtypes 
miR-200b Tissue Up Chromophobe RCC (chRCC) vs. oncocytoma 
miR-211 Tissue Up chRCC and oncocytoma vs. ccRCC and pRCC 
miR-210 Tissue Up Conventional RCC (cRCC) vs. healthy controls 
Lung 
Cancer 
miR-21, miR-29b Tissue Up NSCLC vs. SCLC 
miR-21, miR-126, miR-210, miR-182 Serum Up/Down Diagnosis of stage-I NSCLC – 
lung adenocarcinoma vs. squamous cell cancinoma 
miR-205 Tissue Up Squamous vs. non-squamous  NSCLC 
Pancreatic 
Cancer 
mR-375 Plasma Up (PDAC) vs. others  pancreatic and gastric carcinoma 
DLBCL 
miR-21, miR-155 and miR-221 Different Up ABC-DLBCL vs. GCB-DLBCL subtypes 
miR-10393-3p Tissue Up Diagnosis of DLBL patients 
miR-10397-5p Tissue Up ABC-DLBCL vs. other DLBC 
miR-5586-5p Tissue Up GCB-DLBCL vs. ABC-DLBCL and unclassified DLBCL 
miR-30b Tissue Down GCB-DLBCL vs. other DLBCL 
miR-515-3p, miR-155, miR-598, miR-625, miR-199a-5p Tissue Up/Down PTCL-NOS vs. ALCL/ALK- 
miR-652, miR-627, miR-519e,  miR-487b, miR-324-5p, 
miR-449a,  miR-381, miR-574-3p 
Tissue Up/Down PTCL-NOS vs. AITL 
miR-124, miR-325, miR-181a,  miR-618 Tissue Up/Down ALCL/ALK− vs. ALCL/ALK+ 
PTCL 
miR-512-3p, miR-886-5p, miR-886-3p, miR-708, miR-135b Tissue Up Diagnosis of ALCL/ALK+ disease vs. ALCL/ALK− + other 
PTCLs 
miR-146a,  miR-155 Tissue Down  
miR-210, miR-197, miR-191, miR-512-3p Tissue Up Diagnosis of ALCL/ALK− vs. ALCL/ALK+ and other PTCLs 
 
Abbreviations: ccRCC,  clear  cell renal  carcinoma; chRCC,  chromophobe renal  cell carcinoma; NSCLC,  non-small  cell lung  cancer;   SCLC,  small  cell lung  cancer;   
PDAC, pancreatic ductal adenocarcinoma; DLBCL, diffuse large  B-cell lymphoma;  ABC, activated  B cell-like; GCB,  germinal  center  B cell like; PTCL, peripheral  T-
cell lymphoma;  PTCL-NOS,  PTCL-not otherwise  specified;  AITL, angioimmunoblastic T-cell lymphoma;  ALCL, anaplastic large-cell lymphoma;  ALCL/ALK+,  
ALCL−  anaplastic lymphoma  kinase  present; ALCL/ALK−, ALCL− anaplastic lymphoma kinase absent.
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1.8.2.2. Circulating miRNAs – cancer 
 
The vast majority of miRNA expression profile reports in cancer stem from solid 
tissues. However, the high stability of the miRNAs allows them to be readily detected in 
human plasma, serum or total blood. Early studies on circulating miR-21 in serum in patients 
with diffuse large B-cell lymphoma, highlighted the potential of circulating miRNAs as 
biomarkers (Lawrie et al., 2008). In 2008 Markou et al. published for the first time evidence 
for the prognostic value of the miRNAs in a clinical study on lung cancer. The authors 
characterized the overexpression of miR-21 in patients with lung cancer as a negative 
prognostic factor (Markou et al., 2014). Three years later, an important study from Boeri et 
al. also, demonstrated that circulating miRNAs can produce a miRNA signature with strong 
predictive value in lung cancer patients years before the onset of disease by analyzing 
expression in samples taken before diagnosis, at the time of detection by computed 
tomography and in disease-free smokers (Boeri et al., 2011). An important study by Keller et 
involved the analysis of 863 miRNAs in 454 human blood samples from patients suffering 
from 14 separate diseases including lung cancer, prostate cancer, pancreatic ductal 
adenocarcinoma, melanoma, ovarian cancer, gastric tumors, Wilms tumor, pancreatic tumors, 
multiple sclerosis, chronic obstructive pulmonary disease, sarcoidosis, periodontitis, 
pancreatitis and myocardial infarction. In that study, on average, more than 100 miRNAs 
were found deregulated in the blood for each different disease. By utilizing this data and 
developing mathematical algorithms and probability plots the authors were able to accurately 
predict the disease in more than two thirds of individuals involved in the study (Keller et al., 
2011).  
 
1.8.2.3. Clinical miRNA diagnostics - cancer 
 
The closest potential of miRNAs use in current diagnostics started with a study 
comparing miRNA expression, using miRNA microarrays, in tissue of 205 primary versus 
131 metastatic tumors covering 22 different tumor origins. Rosenfeld et al. developed a 
binary decision tree classifier based on miRNA expression with tissues displaying the highest 
specificity of certain miRNAs placed at the top of the tree. The result of this classifier was 
that a low number of miRNAs (n=48) could predict tumor origin with a 90% accuracy when 
tested on a blinded set (Rosenfeld et al., 2008). This study, together with other studies which 
followed with the same concept confirmed the accuracy of using miRNAs as diagnostics for 
tumors of unknown origin (Varadhachary et al., 2011, Mueller et al., 2011), were partly 
driven by the miRNA diagnostics company Rosetta Genomics, Israel. Rosetta Genomics is 
now offering a panel (miRview-mets2) to clinicians to determine the origin of metastatic 
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cancers when the primary origin of metastasis is questionable. The panel consists of a test of 
64 miRNA biomarkers validated on 489 samples of which 146 represent metastatic tumors 
covering 42 tissues of origin (Meiri et al., 2012). In addition to the “miRview-mets2” panel, 
Rosetta Genomics also offers four additional clinical tests: “miRview-lung”, “miRview-
squamous”, “miRview-meso” and “miRview-kidney”. MiRview-lung differentiates four types 
of primary lung cancer (small cell lung cancer, squamous non-small cell lung cancer 
(NSCLC), non-squamous NSCLC and carcinoid) using eight separate miRNA biomarkers 
(Gilad et al., 2012). MiRview-squamous separates non-small cell lung cancers (NSCLC) into 
squamous cell carcinomas and adenocarcinomas using only miR-205 (Lebanony et al., 
2009). MiRview-meso defines samples into a mesothelioma or nonmesothelioma origin based 
on three separate miRNAs (Benjamin et al., 2010) and miRview-kidney separates kidney 
cancer into its four primary types (benign oncocytoma, clear cell renal carcinoma, papillary 
renal carcinoma and chromophobe renal carcinoma) using six miRNAs (Fridman et al., 
2010).  
The move of miRNA diagnostics into the clinics led by Rosetta Genomics and others 
may aid the use of personalized medicine in the treatment of cancers. However, miRNA 
diagnostics are still far from entering the clinical routine and their use is focusing mainly on 
cancer. Hayes et al. discuss in their review on the diagnostic value of miRNAs in cancer a list 
of miRNAs which are now in clinical trials for biomarkers (Hayes et al., 2014) (Table 7).  
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Table 7: miRNA studies that are under clinical trials for use as biomarkers in different cancer types. 
Table from (Hayes et al., 2014). (Numerous=miRNAs from different sample origins, Circulating=only 
miRNAs from blood) 
 
MicroRNA 
Trial 
reference 
Disease Trial 
Numerous NCT01964508 Thyroid cancer 
Observational study of microRNA expression  in 
fine  needle aspirates 
Numerous NCT01722851 Breast cancer 
Observational studies of microRNA expression  
levels as  biomarkers of response to treatment in 
the  tumors and circulation 
Numerous NCT01722851 
High-risk 
prostate cancer 
Observational studies of microRNA expression  
levels as  biomarkers of 
response to treatment in the  tumors 
miR-10b NCT01849952 Glioma 
Observational studies of miR-10b expression 
levels as  biomarkers of tumor grade, survival, 
and genotypic variation 
miR-29b NCT02009852 
Oral  squamous 
cell carcinoma 
Observational study to explore the  prognostic 
value of miR-29b in tissue, blood, and saliva 
Numerous NCT02127073 Breast cancer 
Interventional study employing intranasal 
oxytocin to increase the  volume of nipple 
aspirate fluid  for biomarker identification and 
subsequent  microRNA profiling of this  aspirate 
Numerous NCT01595139 
Low-grade 
glioma 
Observational study of the  circulating 
microRNA expression  patterns  in low grade 
glioma as  early  predictors of cancer and as  a 
marker of response to therapy 
Numerous NCT01828918 
Colorectal 
carcinoma 
Observational study identifying biomarkers for 
patient stratification in tissue samples 
Numerous NCT01119573 
Endometrial 
cancer 
Observational study of association of microRNA 
expression and lymph node metastasis in tissue 
samples 
Numerous NCT01595126 
Central nervous 
system cancer 
Observational study of microRNA expression in 
the  blood, cerebrospinal fluid and urine of 
patients through the  course of their treatment 
miR-29  
family 
NCT01927354 
Head and neck  
squamous cell 
carcinoma 
Observational study to investigate the  role  of 
microRNA in Twist1-mediated cancer metastasis 
Numerous NCT01453465 
Rhabdoid 
tumors 
Observational study to identify microRNA 
expression patterns between rhabdoid tumors of 
the  kidney and atypical teratoid rhabdoid tumors 
Numerous NCT01391351 Ovarian cancer 
Observational studies of biomarker of response 
to treatment 
Numerous NCT01505699 
B-cell acute 
lymphocytic 
leukemia 
Observational studies of biomarkers of clinical 
outcomes 
Numerous NCT01957332 Breast cancer 
Observational study correlating microRNA 
expression  patterns  with  imaging and clinical 
data 
Numerous NCT01556178 
Pediatric brain 
cancer 
Observational study of microRNAs in the  blood 
and cerebrospinal fluid  as biomarkers 
Numerous NCT01050296 
Pediatric solid 
tumors 
Observational study of microRNA expression 
profiles in different tumor types 
Numerous NCT00864266 
Non-small-cell 
lung cancer 
Interventional study to identify a signature of 
response to chemotherapy 
Numerous NCT01108159 
Hematologic 
cancer 
Observational studies of biomarker of expression 
profiles in initiation, progression and treatment 
response 
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1.10. Conclusion 
miRNAs have a key role in maintaining cellular homeostasis by regulating many biological 
functions. They have been studied under many pathological conditions to exploit their potential as 
biomarkers or therapeutic targets of disease. The early output of miRNA research is encouraging. 
However, some limitations of using miRNAs in the clinical practice should be mentioned. First, little 
is known about the phenotypical consequences of miRNA targeting when the results are transferred 
from the in vitro to the in vivo setting. In addition, the multiple-targets of miRNAs and the regulation 
of a single mRNA from a variety of miRNAs render the targeting therapy difficult to monitor, eg the 
off-target side effects (Tarang and Weston, 2014). Moreover, the lack of in vivo validation can be 
due to the lack of robust and efficient miR target prediction tools. Development of effective 
bioinformatics analysis methods should lead to confident miRNA-mRNA interaction results. 
Therefore a more integrated collaboration between clinical and molecular methods with a strong 
biostatistical and bioinformatics foundation to bridge the gap between research and clinical 
applications and increase the possibilities for validating miRNAs as important biomarkers or drug 
targets is needed (Hunt et al., 2015). As technology is evolving, new and exciting information will be 
added to the miRNA biology research; pathway regulations will be revealed and allowed to be 
manipulated potentially allowing entry of miRNAs in personalized medicine.  
In this thesis, we are investigating the role of miRNAs in two major kidney pathologies: 
Chronic kidney disease in adults and obstructive nephropathy in children.  
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2. (CHRONIC) KIDNEY DISEASE and miRNAs  
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2.1. The kidney 
The kidneys are bean-shaped organs with the size of a fist and are located below the rib cage 
near the middle of the back (Figure 11). Their main function is to filter around 180 L of plasma every 
day in order to remove the waste products from the activities of the body before they become toxic. In 
addition, kidneys secure the right amount of water and electrolytes in the body, like sodium, potassium 
and phosphorous (Chmielewski, 1992).  
 
Figure 11: Location, macro and micro structure of the kidney (taken from Pearson Education Inc.).  
 
The gross structure of the kidney consists of two major parts: the renal cortex and the renal 
medulla (Figure 11). Along the cortex and medulla are spread over 1 million multicellular functional 
units, so-called nephrons. The main blood filtration section of the nephron is the glomerulus to 
produce the primary urine. This primary urine is further concentrated in the tubuli, where valuable 
minerals, proteins, etc, are also resorbed and/or secreted  (Preuss, 1993).  
The kidneys also contribute to the homeostasis of the body by releasing among other 
compounds erythropoietin (stimulates the production of red blood cells in the bone marrow), renin (for 
the stability of blood pressure) and calcitriol (a form of vitamin D - helps to the maintenance of the 
bones and calcium level in the body) (Chmielewski, 2003). 
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2.2. miRNAs in kidney physiology 
 
A number of miRNAs have been characterized as kidney specific (miR-215, miR-146a and 
miR-886) or enriched in kidney as well as other organs (miR-192, miR-194, miR-21, miR-200a, miR-
204, let-7a-g) (Baskerville and Bartel, 2005, Sun et al., 2004, Landgraf et al., 2007). But, the 
evidence of the significance of miRNAs in kidney development and normal function derive from 
studies on Dicer. Deletion of Dicer has been associated with premature termination of nephrogenesis, 
formation of tubular and glomerular cysts, disruption of podocyte homeostasis causing dysfunctions at 
the glomerular filtration barrier leading to glomerulopathy and glomerular and tubulointerstitial 
fibrosis and deregulation of the control of the blood pressure, reduced rennin concentration, 
hypertension, kidney fibrosis and disruption of electrolyte homeostasis (Nagalakshmi et al., 2011, Shi 
et al., 2008, Patel et al., 2012, Harvey et al., 2008, Ho et al., 2008, Sequeira-Lopez et al., 2010). 
 Specific miRNAs with involvement in kidney development are: 
 miR-17~92 cluster: depletion leads to reduced numbers of nephrons, renal hypodysplasia, 
glomerular dysfunction and proteinuria (Marrone et al., 2014) 
 miR-192: part of electrolyte homeostasis. Suppresses the Na+/K+ ATPase β1 subunit gene in 
human renal epithelial cells and inhibits the serine/threonine kinase WNK1 in the distal 
nephrons (Mladinov et al., 2013, Elvira-Matelot et al., 2010) 
 miR-802 and miR-194: they regulate the  renal outer medullary potassium channel (ROMK) 
by targetin caveolin-1 (a negative regulator of the channel) and intersectin-1 (involved in 
mediating the WNK-induced endocytosis of the ROMK channel) (Lin et al., 2011, Lin et al., 
2014) 
 miR-9 and miR-374: regulate the expression of claudin-14 (critical for Ca+ reabsorption in the 
kidney) in the thick ascending limb of Henke (Gong et al., 2012) 
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2.3. Chronic Kidney Disease 
The KDIGO guideline defines CKD as abnormalities of kidney structure or function, present 
for more than 3 months, with implications for health (Stevens et al., 2013). It is one of the major 
public health problems worldwide. CKD and its final stage (end stage renal disease, ESRD) represent 
a huge burden. According to Global Burden of Disease study in 2010, CKD recorded an increase in 
absolute number of deaths by 82% from 1990 to 2010 climbing from 27
th
 to 18
th
 place as cause of 
death, setting CKD to the top three fastest growing main causes of death worldwide behind HIV and 
diabetes (De Nicola and Minutolo, 2016, Lozano et al., 2012). Age-standardized death rates from 
CKD increased by 15% in this period, while rates for most diseases fell, including other non-
transmissible diseases such as major vascular diseases, chronic pulmonary disorders, most forms of 
cancer and liver cirrhosis. Interestingly, it was observed in that study that for most non-transmissible 
causes of death, the global increase in the number of deaths was due to ageing of the population, while 
for CKD both ageing of the population and ageing-independent factors were contributing (Lozano et 
al., 2012). Age-independent CKD risk factors include sex, obesity, smoking and high cholesterol and 
triglyceride levels (Ortiz, 2015, White et al., 2005). CKD is associated with an increased risk of 
dying from cardiovascular causes (including atherosclerosis, arrhythmia, etc), but also from non-
cardiovascular diseases including pulmonary embolism, infection and cancer (James et al., 2008, 
Thompson et al., 2015, Kurella et al., 2005).  
CKD is divided into 5 stages. These stages are mainly based on measured or estimated GFR 
(Figure 12). There are five stages but kidney function is normal in Stage 1, and minimally reduced in 
Stage 2.  
 
 
 
 
 
Figure 12: The stages of CKD 
according to eGFR 
measurements.  
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2.4. Known mechanisms in CKD and involvement of miRNAs  
2.4.1. Inflammation 
Inflammation is a natural mechanism of defense enabling the removal of inciting agent and 
initiates the healing process as response to injury, infection, ischemia and autoimmune diseases 
(Gabay and Kushner, 1999, Kimmel et al., 1998). The damaged cells and immune cells (which are 
close to the injury) mediate a number of substances to activate a response common to several tissue 
types (Gerard and Rollins, 2001, Tracey, 2002, Moss et al., 2004). Activation of the immune system 
due to tissue damage, with consequently enhanced inflammation, may facilitate disease onset and 
progression (Gerard and Rollins, 2001). An increased inflammatory response leads to loss of 
peripheral tolerance to the components of the tissues themselves, which become antigenic and develop 
local inflammation (Moss et al., 2004). Inflammatory mediators act on target cells, which may be 
localized in any body compartment, thus leading to different morbid processes, such as CKD (Moss et 
al., 2004, El Nahas, 2005). 
Regarding renal tissue, inflammation actively participates in the mechanisms of renal damage 
progression in diseases of several etiologies with some key events occurring to include 1) increased 
production of angiotensin II and promotion of inflammatory mediators (cytokines and chemokines) 
due to glomerular proteinuria,; 2) initial neutrophyl recruitment followed by by macrophages and T 
lymphocytes recruitment, which unleash the immune response, producing interstitial nephritis; 3) 
tubular cells respond to this inflammatory process by changes in their phenotype (potentially 
epithelial-mesenchymal transition) that might lead to transformation of tubular cells into interstitial 
(myo)fibroblasts,; 4) (myo)fibrobrasts producing collagen which, in turn, injuries the renal vessels and 
tubules, eventually generating an acellular scar (Vianna et al., 2011). 
Toll-like receptors and nuclear facter-kβ (NF-kB) pathways are associated as inflammation 
mechanisms by controlling necrosis mechanisms and activating proinflammatory responses 
(Backdahl et al., 2009, McCall et al., 2011). 
Many miRNAs have been recognized to have a key role in inflammation response. Some of 
the most studied are miR-181a and miR-223 on establishing and maintaining the cell fate of immune 
cells, miR-146 for being involved in innate immunity by regulating Toll-like receptor signaling and 
ensuing cytokine response, miR-155 on the regulation of the  central elements of the adaptive immune 
response such as antigen presentation. miR-181a is also responsible for T cell receptor signaling while 
alterations on miR-203 and miR-146 expression in chronic inflammatory diseases suggests their 
involvement in immune-mediated diseases (Sonkoly et al., 2008, Ichii et al., 2012). Finally a high-
throughput miRNA sequencing of peripheral blood mononuclear cells from ten clinically stable 
hemodialysis patients and ten healthy controls identified 182 differentially expressed miRNAs 
(including miR-21, miR-26b, miR-146b, miR-155) and correlated their dysregulation with 
inflammation (Zawada et al., 2014). 
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2.4.2. Epithelial Mesenchymal Transition (EMT) 
A molecular reprogramming of the cell is responsible for the differentiation of the epithelial 
cell to assume the phenotype of matrix-producing fibroblasts and myofibroblasts. As CKD progresses, 
the tubular epithelial cells at the site of injury start to transform to fibroblasts (more than 30% of the 
fibroblasts) via the EMT process, (Iwano et al., 2002). In favour of the activation of the EMT process 
are various profibrotic growth factors including transforming growth factor (TGF), fibroblast growth 
factor-2, connective tissue growth factor, and angiotensin II (Kalluri and Weinberg, 2009). In 
response to these autocrine and/or paracrine signals, the tubular cells undergo down-regulation of their 
epithelial and up-regulation of a mesenchymal genetic program, resulting in loss of epithelial proteins 
such as E-cadherin, zonula occludens-1, and cytokeratin, and acquisition of mesenchymal markers 
such as vimentin, matrix metallopeptidase-2, fibroblast-specific protein-1, type I collagen, and 
fibronectin (Kalluri and Weinberg, 2009, Zeisberg and Neilson, 2009). Additional alterations of the 
cells include phenotypic changes, loss of epithelial cell adhesion and polarity, actin reorganization and 
α-smooth muscle actin (SMA) expression, tubular basement membrane disruption, and increased cell 
migration and invasion (Liu, 2004). 
One miRNA has been well studied to have an energetic role in EMT. miR-200 has been 
shown to regulate negatively EMT by targeting ZEB1 and ZEB2, two important transcriptional 
repressors of genes regulating cell adherence (E-cadherin) and polarity (CRB3 and LGL2) (Davalos et 
al., 2012).  
 
2.4.3. Renal Fibrosis 
 TGF-β expression and activity is key in the development of fibrosis, a hallmark of CKD (Liu, 
2004). Various stimuli, including high glucose, angiotensin II and reactive oxygen species trigger a 
response from distressed renal cells and inflammatory cells to produce TGF-β and, thus, promoting 
renal fibrogenesis and pathological events in the glomerular, tubulointerstitial and vascular 
compartments. TGF-β is responsible for mesangial cell hypertrophy and proliferation, podocyte 
apoptosis and detachment from the glomerular basement membrane and endothelial-to mechenchymal 
transition (Trionfini et al., 2015). This molecule acts by activating the type I TGF-β receptor by 
binding to type II TGF-β receptor. Type I TGF-β receptor phosphorylates receptor-regulated Smad2 
and Smad3, which binds to Smad4 and translocates to the nucleus to bind and activate its target genes 
(Meng et al., 2013).  
miRNAs have been studied in the context of fibrosis. miR-192 is positively regulated by TGF-
β to promote fibrosis in the mouse model of unilateral ureteral obstruction and in the rat model of 
remnant kidney disease. Knocking down miR-192 in these animal models prevents TGF-β–mediated 
collagen matrix expression (Chung et al., 2010). Another profibrotic, and mostly documented miRNA 
related to kidney fibrosis, is miR-21 which is, also, positively regulated by TGF-β to target Smad7, a 
TGF-β suppressor, resulting in promoting fibrosis (Trionfini et al., 2015). miR-21 is over-expressed 
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both in animal models of kidney disease and human acute and/or chronic kidney disease (Markou et 
al., 2014). In particular, miR-21 is up regulated in kidney tissue of patients with diabetic nephropathy 
targeting PTEN and SMAD7 resulting to renal fibrosis progression (Boeri et al., 2011), and also up 
regulated in kidney tissue of patients with IgA nephropathy associated to activation of fibrogenesis in 
podocytes and tubular cells (Keller et al., 2011). Interestingly, Gomez et al. recently presented the 
potential therapeutic value of miRNA silencing in Alport nephropathy, a genetic disease characterized 
by glomerulonephritis leading to end stage CKD in early adult years. In particular, they injected 
antagomir against miR-21 (ant-miR-21) in a Col4a3
-/- 
mouse model to observe that compared to the 
control model, ant-miR-21 prevented from glomerulosclerosis, tubular atrophy and interstitial fibrosis, 
as well as preserving the number of podocytes. Furthermore, the authors showed reduced tubular 
injury, inflammation and myofibroblastes and, in total, improvement of the kidney function, disease 
pathology and life span of the treated mice compared to the non treated Col4a3
-/- 
mice. They 
concluded that up-regulation of miR-21 plays an important role in the development of Alport 
nephropathy and targeting miR-21 with antagomirs is an effective treatment, leaving promises for the 
use of miRNA inhibitors (or mimics) as potential therapeutic methods for kidney pathologies (Gomez 
et al., 2015).  
The role of the protector against fibrosis is awarded to miR-29. Qin et al showed that wild-
type mice with obstructive nephropathy had reduced expression of miR-29 and progressive renal 
fibrosis, whereas Smad3 knockout mice had up-regulation of miR-29 without renal fibrosis (Qin et 
al., 2011). In vitro experiments in renal tubular cells showed that miR-29b overexpression inhibited 
TGF-β up-regulation of collagens I and III. Smad7 also is involved in controlling the TGF-β/Smad3-
regulated miRNAs, and its overexpression protects the kidney from renal fibrosis by suppressing 
expression of miR-192 and miR-21, and restoring expression of miR-29b (Chung et al., 2013). 
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2.5. Major etiologies responsible for of CKD 
  
The leading cause of CKD is diabetic kidney disease as result of increased cases of diabetes 
which is estimated to affect globally more than 285 million adults aged 20 - 70 years (Ayodele and 
Alebiosu, 2010). The second cause is hypertensive kidney disease. Other frequent etiologies include 
chronic glomerulonephritis, chronic interstitial nephritis and renovascular disease (Figure 13).  
 
 
 
Figure 13: global causes of CKD. (CGN=chronic glomerulonephritis, HT=hypertensive nephrosclerosis, 
CIN=chronic interstitial nephritis, RVD=renovascular disease) (Jha et al., 2013) 
 
 
 
Below are discussed the 2 major causes of CKD: diabetes and hypertension.  
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2.5.1. Diabetic nephropathy 
About 25 - 40% of patients suffering from diabetes, either type I (T1D) or type II  (T2D), will 
be diagnosed later with diabetic nephropathy (DN) (Conserva et al., 2013).  
 The clinical history steps of a typical patient are (Schena and Gesualdo, 2005):  
1. Symptoms of hyperfiltration (elevated values of GFR) and occasional microalbuminuria, 
which may last approximately 5 years.  
2. During the following ∼20 years, microalbuminuria turns into progressively higher proteinuria, 
whereas GFR declines.  
3. The patient undergoes renal insufficiency with severe proteinuria, which eventually evolves 
towards ESRD.  
 
The pathophysiology of DN involves progressive thickening of the glomerular basement 
membrane, podocyte loss and mesangial proliferation in the glomerulus, and tubulointerstitial fibrosis 
characterized with uncontrolled deposition of extracellular matrix and low-grade inflammation 
(Brosius, 2008, Lan, 2012, Conserva et al., 2013). 
It is important to consider that hyperglycemia is a primary initiator of diabetic nephropathy. Very 
early, hyperglycemia leads to vasodilation and increased GFR because of increase of endothelial NO 
synthase (eNOS) expression in afferent arteries and glomerular capillaries (Sugimoto et al., 1998). 
Progressively, glomerular distension causes endothelial dysfunction and hemodynamic alterations, 
loss of the glomerular basement membrane (GBM) electric charge and GBM thickening, decreased 
number of podocytes, foot process effacement and mesangial expansion as signs of the initial 
glomerular injury which eventually leads to glomerulosclerosis (Lehmann and Schleicher, 2000, 
Wolf and Ziyadeh, 2007, Munusamy and MacMillan-Crow, 2009).  
This glomerular damage causes tubular injury by different mechanisms. Proteinuria derived 
from GBM alterations activates tubular cells to produce pro-fibrotic mediators (TGF-β, angiotensin-II, 
etc.) and proinflammatory cytokines and promotes cell death. Moreover, microangiopathy results in 
reduced postglomerular blood flow to peritubular capillaries. The result is the activation of 
mechanisms responsible for tubular cell death, EMT, cell infiltration, tubule degeneration and 
interstitial fibrosis (Remuzzi et al., 2006, Ziyadeh and Wolf, 2008). As a result, diabetic nephropathy 
is a disease affecting the whole nephron. 
 
2.5.2. Hypertensive nephropathy 
Hypertension causes a nephrosclerotic glomerulopathy characterized by (1) renal vasculopathy 
affecting preglomerular arteries and arterioles, endothelial dysfunction, wall thickening and fibrosis; 
(2) microvascular disease of the glomerular tuft capillaries; (3) diffuse glomerulosclerosis and, less 
often, focal and segmental glomerulosclerosis (FSGS), involving damage to the filtration barrier 
constituents (podocytes, mesangial cells and basement membranes); and (4) interstitial fibrosis 
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(Rosario and Wesson, 2006). Overall, arteriolar vasculopathy, vascular obstruction and decreased 
vascular density lead to decreased renal blood flow. However, GFR initially stays relatively stable. 
This is due to increased glomerular capillary pressure resulting from deficient or upwardly reset renal 
autoregulation and due to damage to the filtration barrier resulting in greater permeability. In the end, 
GFR decreases because of a progressive loss of surface area, mesangial hypertrophy and increasing 
glomerular and peritubular fibrosis. Moreover, basement membrane alterations induce albuminuria 
and protein hyperfiltration (Lopez-Novoa et al., 2010). 
 
2.6. Current detection and treatment of CKD  
2.6.1. Detection 
Current clinical detection of kidney damage is based on pathological persistent albuminuria 
(>30 mg/g creatinine), urine sediment abnormalities, electrolyte and other abnormalities due to tubular 
disorders, abnormalities detected by histology, structural abnormalities detected by imaging or history 
of kidney transplantation. In addition kidney damage is also established based on the calculation of a 
decreased eGFR (<60 ml/min/1.73 m2). (Otero et al., 2010, Stevens et al., 2010, Coresh et al., 2014, 
Parving et al., 2015). However, despite the importance of for example albuminuria in the clinical 
practice, this marker frequently falls short in the selection of individuals that would benefit most from 
timely therapeutic interventions (Mischak et al., 2015, Miller et al., 2009). Furthermore, eGFR 
informs on the actual-, but not on future-renal function, that necessitates multiple measurements. 
Finally, a low eGFR (<60 ml/min/1.73 m2) is a late marker of disease where (irreversible) damage is 
already advanced.   
A number of laboratories have tried to identify novel markers of CKD and its progression. 
These candidate markers include: 1) kidney injury molecule (KIM-1), a transmembrane protein 
increased in urine and plasma after kidney injury and associated with fibrosis, inflammation and acute 
tubular necrosis (ATN) in CKD patients  (Han et al., 2002, Hsu et al., 2009), 2) the neutrophil 
gelatinase-associated lipocalin (NGAL) a lipocalin iron-carrying protein which is expressed at tubular 
renal epithelial cells after tubular injury and increases in serum and/or in urine is a strong marker of 
CKD diagnosis and prognosis (Mishra et al., 2004, German et al., 2008, Addo-Quaye et al., 2008, 
Llave et al., 2002), 3) fibroblast growth factor 23 (FGF-23) a phosphaturic protein secreted from bone 
osteocytes and has been shown to correlate with CKD progression (Nakai et al., 2010, Isakova et al., 
2011) and, 4) monocyte chemoattractant protein 1 (MCP-1) an inflammatory chemokine which is 
upregulated in serum and urine in kidney diseases, including CKD (Melgarejo et al., 2009, Wada et 
al., 2000, Thomson et al., 2011). Finally, a new approach to identify reliable biomarkers in the early 
stage of the development of CKD involves a panel of urinary peptides, which is shown to have better 
clinical value as a marker for CKD progression compared to albuminuria changes in the early stages of 
CKD (Rosenfeld et al., 2008).  
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2.6.2. Treatment 
At the early stages of CKD the current treatment is focus on drugs that block CKD progression by 
controlling blood pressure. Two are now the most recognized:  
1. Renin–angiotensin aldosterone system (RAAS) inhibition: RAAS inhibition has shown to be 
the most effective therapy at reducing proteinuria and slowing CKD progression in animals 
and humans (Perico et al., 2008). Furthermore, in experimental models, RAAS inhibition has 
led to regression and repair of certain aspects of CKD, such as glomerular fibrosis (Fogo, 
2006, Remuzzi et al., 2006).  
RAAS inhibitors are considered as first in line therapy for patients with diabetic and non-
diabetic kidney disease (Brewster and Perazella, 2004). Clinical studies, trials and 
experience over the last several decades with RAAS blockers have demonstrated that RAAS 
inhibition using angiotensin converting enzyme inhibitors (ACEIs) and angiotensin AT-1 
receptor antagonists (ARA) is the most effective single therapy to attenuate progression of 
CKD, despite being almost equally effective to other antihypertensive drugs at reducing blood 
pressure (MacKinnon et al., 2006). 
The highly active octapeptide angiotensin II is produced by an initial cleavage of 
angiotensinogen by the enzyme renin into the decapeptide angiotensin I, which in turn is 
cleaved by the zinc metallopeptidase ACE and other carboxypeptidases. Angiotensin II has 
functional and structural effects on the vascular wall, heart, renal tissues, nervous system and 
many others (Mire et al., 2005). ACEIs and ARA are the two families of compounds for 
RAAS inhibition (Sica, 2005). Both drug types are clinically approved and commonly used 
for the treatment of hypertension as well as other cardiovascular disorders. Good 
pharmacological profiles with high efficacy and low toxicity characterize both families of 
compounds. ACEIs (e.g. enalapril, trandolapril, ramipril, lisinopril, benazepril and fosinopril) 
prevent angiotensin II from being produced by ACE, whereas ARA (e.g. losartan, valsartan, 
irbesartan, candesartan, eprosartan, olmesartan and telmisartan), which are selective for the 
AT-1 receptor prevent angiotensin II from binding and activating its receptor. RAS inhibitors 
are superior to other antihypertensive agents at reducing progression of CKD, proteinuria and 
mortality end-points not only due to blood pressure control, but also holding pressure-
independent, beneficial actions on diseased kidneys (Pugsley, 2005, Lewis, 2002).  
2. Calcium channel antagonists: Calcium channel antagonists (CAs) are a family of compounds 
that inhibit L and T voltage dependent calcium channels. There are two categories of 
molecules: the dihydropyridine (nifedipine, nisoldipine, amlodipine, nicardipine, nitrendipine) 
and the non-dihydropyridine (verapamil, diltiazem) chemical structures. Each category acts 
differently because of lipophilicity differences. Non-dihydropyridines have both vascular and 
cardiac effects (vasodilation and negative inotropy, respectively), whereas dihydropyridines 
are quite selective for the vasculature (Abernethy and Schwartz, 1999). CAs are widely 
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used for the treatment of cardiovascular diseases, including hypertension, whose main side 
effect is oedema of the lower extremities (Weir et al., 2001, Nathan et al., 2005). CAs 
attenuate hypertension-related renal damage progression, when administered during incipient, 
non-proteinuric stages of disease, as all other antihypertensive agents (Nathan et al., 2005). 
In these cases, both dihydropyridines and non-dihydropyridines substantially reduce 
progression rate and proteinuria with non-dihydropyridines, to be mostly preferred, as they 
are more effective, in overtly proteinuric renal disease and renal dysfunction, especially in 
non-insulin dependent diabetic nephropathy (Nathan et al., 2005, Nielsen and Flyvbjerg, 
2000).  
In general, both subclasses of CAs, help to the control of blood pressure, either alone or in 
combination with ACEIs or ARA, and exert beneficial effects on renal damage and 
progression of renal dysfunction (Segura et al., 2005, Nielsen and Flyvbjerg, 2000). In 
addition, studies with CAs suggest that these molecules provide an additive renal protective 
effect in multidrug therapies (along with RAAS inhibitors), an effect independent from blood 
pressure reduction. This is because CAs acts on the renal vasculature by producing 
vasodilation preferentially at the afferent level, which results in an increased GFR (Epstein, 
1993).  
 
2.7. The future needs in CKD  
The main need in CKD is observed in the development of novel diagnostic and risk 
stratification tools and tools to personalize therapeutic approaches. To do this, accurate, sensitive, 
specific and non-invasive diagnostics tests should be designed to allow the identification of the 
etiology of CKD both early in the course of the disease and when patients seek medical care at a later 
stage. In addition, therapies that can slow-down or halt the progression CKD are currently lacking. 
Ideally therapies should be able to reverse established kidney damage (Ortiz, 2015, Lopez-Novoa et 
al., 2010).  
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2.8. Urinary miRNAs as potential biomarkers of CKD 
Since miRNAs are involved in so many (patho)physiological processes it is not a surprise that 
laboratories have been studying association of urinary miRNAs with CKD.  
 
2.8.1 CKD, all cause 
One of the first reports on urinary miRNAs in CKD described significantly increased levels of 
miR-638 in urine samples from patients with stages 3, 4 and 5 (ESRD) compared to samples from 
healthy volunteers (Neal et al., 2011). MiR-638 has been shown to be associated with the maintenance 
of the epithelial cell phenotype (Ma et al., 2014). In another report, differential urinary miRNA 
abundance was found to be associated to different CKD etiologies: reduced levels of urinary miR-15 
were observed in diabetic glomerulosclerosis, increased levels of miR-17 in IgA nephropathy and 
increased miR-216a and miR-21 levels in hypertensive nephrosclerosis (Szeto et al., 2012). More 
importantly, urinary miR-21 and miR-216a abundance was correlated with the rate of renal function 
decline (Szeto et al., 2012). miR-21, in particular, is known  to participate in the development of 
kidney fibrosis, a key mechanism leading to CKD (Patel and Noureddine, 2012, Chau et al., 2012, 
Glowacki et al., 2013, Wang et al., 2012b). Reduced urinary abundance of miR-29a, miR-29b, miR-
29c and miR-200a, miR-200b and miR-200c, have been observed in CKD patients originating from a 
variety of etiologies including diabetic nephropathy, focal segmental glomerulosclerosis, IgA 
nephropathy, membranous nephropathy and mesangial proliferative glomerulonephritis (Lv et al., 
2013b, Wang et al., 2011a, Oba et al., 2010, Qin et al., 2011, Tang et al., 2013). As miR-21, these 
miRNAs are known to be associated with the development of kidney fibrosis. MiR-29, known as an 
antifibrotic miRNA (see above section Renal Fibrosis, page 48) is also reported to control the 
expression of Tropomyosin 1 (TPM1), a protein involved in the epithelial to mesenchymal transition 
(EMT) mechanism, and collagen isoform COL2A1  (Fang et al., 2013b, Wang et al., 2012a). The 
mir-8 family (miR-200a, miR-200c, miR-141, miR-429) is found to target ZEB1, ZEB2 and SIP1 
known to be involved in the EMT process, in fibrosis and in maintenance of the cell phenotype 
(Gregory et al., 2008, Xiong et al., 2012). 
 
2.8.2. Diabetic CKD 
MiRNAs have also been shown to have an active role in diabetic nephropathy (DN), the main 
cause of CKD. Argyropoulos et al. studied urinary miRNA abundance in either normo-, micro- or 
macroalbuminuric type 1 diabetic (T1D) patients and in patients with overt diabetic nephropathy. They 
observed that urinary levels of miR-323b-5p, miR-429 and miR-17-5p were associated with persistent 
micro-albuminuria in patients with long standing T1D (Argyropoulos et al., 2013). After predicting 
the targets of these miRNAs, it was hypothesized that miR-323b-5p may regulate Claudin-16, which is 
a vital component of the tight junction in the thick ascending limb of Henle in the tubular section of 
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the kidney (Hou et al., 2007) and that miR-17-5p targets fibronectin (Shan et al., 2009), an 
extracellular matrix protein increased in DN (Miller et al., 2014). In addition, miR-429 belongs to the 
same fibrosis-related mir-8 family mentioned above (Padmashree and Swamy, 2013).  
Another study analyzed the abundance of urinary miRNAs in urine of T1D patients with 
microalbuminuria as well (Barutta et al., 2013). The authors observed decreased urinary levels of 
exosomal miR-155 and miR-424 and increased levels of miR-145 in T1D patients with 
microalbuminuria compared to T1D patients with normoalbuminuria or non-diabetic controls 
(Barutta et al., 2013). Interestingly, in vivo and in vitro studies suggest that glomerular miR-145 
overexpression might be triggered by hyperglycaemia, potentially stimulating mesangial cell 
hypertrophy and cytoskeleton remodeling, key early features of DN (Wiggins et al., 2010, Cordes et 
al., 2009). MiR-424 was found to be involved in the regulation of angiogenesis (Ghosh et al., 2010, 
Chamorro-Jorganes et al., 2011) and miR-155 has been shown to regulate angiotensin 2 (Martin et 
al., 2006) and SMAD proteins related to fibrosis (Louafi et al., 2010, Rai et al., 2010). 
Besides glomerular and interstitial damage, DN is also characterized by vascular lesions. Liu 
et al. found that miR-126 abundance was increased in urine of type 2 diabetic (T2D) patients suffering 
from DN compared to diabetic patients without DN and healthy volunteers. MiR-126 is a miRNA 
highly enriched in endothelial cells and is a key player in maintaining endothelial homeostasis and 
vascular integrity. The authors therefore suggested that urinary miR-126 originates from endothelial 
cells-derived exosomes and propose that urinary miR-126 could serve as a biomarker to identify T2D 
patients with DN and monitor progression of the disease (Liu et al., 2014), although this remains to be 
confirmed in independent studies.  
 
2.8.3. Glomerulopathies 
 Primary glomerulopathies, such as minimal change disease (MCD), focal segmental 
glomerulosclerosis (FSGS), membranous glomerulonephritis (MGN), immunoglobulin A nephropathy 
(IgA Nephropathy) and membranoproliferative glomerulonephritis (MPGN) are disorders affecting the 
glomerular structure and function (Jiang et al., 2013, Glassock and Cohen, 1996).  
IgAN is characterized by mesangioproliferative changes in glomeruli with deposition of 
Immunoglobulin A in the mesangium (Szeto and Li, 2014). Research on miRNAs in urine of IgAN 
patients detected decreased abundance of miR-200a, miR-200b and miR-429 (mir-8 family) and 
correlated with disease severity and rate of progression. Decreased urinary levels of miR-429 were 
also found to be correlated to an increased rate of renal function decline (Wang et al., 2010a). 
Furthermore, it has been shown that increased levels of miR-146a and miR-155 in urine and tissue are 
associated with reduced production of pro-inflammatory cytokines interleukin IL-1β, IL-6 and tumor 
necrosis factor TNFα, molecules involved in the pathogenesis of IgAN (Wang et al., 2011b, Faraoni 
et al., 2009, Qu et al., 2014).  
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 Wang et al. demonstrated that the levels of urinary miR-10a and miR-30d were elevated in 
patients suffering from FSGS compared to healthy donors (Wang et al., 2012c). MiR-10a and miR-
30d are reported as kidney specific miRNAs serving a protective role against kidney tissue injuries by 
targeting IL-12/IL-23p40 (Xue et al., 2011), the pro-apoptotic protein Bim (Chu et al., 2014), 
apoptotic caspase CASP3 (Li et al., 2012) and tumor suppressor gene p53 (Kumar et al., 2011).  
In another report, urinary miR-155, miR-196a, miR-30a-5p, and miR-490 levels have been 
shown to increase in FSGS patients compared to healthy controls, and moreover miR-196a, miR-30a-
5p, and miR-490 levels significantly decreased in FSGS patients under treatment with steroids, a 
common immunosuppressive therapy employed in FSGS patients leading to remission (Ren et al., 
2013), suggesting a potentially predictive use for the response on steroid therapy (Zhang et al., 2014).  
  
2.9. Conclusion 
 CKD is an ongoing worldwide burden in public health. It affects the quality of life of millions 
of people, placing CKD as the fastest growing causes of premature death worldwide. The main issues 
remain the heterogeneity of the disease and the lack of tools for efficient diagnosis and prognosis. 
miRNAs have been shown to play a key role in different pathological conditions, including CKD, and 
could serve as biomarkers and/or therapeutic targets. Urinary miRNAs may also serve as non – 
invasive biomarkers, a tool needed for accurate and fast diagnosis and prognosis of CKD, to replace 
kidney biopsies.  
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3. OBSTRUCTIVE NEPHROPATHY AND miRNAs 
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3.1 Introduction 
In contrast with CKD in adults, which for the greater part originates from T2D and 
hypertension (Zhu et al., 2007), the most common cause of CKD in children are congenital anomalies 
of the kidney and the urinary tract (CAKUT) counting for more than half of the incidence of CKD in 
children. Furthermore congenital obstructive nephropathy (CON) is the main cause of ESRD in 
children (Thompson et al., 2015).  
 
3.2 Ureteropelvic junction (UPJ) obstruction 
 
The most frequent cause of congenital urinary tract obstruction is ureteropelvic junction (UPJ) 
obstruction with an estimated incidence of 1 in 1000–1500 (Chang et al., 2004). It is caused by a 
stenosis of the ureter at the connection point with the pelvis which prevents the normal flow of the 
urine to the bladder, resulting in severe cases of obstruction in hydronephrosis (enlargement of the 
kidney because of urine accumulation (National Kidney, 2002) (Figure 14).  
 
 
Figure 14:  A stenosis of the ureter at the connection point with the pelvis results in obstructive nephropathy. 
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3.2.1 Histological and functional changes in UPJ obstruction  
 
The histological alterations of the kidney varies greatly in UPJ obstruction ranging from subtle 
changes such as modified proximal or tubular size, chronic tubulointerstitial injury, 
glomerulosclerosis, fibrosis, aberration of nephron development and in severe cases (less than 1%) 
renal dysplasia (German et al., 2008). Altogether, reduction of nephrogenesis associated with 
glomerular and tubular apoptosis lead to a significant reduction in the number of functional nephrons 
(Addo-Quaye et al., 2008, Llave et al., 2002). All these changes affect the function of the kidney by 
reducing the renal blood flow, the glomerular filtration rate and the reabsorption of water and solutes 
from the tubules (e.g. sodium reabsorption, solute-free water) (Klein et al., 2011).   
A list of histological lesions modifications and functional modifications in obstruction is 
summarized in figure 15.  
 
 
 
Figure 15: UPJ obstruction: histological modifications and functional modifications in obstruction (Klein et 
al., 2011) 
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3.2.2 Diagnosis and management of UPJ obstruction 
 
The gold standard in diagnosis of UPJ obstruction is by prenatal ultrasonography with 
subsequent evaluation in the postnatal period (Chevalier, 2015b). However, this method is not 
sensitive enough to accurately estimate renal function and functioning nephron number (Waikar et 
al., 2009). Approximately 5% of pregnancies are diagnosed with fetal hydronephrosis, but after birth 
most infants do not show signs of obstruction, while around 1.5% of the initial screening population 
may need long term health care (Parving et al., 2015, Mischak et al., 2015). This uncertainty on the 
severity of the status of the obstruction has led to a debate among the nephrologists and pediatricians 
about the necessity and the time to perform corrective surgery, pyeloplasty. On one hand, surgery, and 
especially surgery on infants and babies is not innocuous. On the other hand, a “wait and see” 
approach in order to allow the full development and stability of the kidney bears the risk of waiting too 
long, and to damage parts of the kidney. This has led to an urgent need for the development of 
biomarkers to assess the severity of UPJ obstruction and to help the clinicians to decide if and when 
pyeloplasty is required (Chevalier, 2015b, Chertin et al., 2006).  
Furthermore, it is becoming increasingly clear that patients with congenital urinary tract 
obstruction must be followed into adulthood, as the lesions can progress over the entire life and the 
optimal biomarkers need to be age-specific to follow all stages of a patient’s development from birth 
to childhood and adulthood (Zhu et al., 2007, Chevalier, 2016). To this direction, a panel of 53 
urinary polypeptides has been proposed as a marker to estimate the severity of the obstruction and the 
immediate need for pyeloplasty or not (Varadhachary et al., 2011, Mueller et al., 2011). Finally, a 
label-free quantitative urinary proteomics study in individuals with UPJ obstruction and in mouse 
model of obstructive nephropathy suggested that the arginine metabolism is disturbed in obstructive 
nephropathy (Meiri et al., 2012). 
 
3.2.3 Animal models for better understanding of the pathophysiology of UPJ obstruction 
 
Due to the fact that limited human kidney samples are available, almost all observations on the 
pathophysiology of UPJ obstruction are based on animal models, which potentially limit the 
transferability of the observations in the clinical context. As a consequence, the pathophysiological 
mechanisms of UPJ obstruction remain incompletely understood, even though the modifications of the 
renal lesions in UPJ obstruction are known (tubular proliferation/apoptosis, renin-angiotensin system 
activation, inflammation, and fibrosis) (Klein et al., 2011, Chevalier, 2015b, Chevalier et al., 2014, 
Meiri et al., 2012).  
One factor for the lack of understanding of the mechanisms is the difference in the development of 
the kidney in human and mice and rats. Humans are born with fully developed urinary system (kidney, 
urinary tract etc.) while in mice and rats it is finalized after birth until 18
th
 postnatal day (Nishimura et 
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al., 1999). To study the outcomes of obstruction, surgical animal models of unilateral ureteral 
obstruction (UUO) have been developed in adult rodents and mice. These models are excellent to 
study tubulointerstitial fibrosis in severe obstruction, but fail to recapitulate what happens during the 
development of the kidney in which obstruction can interfere with kidney morphogenesis, growth and 
maturation (Ong et al., 2002).  
In order to better mimic UPJ in the developing kidney, two rodent models of UUO have been 
developed in neonatal mice or rats. The first is complete UUO, achieved by a simple suture ligation of 
the ureter to mimic severe UPJ obstruction, progressing fast to hydronephrosis and loss of renal 
parenchyma (65%). Complete UUO in neonatal mice impairs nephron maturation and tubular 
oxidative stress, activates intrarenal renin-angiotensin system, promotes the production of TGF-β and 
fibrosis and as the injury progresses macrophages and fibroblasts are also entering the game (Zhu et 
al., 2007, Chevalier, 2016). The second UUO model, which mimics better the conditions during 
human kidney development with obstruction, is the partial neonatal UUO. A stainless steel wire of 
known diameter is placed in parallel to the ureter, followed by ligature of both the ureter and the 
stainless steel wire. Once the wire is withdrawn the result is a well calibrated partial obstruction. This 
technique offers reproducibility and by choosing the diameter of the wire, control of the severity and 
the duration of the obstruction (Hafner et al., 2010). Experiments also revealed that individual 
nephron responses to partial neonatal UUO in the developing kidney are heterogeneous, with some 
nephrons showing reduced tubular fluid flow, while others maintain their normal function (Kulkarni 
et al., 1971).  
 
3.3 miRNAs in Obstructive nephropathy 
Few reports are available on miRNAs and their role in obstructive nephropathy and all studies 
used the complete adult UUO model. Most reports focus on the role miRNAs have to control the TGF-
β/Smad pathway responsible for kidney fibrosis (Chevalier, 2016). In particular, Li et al. observed 
that miR-483-5p and miR-483-3p may be involved in renal fibrosis development in the adult mouse 
model of complete UUO by promoting the expression of their host gene Igf2 and other cytokines (Li 
et al., 2015b). Two reports support the therapeutic potential of the use of miRNAs against renal 
fibrosis using the complete adult UUO model. In both reports, miRNAs were injected in the tail vein 
during UUO (mimic of miR-34c and polyethylenimine nanoparticles with miR-146 respectively) and 
in both occasions renal fibrosis attenuation was observed (Morizane et al., 2014, Morishita et al., 
2015). Administration of mimic-34c led to decrease of the kidney fibrosis area, inhibition of EMT and 
the expression of fibrotic molecules including connective tissue growth factor, α-SMA, collagen type 
1, collagen type 3 and fibronectin (Morizane et al., 2014), while administration of miR-146 contained 
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renal fibrosis by inhibiting the transforming growth factor beta 1–Smad and tumor necrosis factor 
receptor-associated factor 6–nuclear factor kappa B signaling pathways (Morishita et al., 2015).  
 There are also reports that correlate miRNAs with development of CAKUT, not necessarily 
caused by obstructive disease. For example, Medrano et al. showed that miR-143/145 deficient mice 
developed hydronephrosis rapidly after birth (within 2 weeks) due to abnormal ureter peristalsis but 
without any obvious signs of obstruction (Medrano et al., 2014). Interestingly, one of the most 
important reports on the key role the miRNAs have in kidney development that could lead to CAKUT 
was by Bartram el al. In this report, knocking down Dicer (the protein responsible to produce the 
mature miRNA during miRNA-biogenesis) in embryotic mice resulted in alterations in morphology of 
the kidneys, the ureters and reduction in tubular branching (Bartram et al., 2013). Further reports 
from the same team on Dicer and Drosha/Dgcr8 complex revealed that any obstacle in the biogenesis 
process of miRNAs can lead to poor development of renal structure and function (Bartram et al., 
2016).  
 Finally, since obstructive nephropathy is characterized by fibrosis, miR-21 could not be absent 
from studies related to UUO. The activation of the TGF-β/Smad signaling promotes the expression of 
miR-21 in UUO mouse model and blocking miR-21 in a UUO model reduced the deposition of 
collagen, fibronectine, SMA-a and PAI-1 and macrophage infiltration, molecules that are up-regulated 
in fibrosis, showing, in total, not only the key role of miR-21 in fibrosis and UUO but also the 
therapeutic value of the inhibition of this miRNA (Zarjou et al., 2011). 
 
3.4 Conclusion 
The main risk factor leading to pediatric kidney disease is obstructive nephropathy due to 
developmental disease. The challenge of research is to enrich the limited knowledge and 
understanding on the pathological mechanisms responsible for obstructive nephropathy true the use of 
UPJ obstruction models. To this direction are focused the experiments on the animal model closest to 
human pathology, the partial UUO mouse model. A second challenge deriving from the use of the 
UUO animal model is the transferability of the results to human pathology. Finally, there is a strong 
need for non-invasive biomarkers which can diagnose and predict with high specificity and sensibility 
the severity of the condition of the kidney in an infant or a child and guide the nephrologist to the 
correct decision for monitoring and treatment.  
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4. OBJECTIVE OF THE THESIS 
miRNAs are now recognized as key players in the regulation of proteins and any abnormality in their 
function is a cause for pathway instability, leading to pathological conditions. Numerous reports from 
a variety of pathologies provide new data about miRNAs function, their targets, their potential as 
biomarkers and possible ways to control miRNAs’ expression for potential therapeutic purpose.  
A number of reports connect miRNAs with pathological conditions in the kidney and point to the use 
of miRNAs as biomarkers for diagnosis and prognosis of kidney disease in blood, serum, tissue and 
urine samples. In this thesis, we researched: 
1)  a possible role of the miRNAs in the progression of adult CKD, a disease representing a global 
burden with the tendency to rise worldwide. Progression of CKD is still very hard to detect non-
invasively with the currently used clinical tools (eGFR and albuminuria). In our work we attempted to 
identify alterations of the level of the miRNAs in human urine samples and characterize a panel of 
miRNAs as biomarkers for non-invasive progression of CKD.  
2) the presence of urinary miRNAs associated to obstructive nephropathy, a frequently encountered 
disease in children that can lead, in severe cases, to early ESRD. In this study we used a 
comprehensive system biology study in which we combined mi- and mRNA data from human and 
animal obstructive nephropathy to obtain information on possible mechanisms involved in obstructive 
nephropathy.   
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5. ASSOCIATION OF URINARY MIR-145 TO PROGRESSION OF 
CHRONIC KIDNEY DISEASE.  
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5.1. The context of this study: The iMODE – CKD project.  
iMODE-CKD (Clinical and system –omics for the identification of the MOlecular DEterminants of 
established Chronic Kidney Disease) is a European Project which integrates multi-disciplinary 
expertise in proteomics, metabolomics, transcriptomics, bioinformatics, pathology, and clinical 
science from leading academic and industrial investigators, establishing a unique training platform on 
biomarker research and Systems Biology. The main goals of the iMODE-CKD are to improve the 
quality of life of patients with chronic kidney disease (CKD) and diminish the severe health and 
economic burden imposed by this disease, by providing better diagnostic and prognostic means. In 
order to do so, we aimed to identify and validate molecules involved in progression of renal 
complications trough clinical –omics in established CKD and to understand the molecular 
determinants of established CKD through integrative Systems Biology.  
As part of iMODE - CKD this study focused on miRNA modifications in urine samples of established 
CKD patients and correlate their expression profiles to disease progression. Global miRNA was 
detected by Next Generation Sequencing (NGS). Differentially expressed miRNAs in relation to CKD 
progression that survive multiple testing were validated using Applied Biosystems low-density 
miRNAs arrays  in a new set of patients. Targets of validated differentially expressed miRNAs were 
selected using pathway analysis and correlated to proteomics changes. The most significant miRNA-
mRNA/protein correlations were validated in renal HK2 cells by modification of expression of 
selected miRNA (antagomers) and study of effects on target mRNAs. 
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5.2 ABSTRACT 
 
Chronic kidney disease (CKD) has become one of the major non-communicable diseases and its 
management implies early detection and identification of individuals that display progressive disease. 
Body fluid miRNAs have been increasingly found to be associated to (kidney) disease and might serve 
as markers of CKD progression as well. In this study, using Next Generation Sequencing, we analyzed 
urinary miRNA modifications in urine samples of 70 patients with established CKD, 35 non-
progressors (≤2% reduction and ≤4.5% increase of estimated glomerular filtration rate (eGFR) slope 
per year) and 35 progressors (≥3.3% reduction of eGFR slope per year). We correlated the miRNA 
expression profiles to disease progression. This lead to the identification of 24 urinary miRNAs that 
were significantly associated to CKD progression. The combination of the 24 miRNAs with 142 
proteins, found statistically different in the same cohort of samples, led to the selection of 4 miRNAs 
for validation in a new cohort of 52 patients (19 non-progressors and 33 progressors). Among these 
four, we validated the increased abundance of hsa-miR-145-5p in urine of patients with progressive 
CKD using Taqman based technologies. Urinary abundance of hsa-miR-145-5p was significantly 
inversely correlated to eGFR decline (r=-0.5, p=0.02) and showed a possible predictive marker value 
(AUC 0.733). Proteome analysis of HK2 kidney cells with artificially reduced expression of hsa-miR-
145-5p predicted an association of this miRNA to necrotic processes. In conclusion we have identified 
hsa-miR-145-5p as potential urinary miRNA marker of CKD progression that could be linked via its 
targets to CKD progression.  
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5.3 INTRODUCTION 
Chronic kidney disease (CKD) is a general term for kidney failure classified into 5 stages 
defined by the decline in the glomerular filtration rate (GFR) (Levin and Stevens, 2014). It is 
characterized by the progressive loss of kidney function and is considered as a global major health 
burden and is associated with high-cost of treatment (Jha et al., 2013). The Global Burden of Disease 
study data (GBD2013) (De Nicola and Minutolo, 2016) showed that CKD was the fastest growing 
non-communicable cause of death. Multiple factors contribute to the incidence and prevalence of the 
disease, including age, diabetes, hypertension, obesity, smoking and autoimmune diseases (Jha et al., 
2013). CKD is most frequent in elderly with around two thirds of persons aged 80, or more, having 
CKD (Stevens et al., 2010). Progression of CKD ultimately leads to end-stage renal disease (ESRD) 
which occurs when the kidneys functions are impaired to a very large degree and thus cannot support 
everyday needs of the organism. When a patient reaches ESRD, he or she has to undergo kidney 
transplantation or dialysis to survive. 
The main issues in CKD management are 1) the early detection of disease in patients at risk 
(i.e. in individuals with diabetes, hypertension, etc) and 2) the identification of patients with already 
established CKD that will (rapidly) progress towards ESRD (Ecder, 2013, Lutz et al., 2014). 
Identification of individuals with CKD is currently depending on a reduced estimated GFR (eGFR) 
(Coresh et al., 2014) and/or increase of urinary albumin excretion (Parving et al., 2015). However, 
even if routinely used in the clinic, albuminuria often falls short to identify individuals with 
progressive CKD and several eGFR measurements are necessary to firmly establish disease 
progression (Pontillo et al., 2016). To tackle this issue, several putative urine and plasma biomarker 
candidates for the estimation of CKD progression have emerged. The most classical example is 
proteinuria. However, proteinuria may lack appropriate specificity, as its variability (especially in the 
case of response to treatment) indicates that it may be an appropriate surrogate for progression only in 
some kidney diseases (Levey et al., 2009). Other prominent examples of biomarkers include: 
neutrophil gelatinase-associated lipocalin, kidney injury molecule-1 (KIM-1), liver-type fatty acid 
binding protein, fibroblast growth factors or tumour necrosis factor receptor 1 and 2 (Fassett et al., 
2011, Looker et al., 2015, Rebholz et al., 2015, Krolewski et al., 2014, Addo-Quaye et al., 2008, 
Devarajan, 2010, Hojs et al., 2015, Bhavsar et al., 2012). The clinical utility of these putative 
predictive biomarkers is currently evaluated and, as in the case of KIM-1 (Bhavsar et al., 2012), the 
obtained results seem inconclusive, questioning their added value for the prediction of CKD 
progression. Therefore the field can benefit from the development of more sensitive and reliable 
biomarkers of CKD progression.  
MicroRNAs (miRNAs) are small non-coding RNAs (20 - 24 nt) that regulate gene expression 
by blocking the translation of mRNAs into proteins and are involved in multiple molecular pathways 
and pathologies. MiRNAs are now considered promising molecules for biomarkers and/or targeted 
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therapy of multiple diseases (Hammond, 2015, Almeida et al., 2011, van Rooij and Kauppinen, 
2014, Esteller, 2011). Significant variations in urinary miRNA abundance have been associated to 
different CKD etiologies including diabetic glomerulosclerosis (decrease of miR-15), IgA 
nephropathy (increase miR-17) and hypertensive nephrosclerosis (increase of miR-21 and miR-216a) 
(Szeto et al., 2012). A number of specific miRNAs, known to be associated to renal fibrosis (a 
hallmark of CKD), including miR-192, miR-29a, miR-29b, miR-29c and miR-200a, miR-200b and 
miR-200c, displayed reduced urinary abundance in CKD (Lv et al., 2013b, Szeto et al., 2012). In 
contrast, miR-21 is considered as a pro-fibrotic miRNA with increased urinary abundance in renal 
fibrosis (Zununi Vahed et al., 2016). 
These observations suggest that studying urinary miRNAs in CKD progression might help to 
understand the development of CKD progression and/or provide markers for prognosis. Here we 
studied urinary miRNAs in a total of 122 patients with established CKD using Next Generation 
Sequencing (NGS) and TaqMan Low Density Arrays (TLDA) in combination with proteomics 
analysis to identify urinary miR-145 as potentially being associated to CKD progression. Proteome 
analysis from human renal HK2 cells treated with an agent blocking the action of miR-145 
(antagomir) combined with pathway analysis revealed the association of this miRNA with necrotic 
processes.     
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5.4 MATERIALS AND METHODS 
 
Study design and population: 
 
Discovery set 
A matched retrospective cohort study was conducted. The source population consisted of 491 patients 
aged from 17 years to 89 years old attending the Nephrology Outpatient Clinic at Ghent University 
Hospital, Ghent, Belgium (the “Ghent cohort”). Patients were recruited during their referrals at the 
Clinic. Patients with renal transplantation or receiving renal replacement therapy (hemo- or peritoneal 
dialysis) were excluded. Samples were collected in the period of 17/01/2011 to 07/07/2015. Sample 
collection was performed in accordance to local ethics requirements and the study was approved by 
the local ethics committee. All individuals gave written informed consent under Institutional Review 
Board approved protocols. Second morning mid-stream urine samples were collected. To remove cell 
debris, urine samples were centrifuged at 1,000xg for 10 min at 4˚C. To reduce freeze-thaw cycles, 
samples were aliquoted in 500 μL and stored at -20˚C. In cases protein precipitation occurred, prior to 
the protein concentration measurement with Bradford method, 10 to 20 μL of 1M ammonia solution 
(pH 10) was added to dissolve the precipitate. 
The following clinical and laboratory measurements were collected for all participants: eGFR 
and CKD-stage, follow-up serum creatinine measurements, baseline and last follow-up date, number 
of time-points (referrals), annual % changes in eGFR slope and use of medication. Estimated 
glomerular filtration rate (eGFR) was calculated using the CKD-EPI equation (Florkowski and 
Chew-Harris, 2011). 
Of the original study population, 183 patients were excluded from the analyses as they 
displayed tubulointerstitial diseases, familial/hereditary nephropathies, and/or malignancies. 
Additional 44 patients were excluded as they did not have sufficient follow-up data, including at least 
3 serum creatinine measurements and 2 years of clinical follow-up.  
For the purpose of the study, progressors were defined as CKD patients with ≥3.3% reduction 
of eGFR slope per year (according to (Merchant et al., 2009)), while non-progressors were defined as 
CKD subjects with ≤2% reduction and ≤4.5% increase of eGFR slope per year.  
Progressors were matched to non-progressors for multiple variables as sex, age, body mass index, 
pulse, systolic blood pressure, diastolic blood pressure, presence of diabetes, baseline serum creatinine 
and baseline eGFR leading to the selection of 70 patients including 35 non-progressors and 35 
progressors as the final selection (Table 1). Statistical difference in the use of drugs between 
progressors and non-progressors was observed. Significantly more progressor patients were receiving 
the following drugs: angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers 
(ACEi and ARB; p=0.04), statins (p=0.01) and vitamin D (p=0.03). As expected, progressors showed 
a significantly higher average last follow-up creatinine concentrations and lower average last follow-
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up eGFR (Table 1). A detailed description of the study population is presented in Supplementary 
Table 1A.  
 
Table 1: Comparison of clinical data for CKD progressors compared to non-progressors of the discovery 
set. The patients are matched for gender, age, BMI, pulse, systolic blood pressure, diastolic blood pressure, 
presence of diabetes, baseline serum creatinine, and baseline eGFR. The patients were not matched for drug use. 
* denotes significant difference (p ≤ 0.05). 
 
Variable 
All 
samples 
n=70 
Non-
progressors 
n=35 
Progressors 
n=35 
p-value Mann-
Whitney 
% change in eGFR/year (mean ± SD) -6.7±9.1 0.3±1.5 -13.7±7.9 0.0001* 
Gender [F/M] 23/47 11/24 12/23 0.81 
Age [years] 65±15 63±15 67±15 0.10 
Body Mass Index [BMI] 29±5 29±5 30±5 0.25 
Systolic blood pressure [mmHg] 138±18 133±18 144±18 0.02* 
Diastolic blood pressure [mmHg] 79±9 80±7 78±10 0.14 
Pulse 68±12 67±11 69±13 0.56 
Diabetes [Y/N] 25/45 11/24 14/21 0.47 
Baseline Serum creatinine [mg/dl] 1.6±0.5 1.6±0.5 1.7±0.6 0.32 
Baseline eGFR [ml/min/1.72] 46±19 49±19 42±18 0.10 
Last follow-up serum creatinine [mg/dl] 2.1±1.2 1.5±0.5 2.6±1.5 0.0002* 
Last follow-up eGFR [ml/min/1.72] 39±20 49±19 28±15 0.0001* 
Drug use 
ACEi and ARB [Y/N] 60/10 27/8 33/2 0.04* 
Statins [Y/N] 53/17 22/13 31/4 0.01* 
Anticoagulants [Y/N] 10/60 3/32 7/28 0.17 
Vitamin D [Y/N] 27/43 9/26 18/17 0.03* 
 
 
Validation set 
The validation cohort was comprised of patients from the Ghent cohort (see discovery) and the 
CKD-BIO cohort. The CKD-BIO cohort consists of 155 patients with CKD attending various clinical 
centers across the Europe (Belgrade, Leipzig, Reggio Calabria, Wroclaw, Madrid, Prague, Napoli, 
Nicosia, Tirana, Timisoara, Rijeka and Skopje). Sample collection began at 28/03/2012 and is still 
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ongoing. All sample collection procedures were performed in accordance to local ethics requirements 
and the studies were approved by local ethics committees.  
To obtain the largest number of samples for validation the follow-up criteria were relaxed 
compared to the selection of the discovery cohort. Patients were included if at least 2 serum creatinine 
measurements were available for a minimum follow-up of one year. Moreover, patients reaching 
hemodialysis during follow-up period were also considered as progressors. This lead to the selection 
of 13 non-progressors and 11 progressors from the Ghent- and 6 non-progressors and 22 progressors 
from the CKD-BIO cohort yielding a total of 19 non-progressors and 33 progressors. 
The following clinical and laboratory measurements were collected for all validation set 
participants: eGFR measurements by CKD-EPI equation, CKD stage by CKD-EPI equation, follow-up 
serum creatinine measurements, baseline and last follow-up date, number of time-points (referrals), 
annual % changes in eGFR slope and use of medication (Supplementary Table 1B). The cohort was 
not matched for any factors prior to the analysis, as in the case of discovery set. Nevertheless, no 
significant difference in gender distribution, age, diabetes, baseline serum creatinine, baseline eGFR or 
use of medicaments was observed (Table 2). Significant difference between CKD progressors and 
non-progressors was observed in the case of last follow-up serum creatinine and last follow-up eGFR.  
 
Table 2: Comparison of clinical data for CKD progressors compared to non-progressors of the validation 
set. The patients show no statistical difference in case of gender, age, presence of diabetes, baseline serum 
creatinine, baseline eGFR values and use of medicaments. * denotes significant difference (p ≤ 0.05)  
 
Variable 
All samples 
n = 52 
Non-
progressors 
n = 19 
Progressors 
n = 33 
p-value 
Mann-
Whitney  
% change in eGFR/year (mean ± SD) -13.8±21.7 2.1±3.3 -23.6±22.4 0.0001* 
Gender [F/M] 16/36 6/13 10/23 0.93 
Age [years] 58±17 57±16 58±18 0.85 
Diabetes [Y/N] 11/41 4/15 7/26 0.98 
Baseline Serum creatinine [mg/dl] 1.70±0.80 1.38±0.43 1.89±0.91 0.09 
Baseline eGFR [ml/min/1.72] 50.9±23.7 58.1±21.0 46.9±24.5 0.09 
Last follow-up serum creatinine [mg/dl] 2.1±1.4 1.4±0.5 2.6±1.6 0.00024* 
Last follow-up eGFR [ml/min/1.72] 43.6±23.7 58.0±21.8 34.8±20.5 0.00065* 
Drug use 
ACEi and ARB [Y/N] 36/16 12/7 24/9 0.49 
Statins [Y/N] 21/31 6/13 15/18 0.33 
Anticoagulants [Y/N] 3/35 1/18 4/29 0.38 
Vitamin D [Y/N] 14/38 5/14 9/24 0.94 
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RNA extraction (discovery and validation cohort) 
Total RNA from the urine samples was extracted using Illumina’s MasterPure RNA extraction 
kit according to manufacturer’s guidelines. In detail, 500 μl of lysis solution (provided by Illumina’s 
extraction kit) was added to the 500 μl of urine sample together with 3.5 μl of 50 μg/μl Proteinase K 
(Thermo Fisher Scientific) followed by incubation at 65
o
 C for 15 min. Next, 585 l of MPC Protein 
Precipitation Reagent (provided by Illumina’s extraction kit) were added, mixed, followed by 
centrifugation at 4°C for 10 minutes at ≥10,000 x g  to pellet the debris. The supernatant was 
transferred to 15 ml falcon tubes and the pellet was discarded. This step was repeated two times. In the 
recovered supernatant 1700 l of isopropanol was added followed by multiple inversions of the tube 
and by centrifugation at 4°C for 30 minutes at ≥4,000 x g in a microcentrifuge to pellet the nucleic 
acids. Then, the isopropanol was poured off and the total nucleic acid pellet was washed with 200 - 
250 μl of 70% ethanol. Finally, the total nucleic acids were resuspended in 30μl of H2O and stored in -
20°C.   
 
Next Generation Sequencing and data analysis (discovery cohort) 
 
Library preparation and sequencing 
The RNA quality and RNA concentration of each sample was performed using a Fragment 
Analyzer (Advanced Analytical Technologies). The sequencing library was built using the Illumina® 
Truseq small RNA Sample Prep Kit according to kit protocol “Truseq small RNA Sample 
Preparation” (15004197bRev. D). The obtained small RNA library of fragment length of 
approximately 150 bps was sequenced using the Illumina HiSeq 2500 platform.  
 
Data processing 
Clean sequenced reads were obtained by removing adapter sequences using Trimmomatic 
v0.30. Reads and were aligned against the human reference sequence GRCh37.75 using TopHat 
v.1.4.0 with Bowtie v.0.12.7. Feature counting of miRNAs was performed using HTSeq v.0.6.1p1 
tools providing miRNA annotation in GTF format adapted from Ensembl Homo sapiens annotation 
v.75. The obtained miRNA expression data was used as the source file for downstream statistical 
analysis to determine differential expression of miRNAs using the DESeq package v.1.10.1 from the R 
statistical computing software.  
 
TaqMan low-density microRNAs arrays and statistical analysis (validation cohort) 
For the validation phase, the Custom TaqMan® Array MicroRNA Cards of Applied 
Biosystems (Publication Part Number 4478705) were used according to manufacturer’s protocol. In 
brief, total RNA was extracted as mentioned above with Illumina’s MasterPure RNA extraction kit. 
Next, by using 3μl of total RNA, a reverse transcription was performed with the custom RT Primer 
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Pool (Applied BioSystems, 30 min at 16
°
C, 30 min at 42
°
C, 5 min at 85
°
C and pause at 4
°
C in a 
ThermoCycler). Next, 2.5μl of the RT product was used for the preamplification reaction with 
TaqMan® PreAmp Master Mix and Custom PreAmp Primer Pool (Applied BioSystems, 10 min at 
95
°
C, 2 min at 55
°
C, 2 min at 72
°
C, 12 cycles of 15 sec at 95
0°
C followed by 4 min at 60
°
C, 10 min at 
99.9
°
C and finally, pause at 4
0
C in the Thermocycler). The preamplified product was diluted 1/20 with 
the PCR Master Mix (Applied BioSystems) and nuclease-free water and applied to Custom TaqMan® 
Array MicroRNA Cards. Analysis was performed using an Applied Biosystems 7900HT/7900HT Fast 
Real-Time PCR System with default settings.  The analysis of the results was performed using Thermo 
Fischer Cloud 2.0.   
 
 
Urine sample preparation for LC-MS/MS analysis (discovery cohort) 
  
Five hundred μL of urine samples were processed following the FASP protocol, as described 
previously (Filip et al., 2015) with minor modifications. Specifically, if protein concentration was 
below the limit of detection for Bradford assay (≤0.2 μg/μL), 0.25 μg of trypsin per sample was added. 
Additionally, after peptide digestion, the concentration of peptide mixture in the sample was estimated 
using NanoDrop 2000 spectrophotometer (Thermo Scientific). The peptide mixture was lyophilized 
and stored at -20°C before reconstituted and loaded onto the LC-MS/MS column. 
 
LC-MS/MS analysis 
Eight μg of protein digest were loaded onto a Dionex Ultimate 3000 RSLS nano flow system 
(Dionex, Camberly UK). After loading onto a Dionex 0.1×20 mm 5 μm C18 nano trap column at a 
flow rate of 5 μl/min in 0.1% formic acid and 2% acetonitrile (ratio 98:2), samples were applied onto 
an Acclaim PepMap C18 nano column 75 μm×50 cm, 2 μm 100 Å at a flow rate of 0.3 μl/min. The 
trap and nano flow column were maintained at 35°C. The samples were eluted with a gradient of 
solvent A: 0.1% formic acid versus solvent B: 80% acetonitrile starting at 1% B for 5 min rising to 5% 
B at 10 min then to 25% B at 360 min and 65%B at 480 min. 
The eluent was ionized using a Proxeon nano spray ESI source operating in positive ion mode 
into an Orbitrap Velos FTMS (Thermo Finnigan, Bremen, Germany). Ionization voltage was 2.6 kV 
and the capillary temperature was 200°C. The mass spectrometer was operated in MS/MS mode 
scanning from 380 to 2000 amu. The top 20 multiply charged ions were selected from each scan for 
MS/MS analysis using HCD at 40% collision energy. The resolution in MS1 was 60,000 and 7,500 at 
m/z for HCD in MS2.  
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Protein identification and data processing 
Protein identification and data processing was performed as previously described in (Filip et 
al., 2015), with minor modifications. Specifically after merging of obtained sequences from all 70 
analyzed samples and application of “Occam-Razor” rule for assigning of peptides to proteins, we 
considered for further differential expression and pathway analyses only peptides reported in more 
than 60% of the samples in at least one of the compared groups (22 out of 35 samples in at least one 
group). 
Protein peak area was calculated based on the average peak area of top three most abundant 
peptides for a given protein. Subsequently, protein peak areas were normalized based on parts per 
million normalization followed by urine creatinine normalization, as follows: 
                      
                                            
                             
      
                              
                    
                               
  
   
 
 
Cell models and antagomir treatment  
Human HK-2 cells were grown in a DMEM/F-12 Nut Mix medium supplemented with 10% 
heat-inactivated fetal calf serum (FCS; GIBCO, Grand Island, NY, USA), 10 µg/mL of EGF, 5 µg/mL 
of insulin, 4 pg/mL Triiodothyronine (T3), 36ng/mL of hydrocortisone. After 24 hours of FCS 
starvation, HK-2 cells were transfected with 5 nmol IDT

 miRNA inhibitor targeting hsa-miR-145-5p 
(Exiqon miRCURY LNA Inhibitor, sequence: 5’-CGATTCCTGGGAAAACTGGA-3’) or with 
scrambled siRNA (Exiqon miRCURY LNA Inhibitor Control, sequence: 5’-
TAACACGTCTATACGCCCA-3’), using the DharmaFECT Duo transfection reagent (Dharmacon, 
Lafayette, CO, USA).  
 
Protein extraction and GeLC-MS sample preparation protocol  
For protein extraction, cell pellets were re-suspended in isoelectric focusing sample buffer containing 
7M Urea (ApliChem Inc., Missouri, USA), 2M Thiourea (Fluka, Sigma Aldrich Co., St. Louis USA), 
4% w/v CHAPS (ApliChem Inc., Missouri, USA), 1% w/v DTE, (Sigma Aldrich Co., St. Louis USA) 
and 2% v/v IPG ampholytes (BioRad Laboratories Inc., CA, USA). The cells were sonicated for 15 
minutes in a bath sonicator followed by centrifugation at 16.000 rcf for 20 min at RT to collect the 
supernatants. Protease inhibitors 3.6% v/v (Roche) were added to the extracts and the protein 
concentration was determined by Bradford assay (BioRad Laboratories Inc., CA, USA). 
Next, 10 μg of the sample were loaded on SDS PAGE (5% stacking, 12% separating) and the 
electrophoresis was stopped when the samples just entered the separating gel. The gels were fixed with  
30% v/v Methanol (Fisher)  10% v/v Acetic Acid for 30 min at room temperature followed by wash 
with water (2x10 min washes). Gels were stained with coomassie colloidal blue stain o/n at RT. After 
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washing the gels with water, the protein bands were excised from the gels and were sliced in small 
pieces (1-2mm). Gel pieces were destained with 40% Acetonitrile, 50mM NH4HCO3, reduced with 
10mM DTE in 100mM NH4HCO3 for 20 min at room temperature,and alkylated with 10mg/mL 
Iodoacetamide in 100mM NH4HCO3 for 20 min at room temperature, in the dark. After alkylation the 
samples were washed  with 100mM NH4HCO3 followed by another wash with 40% Acetonitrile, 
50mM NH4HCO3and a final wash with ultra pure water  was performed(20 min, at RT for each wash). 
Gel pieces were dried in a centrifugal vacuum concentrator (speed vac). Trypsinization was performed 
o/n at RT in the dark. 600ng of trypsin was added per sample (10ng/μL tryspin stock solution in 
10mM NH4HCO3, pH 8.5).  Finally, the peptides were extracted after incubation with 50mM 
NH4HCO3 for 15min, RT, followed by two incubations with 10% Formic Acid, Acetonitrile (1:1) for 
15 min, RT. The peptide solution was filtered with PVDF filters (Merck Millipore) and was dried in a 
centrifugal vacuum concentrator. Samples were stored at -20
o
 C until further use. 
 
LC–MS/MS analysis  
2.5 μg of protein digest were loaded onto a Dionex Ultimate 3000 RSLS nano flow system 
(Dionex, Camberly UK). After loading onto a Dionex 0.1×20 mm 5 μm C18 nano trap column at a 
flow rate of 5 μl/min in 0.1% formic acid and 2% acetonitrile, samples were applied onto an Acclaim 
PepMap C18 nano column 75 μm×50 cm (Dionex, Sunnyvale, CA, USA), 2 μm 100 Å at a flow rate 
of 0.3 μl/min. The trap and nano flow column were maintained at 35°C. The samples were eluted with 
a gradient of solvent A: 0.1% formic acid versus solvent B: 80% acetonitrile starting at 1% B for 5 
min rising to 5% B at 10 min then to 25% B at 180 min and 45% B at 240 min. The column was then 
washed and re-equilibrated prior to injection of the next sample.  The eluent was ionized using a 
Proxeon nano spray ESI source operating in positive ion mode into an Orbitrap Velos FTMS (Thermo 
Finnigan, Bremen, Germany). Ionization voltage was 2.8 kV and the capillary temperature was 250°C. 
The mass-spectrometer was operated in MS/MS mode scanning from 380 to 1,600 amu. The 
resolution of ions in MS1 was 60,000 and 15,000 for HCD MS2. The top 20 multiply charged ions 
were selected from each scan for MS/ MS analysis using HCD at 40% collision energy. AGC settings 
were 1,000,000 for full scan in the FTMS and 50,000 for MSn.  
 
Data processing 
Protein identification was performed using the SEQUEST search engine (Eng et al., 1994) 
(Proteome Discoverer 1.4, Thermo Scientific). Protein search was performed against the SwissProt 
human protein database (Bairoch and Apweiler, 2000) (30.05.2016) containing 20197 entries without 
protein isoforms. Trypsin was set as protease and two missed cleavage sites were allowed. Precursor 
mass tolerance was set to 10ppm and fragment mass tolerance to 0.05Da. Oxidation of methionine and 
carbamidomethylation of cysteine were set as variable and fixed modifications respectively. False 
discovery rate (FDR) was estimated with the percolator validation node included in the Proteome 
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Discoverer software package. FDR validation was based on q-value. Peptide identifications with false 
discovery rate >1% were discarded. Peptide rank was set to 1.  
 
Bioinformatics analysis  
Pathway analysis of the NGS data were performed using Ingenuity Pathway Analysis (IPA) 
software version 24390178 (IPA

, QIAGEN Redwood City, see http://www.Ingenuity.com). 
Statistical analysis was performed using GraphPad Prism v.5.01.   
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5.5 RESULTS 
 
Next Generation Sequencing (NGS) analysis identifies multiple urinary miRNAs associated to 
CKD progression  
NGS analysis of the urinary miRNA content was obtained from 35 matched patients with 
progressive CKD (≥3.3% reduction in eGFR slope/year) and 35 patients with non-progressive CKD 
(≤2% reduction and ≤4.5% increase in eGFR slope/year, Table 1, Supplementary Table 1A). When 
comparing the two groups, we identified 91 miRNAs with significantly (p<0.05) different urinary 
levels. Upon correction for multiple testing, 24 of the 91 remained significant (adjusted p-value of 
p<0.05) (Table 3, Supplementary Table 2). Eighteen miRNAs displayed increased and 6 decreased 
urinary abundance in progressors compared to non-progressors (Table 3).  
 
Table 3: List of the 24 miRNAs detected with NGS with significant difference (adj. Pvalue < 0.05) between 
progressors and non-progressors.  
 
miRBase 
Fold change (progressors/ 
non-progressors) 
Unadjusted            
p-value 
Adjusted                   
p-value 
hsa-miR-34c-5p 8,743 4,56E-21 3,16E-18 
hsa-miR-3200-5p 35,233 2,87E-09 0,000001 
hsa-miR-944 9,068 2,26E-08 0,000005 
hsa-miR-34b-3p 39,715 0,000001 0,000203 
hsa-miR-147b 0,727 0,000005 0,000586 
hsa-miR-410-3p 1,734 0,000005 0,000586 
hsa-miR-513c-5p Only in progressors 0,000007 0,000662 
hsa-miR-3928-3p 15,575 0,000017 0,001463 
hsa-miR-1289 Only in non-progressors 0,000027 0,001866 
hsa-miR-1323 Only in non-progressors 0,000027 0,001866 
hsa-miR-324-5p 0,301 0,000039 0,002478 
hsa-miR-3150a-3p 38,655 0,000072 0,004136 
hsa-miR-892c-3p Only in progressors 0,000104 0,005527 
hsa-miR-369-3p 4,228 0,000119 0,005891 
hsa-miR-301b-3p 3,377 0,000381 0,017592 
hsa-miR-449b-5p 3,815 0,000406 0,017592 
hsa-miR-651-5p 6,723 0,000548 0,022325 
hsa-miR-561-5p 1,198 0,000727 0,026699 
hsa-miR-708-5p 0,809 0,000732 0,026699 
hsa-miR-323b-3p 0,717 0,000896 0,029581 
hsa-miR-493-5p 15,238 0,000891 0,029581 
hsa-miR-487b-3p 4,172 0,001150 0,036223 
hsa-miR-145-5p 4,850 0,001387 0,041795 
hsa-miR-508-3p 3,241 0,001559 0,045015 
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Identified proteins and differential expression analysis 
The 70 urine samples (35 progressors and 35 non progressors) were analyzed by high-
resolution mass spectrometry and the resulting spectra were processed by Proteome Discoverer. After 
processing of the data by in-house software and ensuring of peptide consistency (as described in the 
Materials and Methods section), 344 proteins were found reproducibly identified and considered for 
differential expression analysis (Supplementary Table 3). 
A protein was considered as differentially expressed if its corrected p-value was ≤ 0.05 and its 
progressors/non-progressors ratio was ≤0.66 or ≥ 1.5. This resulted in identification of 142 
differentially secreted proteins, from which 34 were up-regulated and 108 down-regulated in CKD 
progressors compared to non-progressors (Supplementary table 3). Up regulated proteins included 
mainly highly-abundant plasma proteins (e.g. albumin, serotransferrin, vitamin D-binding protein), 
while down regulated proteins were more often related to biologically relevant functions in the context 
of CKD including inhibitors, receptors, peptidases and proteases (e.g. tumor necrosis factor receptor, 
plasma serine protease inhibitor, carboxypeptidase ). 
 
Pathway analysis enrichment revealed a relation with kidney pathology 
Pathway enrichment analysis of the 24 miRNAs and 142 proteins revealed that 7 miRNAs are 
predicted to regulate 15 proteins in molecular pathways including Acute Phase Response Signaling, 
Epithelial Adherens Junction Signaling, Regulation of the Epithelial-Mesenchymal Transition 
Pathway, TGF-β Signaling, Wnt/β-catenin Signaling, NF-κB Signaling and ILK Signaling and others 
that are linked with kidney pathology (Supplemmentary Table 4).  
When focusing on involvement in pathological mechanisms, miR-34c-5p, miR-145-5p and 
miR-301b-3p together with some of their targets showed to be potentially involved in kidney damage, 
including growth of epithelial tissue, differentiation and proliferation of the cells, apoptosis, necrosis 
and cell death (Supplementary Table 5).  
 
TaqMan low-density array analysis (TLDA) validates urinary miR-145-5p as associated to 
progression of CKD  
For the validation phase, we selected 4 from the 7 miRNAs that were predicted to target at 
least 2 proteins to increase the stringency of the selection. These miRNAs were miR-34c-5p, miR-145-
5p, miR-301b-3p and miR-401-5p (Table 4). The urinary abundance of the 4 selected miRNAs was 
evaluated in an independent cohort of 52 patients with CKD using TLDA (Table 2, Supplementary 
Table 1B). We also included in the analysis 1) two frequently used miRNAs for normalization in the 
literature, U6 snRNA and RNU48 and 2) the urinary miRNA showing the best normalization potential 
in CKD patients, hsa-miR-30a-5p, as it was detected with highest frequency (in all 70 samples) and 
displayed highest stability (smallest fold change between the groups) (Supplementary Table 2).  
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Table 4: The 4 miRNAs targeting at least 2 proteins that were selected for validation.  
 
Symbol Exp Fold Change Symbol Exp Fold Change 
miR-301b-3p 3.377 
EPHB4 -1.586 
IL6ST -3.173 
LDLR -1.671 
PTPRG -2.078 
TNFRSF1B -1.587 
miR-145-5p 4.850 
ACVR1B -2.278 
CDH2 -2.738 
EGF -2.788 
MUC1 -3.156 
NECTIN1 -5.588 
miR-410-3p 1.734 
FZD2 -1.584 
LDLR -1.671 
miR-34c-5p 8.743 
NECTIN1 -5.588 
PDGFRB -1.921 
SERPINF2 -1.640 
 
Analysis of the 3 miRNAs selected for normalization showed that RNU48 could not serve as 
normalizing miRNA since it was absent in 15 out of 52 samples (Figure 1B). In contrast, U6 and hsa-
miR-30a-5p were detected in all samples (Figure 1A and 1C) with miR-30a-5p displaying the most 
stable expression pattern and hence was chosen for the normalization of the data. 
 
 
 
Figure 1: Assessment of miRNAs stability for normalization. Normalization plots were generated for A) hsa-
miR-30a-5p, B) U6 snRNA and C) RNU48. Stability of miRNAs was assessed by calculation of a stability score 
using ExpressionSuite software (Applied Biosystems), the lower the score being associated with the more stable 
expression of the given miRNA relative to all other miRNAs in the comparison.  
 
 
 
 
 
 
 86 
 
From the 4 miRNAs selected for validation, miR-410-3p and miR-301b-3p were detected with 
very low frequency in the 52 samples (Figure 2). MiR-34c-5p was detected in nearly 20% of the 
samples but did not display a statistically significant difference between progressors and non-
progressors (Figure 2). However, miR-145-5p was detected in 44% of the samples in the validation 
set and could be validated as significantly associated to CKD progression with a fold change close to 
the one observed in the discovery cohort (3.151 versus 4.850) (Figure 2).  
 
Figure 2: Boxplots of the delta Cts (mean + SD) of the six miRNAs studied with TLDA analysis in the 
validation cohort. In dots the values of the individual samples. Only miR-145-5p scored significantly different 
between the two groups under study. Normalization with miR-30a-5p. * pvalue < 0.05.  
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Interestingly, urinary miR-145-5p abundance was not only associated with CKD progression, 
it was also slightly but significantly inversely correlated to eGFR decline in CKD patients from the 
validation cohort (Spearman r=-0.5, p>0.05, Figure 3A), and showed a moderate predictive value with 
an AUC of 0.733 (Figure 3B). 
 
Figure 3: A) Spearman correlation showing the correlation between the increase of miR-145-5p and the annual 
% change in eGFR slope. B) ROC curve showing a possible predictive value of miR-145-5p.   
 
Proteome analysis of human kidney cells treated with a hsa-miR-145-5p antagomir reveals a 
possible role in necrosis 
In order to determine the effect of the alteration of miR-145-5p expression, we performed an 
independent study using human kidney cells. Human kidney cells (HK2) were treated with an 
antagomir of hsa-miR-145-5p in order to inactivate the function of miR-145-5p and study the effect of 
this inactivation on the proteome level. HK2 cells treated with a scrambled antagomir were used as a 
control. LC-MS/MS analysis of the two conditions (5 samples treated with antagomir for miR-145 and 
5 treated with scrambled antagomir) allowed the identification of 26 high confidence proteins with 
significantly different levels (non-adjusted pvalues) between the two conditions. Twelve proteins were 
up- and 14 proteins were down-regulated in the cells treated with the antagomir compared to control 
(Table 5). Pathway analysis of the 26 proteins with revealed cell death and necrosis as the most 
significantly activated mechanism (p-value 1.28E-07 and activation z-score 0.203) in response to 
inactivation of miR-145-5p, in particular through modulation of the expression of splicing factor 
U2AF 65 kDa subunit (U2AF2), probable ATP-dependent RNA helicase DDX17 (DDX17), nucleolin 
(NCL), DNA replication licensing factor MCM7 (MCM7) and transcription intermediary factor 1-beta 
(TRIM28). 
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Table 5: Twenty-six significantly different proteins in HK-2 cell line treated with antagomir against has-miR-
145-5p versus cells treated with the scrambled antagomir. In bold the proteins both related to necrosis and that 
are predicted to be miR-145-5p targets.  
 
Symbol Name Fold change (ant-miR-
145/control) 
p-value Mann-
Whitney 
SNX3 Sorting nexin-3 Only in ant-miR-145 0,0254 
PAICS Multifunctional protein ADE2 Only in ant-miR-145 0,0254 
NAMPT 
Nicotinamide 
phosphoribosyltransferase 
Only in ant-miR-145 0,0254 
GDI2 Rab GDP dissociation inhibitor beta 8,13 0,0449 
PNP Purine nucleoside phosphorylase 6,85 0,0449 
U2AF2 
Splicing factor U2AF 65 kDa 
subunit 
5,96 0,0449 
PRPS1 
Ribose-phosphate pyrophosphokinase 
1 
2,87 0,0367 
DDX17 
Probable ATP-dependent RNA 
helicase DDX17 
2,86 0,0212 
IMPDH2 
Inosine-5'-monophosphate 
dehydrogenase 2 
1,91 0,0367 
VDAC2 
Voltage-dependent anion-selective 
channel protein 2 
1,76 0,0122 
CAPG Macrophage-capping protein 1,51 0,0367 
HNRNPK 
Heterogeneous nuclear 
ribonucleoprotein K 
1,41 0,0122 
LGALS1 Galectin-1 0,70 0,0367 
LMNA Prelamin-A/C 0,69 0,0122 
NCL Nucleolin 0,68 0,0216 
RPS19 40S ribosomal protein S19 0,44 0,0361 
UBA52 Ubiquitin-60S ribosomal protein L40 0,43 0,0367 
MCM7 
DNA replication licensing factor 
MCM7 
0,35 0,0122 
MTHFD1 
C-1-tetrahydrofolate synthase, 
cytoplasmic 
0,35 0,0212 
YWHAG 14-3-3 protein gamma 0,32 0,0112 
TRIM28 
Transcription intermediary factor 1-
beta 
0,32 0,0212 
QPRT 
Nicotinate-nucleotide 
pyrophosphorylase [carboxylating] 
0,13 0,0449 
YWHAH 14-3-3 protein eta 0,11 0,0449 
MCM4 
DNA replication licensing factor 
MCM4 
Only in control 0,0254 
EPCAM Epithelial cell adhesion molecule Only in control 0,0254 
DSTN Destrin Only in control 0,0254 
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5.6 DISCUSSION 
CKD is now recognized as a global health and economical burden affecting millions of 
people worldwide (Ayodele and Alebiosu, 2010, De Nicola and Minutolo, 2016). The limited 
understanding of the molecular mechanisms causing the disease and the lack of reliable 
noninvasive diagnostic and prognostic biomarkers complicates its management (Ortiz, 2015). 
Earlier studies have shown that miRNAs can potentially contribute to the development of CKD or 
its progression (Trionfini et al., 2015, Zhong et al., 2011, Qin et al., 2011). In addition, many 
studies have related urinary miRNAs with different kidney diseases, showing their potential to 
serve as non-invasive biomarkers (Papadopoulos et al., 2015b).   
In our retrospective study we used urinary samples from established CKD patients to 
investigate the association of urinary miRNAs to progressive CKD or non-progressive CKD. We 
were able to identify 24 miRNAs using Next Generation Sequencing that were observed to be 
significantly different between our two groups (adjusted pvalue<0.05) and associated to CKD 
progression. Combination of these 24 miRNAs with a dataset of 142 proteins found in significant 
different levels in the same urine samples, followed by miRNA target prediction showed that 7 
miRNAs and 15 proteins may be connected and involved into pathways related to kidney damage 
in CKD and may associate to progression of CKD in the discovery population  
Four miRNAs out of the 7 were further validated in an independent CKD patient 
population. From these 4 miRNAs, increased urinary abundance of miR-145-5p was confirmed to 
be associated to CKD progression. Previously, MiR-145 was mostly studied in tumors and is 
characterized as tumor suppressor miRNA (Elmen et al., 2008a). MiR-145 has also been 
identified as a regulator of controlling smooth muscle cell phenotype and vascular formation 
(Wiggins et al., 2010, Trang et al., 2011). Recent studies showed decrease of serum miR-145 in 
very early-onset coronary artery disease (CAD) patients compared to healthy controls (Ebert et 
al., 2007, Horie et al., 2009). Furthermore, miR-145 was found to be increased in smooth muscle 
cells of patients with insulin resistance that can lead to type 2 diabetes mellitus (T2DM) 
(Chistiakov et al., 2012).  
MiR-145 has also been previously found to be associated to (chronic) kidney disease. In a 
biopsy study of lupus nephritis patients, miR-145 expression in vascular smooth muscle cells 
(VSMC) was associated to different VSMC phenotypes. High expression level of miR-145 in the 
renal vasculature was associated with VSMCs of the contractile phenotype while a medium 
expression level was associated with VSMCs of the proliferative phenotype (Chen et al., 2010). 
Moreover, miR-145 was found decreased in plasma of CKD patients with correlation to the 
progressive loss of eGFR (Chen et al., 2015b) and elevated in urinary exosomes of type 1 
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diabetic patients with incipient diabetic nephropathy (Barutta et al., 2013, Argyropoulos et al., 
2015). Finally, increased levels of serum miR-145 was found to correlate with CKD severity 
(Brigant et al., 2016). These observations confirm a tight connection of miR-145 with CKD.  
Pathway analysis revealed the possible involvement of miR-145-5p via its targets in 
molecular pathways and mechanisms present in kidney disease (Supplementary table 4 and 5). 
In particular, cadherin-2 (CDH2) and epithelial growth factor (EGF) are proteins involved in 
epithelial adherens junction signaling, in regulation of the epithelial-mesenchymal transition 
(EMT) Pathway, Wnt/β-catenin signaling and NF-κB signaling, pathways that are reported to be 
activated in kidney pathologies that can lead to renal fibrosis, apoptosis and necrosis and may 
lead to CKD (Boussif et al., 1995, Chen et al., 2015b, Zhang et al., 2013, Ghosh et al., 2013, 
Lu et al., 2005, Kumar et al., 2009, Blenkiron et al., 2007, Faruq and Vecchione, 2015, 
Takamizawa et al., 2004, Calin et al., 2005, Hayes et al., 2014). Finally, mucin-1 (MUC-1) a 
protein with role in EMT and in autosomal dominant tubulointerstitial kidney disease  (Pan et al., 
2010), may be part of ILK signaling pathway, a pathway with anti-inflammatory properties in 
renal inflammation (Faruq and Vecchione, 2015, Lawrie et al., 2008).  
An independent proteomics analysis was also performed in human kidney (HK2) cells 
treated with an antagomir against miR-145-5p followed by a bioinformatics analysis predicting 
the possible deregulation of 14 proteins associated with inhibition of necrosis and cell death, a 
feature seen in CKD progression in the form of acute tubular necrosis (ATN). ATN follows acute 
kidney injury and it is very common in patients with progressive CKD and to those who reached 
end-stage renal disease (Zhang et al., 2010, Wu et al., 2011, Hsu et al., 2013). It must be noted, 
however, that none of the 14 proteins modified by the antagomer treatment in cells was detected 
among the 142 proteins associated to CKD progression. This is most likely explained by the fact 
that in patients the changes in protein abundance in urine are multifactorial (eg the CKD 
condition) and that in cells the only perturbant was the miR-145-5p antagomer.  
From the 14 proteins related to necrosis inhibition mechanism, 5 were predicted to be 
targets of miR-145-5p with DIANA-microT web server (version 5.0) (Paraskevopoulou et al., 
2013). These proteins were Splicing factor U2AF (U2AF2), DEAD-Box Helicase 17 (DDX17), 
Nucleolin (NCL), DNA replication licensing factor MCM7 and Transcription intermediary factor 
1-beta (TRIM28). DDX17 is a member of the DEAD-box protein family, which are putative 
RNA helicases involved in alteration of RNA secondary structure, leading to cellular growth and 
division (Kulkarni et al., 1971). DDX17 has been found with increased abundance in the serum 
of patients suffering from IgA nephropathy and correlated to the progression of the disease (Su et 
al., 2011). MiR-145 has been reported to down regulate DDX17 in gut tumors in a mouse model 
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(Chen et al., 2015b). Nucleolin is proposed to be involved in renal tubular crystal retention via 
the form of an acidic fragment of nucleolin-related protein (Panyam and Labhasetwar, 2003) 
and, also, as an antibody target to reduce apoptosis and endothelial cell proliferation in renal 
allograft rejection (Blum and Saltzman, 2008). Finally, in an early stage of kidney embryonic 
development Trim28 is highly expressed in the cap mesenchyme and at the tips of the ureteric 
bud enforcing the development of branches, while in developed kidney it is of minor abundance. 
Experiments of knocking down Trim28 resulted in branching arrest suggest that Trim28 plays an 
important role in kidney branching and morphogenesis (Zhang et al., 2013). For MCM7 and 
U2AF2 proteins no reports in association to kidney physiology or pathology exists.  
This study also represented a number of technical challenges. To our knowledge, this is 
the first report to use Next Generation Sequencing (NGS) to analyze urinary miRNAs from a 
little as 500 μl of urine of archived urine samples and opens up the possibility to perform NGS in 
other (renal) diseases were such small amounts of urine is available. Another challenge is 
represented by the shift in technology between the discovery (NGS) and the validation (Taqman 
technology, a real-time qPCR based method) step which might have a negative effect on the 
number of miRNAs validated. In a recent study, Git et al. compared NGS and PCR and showed 
that the different preparation of the samples before applying the method, as well as the higher 
sensitivity of NGS and the variability of the samples themselves is responsible for producing 
different results between the two methods (Hafner et al., 2010). The change in technology 
potentially only allowed to validate the miRNAs that were the most strongly associated to 
progression of CKD while the more weakly associated most likely need a larger number of 
samples in the validation set to become significant.    
 Overall, we identified urinary hsa-miR-145-5p to be associated with progressive CKD in 
patients from both the discovery and validation phase using two different technologies. Using in 
vitro knockdown studies the most likely mechanism linking mir-145-5p to CKD progression is 
necrosis. Further studies on larger sets of patients are warranted to confirm these associations.  
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5.7 Supplementary Data 
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Supplementary Table 1A: The clinical parameters of the discovery cohort (N=70) 
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Supplementary Table 1B: The clinical parameters of the validation cohort (N=52) 
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Supplementary Table 2: The 24 miRNAs with adjusted p-value < 0.05 and the miR-30a-5p which was selected as normalizer 
miRNA 
mean 
coverage 
A=Non 
Progressor 
B=Progressors 
BaseMeanB 
/ 
baseMeanA 
2log 
(baseMeanB 
/ 
BaseMeanA) 
unadjusted 
p-value 
adjusted p-
value 
rank 
sample 
detected / 
70 
number 
non 
progressors 
/ 35 
number 
progressors 
/35 
hsa-miR-34c-5p 1,125 0,231 2,019 8,743 3,128 4,56E-21 3,16E-18 1 26 8 18 
hsa-miR-3200-5p 0,222 0,012 0,431 35,233 5,139 2,87E-09 9,93E-07 2 14 2 12 
hsa-miR-944 1,408 0,280 2,536 9,068 3,181 2,26E-08 5,23E-06 3 19 7 12 
hsa-miR-34b-3p 0,117 0,006 0,228 39,715 5,312 1,17E-06 2,03E-04 4 9 1 8 
hsa-miR-147b 0,425 0,492 0,358 0,727 -0,459 5,08E-06 5,86E-04 5 18 11 7 
hsa-miR-410-3p 0,672 0,492 0,853 1,734 0,794 4,64E-06 5,86E-04 6 26 11 15 
hsa-miR-513c-5p 0,140 0,000 0,281 Inf Inf 6,69E-06 6,62E-04 7 5 0 5 
hsa-miR-3928-3p 0,192 0,023 0,360 15,575 3,961 1,69E-05 1,46E-03 8 11 3 8 
hsa-miR-1289 0,172 0,345 0,000 0,000 #NAME? 2,69E-05 1,87E-03 9 3 3 0 
hsa-miR-1323 0,049 0,097 0,000 0,000 #NAME? 2,69E-05 1,87E-03 10 3 3 0 
hsa-miR-324-5p 1,061 1,631 0,491 0,301 -1,732 3,93E-05 2,48E-03 11 29 14 15 
hsa-miR-3150a-3p 0,168 0,008 0,327 38,655 5,273 7,16E-05   12 7 1 6 
hsa-miR-892c-3p 0,088 0,000 0,177 Inf Inf 1,04E-04 5,53E-03 13 3 0 3 
hsa-miR-369-3p 0,255 0,098 0,413 4,228 2,080 1,19E-04 5,89E-03 14 8 1 7 
hsa-miR-301b-3p 0,838 0,383 1,293 3,377 1,756 3,81E-04 1,76E-02 15 23 6 17 
hsa-miR-449b-5p 0,228 0,095 0,362 3,815 1,932 4,06E-04 1,76E-02 16 9 3 6 
hsa-miR-651-5p 0,295 0,076 0,513 6,723 2,749 5,48E-04 2,23E-02 17 14 4 10 
hsa-miR-561-5p 0,866 0,788 0,944 1,198 0,260 7,27E-04 2,67E-02 18 33 12 21 
hsa-miR-708-5p 0,333 0,368 0,298 0,809 -0,306 7,32E-04 2,67E-02 19 16 7 9 
hsa-miR-323b-3p 0,156 0,182 0,130 0,717 -0,480 8,96E-04 2,96E-02 20 11 6 5 
hsa-miR-493-5p 0,055 0,007 0,103 15,238 3,930 8,91E-04 2,96E-02 21 6 1 5 
hsa-miR-487b-3p 0,324 0,125 0,523 4,172 2,061 1,15E-03 3,62E-02 22 17 6 11 
hsa-miR-145-5p 0,246 0,084 0,408 4,850 2,278 1,39E-03 4,18E-02 23 10 3 7 
hsa-miR-508-3p 1,190 0,561 1,820 3,241 1,696 1,56E-03 4,50E-02 24 34 13 21 
            
            hsa-miR-30a-5p 15854,12061 16008,5163 15699,72491 0,980710805 -0,028100322 9,04E-01 1  70 35 35 
 
 
  
9
6
 
Supplementary Table 3: The 142 significantly different urinary proteins (corrected p-value < 0.05, ratio ≤0.66 or ≥ 1.5) 
Symbol Name 
Peptide 
occurences 
p-value Mann-
Whitney U-test 
Benjamini-Hochberg corrected p-value 
Mann-Whitney U-test 
ratio progressors/non-
progressors 
TF Serotransferrin 65 1,36E-07 4,69E-05 5,71 
HPX Hemopexin 19 1,48E-06 2,55E-04 8,30 
CP Ceruloplasmin 31 2,52E-06 2,89E-04 3,13 
SERPINA1 Alpha-1-antitrypsin 21 6,64E-06 4,57E-04 6,28 
GC Vitamin D-binding protein 11 1,68E-05 5,26E-04 5,50 
ORM2 Alpha-1-acid glycoprotein 2 11 2,14E-05 6,14E-04 2,84 
IGHG1 Ig gamma-1 chain C region 11 3,86E-05 1,02E-03 3,79 
A1BG Alpha-1B-glycoprotein 11 5,46E-05 1,17E-03 3,15 
AFM Afamin 12 8,83E-05 1,42E-03 3,68 
ALB Serum albumin 80 1,33E-04 1,64E-03 2,86 
IGHG2 Ig gamma-2 chain C region 18 1,75E-04 1,72E-03 2,09 
UBC Polyubiquitin-C 3 2,22E-04 1,96E-03 1,52 
ORM1 Alpha-1-acid glycoprotein 1 7 4,69E-04 3,21E-03 2,86 
CD320 CD320 antigen 2 5,36E-04 3,36E-03 1,71 
Ig heavy chain V-III region BRO Ig heavy chain V-III region BRO 2 1,50E-03 6,88E-03 2,48 
IGHA1 Ig alpha-1 chain C region 15 1,92E-03 8,49E-03 2,54 
LRG1 Leucine-rich alpha-2-glycoprotein 13 2,15E-03 8,93E-03 2,80 
AZGP1 Zinc-alpha-2-glycoprotein 26 3,65E-03 1,23E-02 2,00 
APOA1 Apolipoprotein A-I 5 4,32E-03 1,35E-02 7,55 
NGFR Tumor necrosis factor receptor superfamily member 16 3 4,77E-03 1,46E-02 1,63 
RBP4 Retinol-binding protein 4 6 5,56E-03 1,58E-02 4,14 
SERPINA3 Alpha-1-antichymotrypsin 17 6,55E-03 1,76E-02 2,60 
TFF2 Trefoil factor 2 1 7,35E-03 1,89E-02 1,60 
IGKC Ig kappa chain C region 7 7,69E-03 1,90E-02 2,14 
TTR Transthyretin 1 9,43E-03 2,16E-02 11,95 
AHSG Alpha-2-HS-glycoprotein 10 9,75E-03 2,19E-02 5,21 
HP Haptoglobin 13 1,05E-02 2,32E-02 3,82 
FBLN5 Fibulin-5 2 1,49E-02 3,12E-02 1,69 
AGT Angiotensinogen 4 1,54E-02 3,18E-02 5,09 
SERPINC1 Antithrombin-III 3 1,59E-02 3,27E-02 5,80 
A2M Alpha-2-macroglobulin 1 2,24E-02 4,10E-02 5,71 
VTN Vitronectin 7 2,54E-02 4,41E-02 2,58 
SERPINA7 Thyroxine-binding globulin 5 2,54E-02 4,41E-02 1,92 
KRT10 Keratin, type I cytoskeletal 10 7 2,93E-02 4,92E-02 3,18 
IGSF8 Immunoglobulin superfamily member 8 4 6,56E-06 4,57E-04 0,27 
PGLYRP1 Peptidoglycan recognition protein 1 4 1,24E-05 4,73E-04 0,65 
GP6 Platelet glycoprotein VI 2 1,16E-05 4,73E-04 0,35 
MXRA8 Matrix-remodeling-associated protein 8 4 1,37E-05 4,73E-04 0,32 
DEFB1 Beta-defensin 1 1 9,16E-06 4,73E-04 0,21 
RELT Tumor necrosis factor receptor superfamily member 19L 1 1,03E-05 4,73E-04 0,13 
COL15A1 Collagen alpha-1(XV) chain 3 4,70E-05 1,15E-03 0,13 
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Symbol Name 
Peptide 
occurences 
p-value Mann-
Whitney U-test 
Benjamini-Hochberg corrected p-value 
Mann-Whitney U-test 
ratio progressors/non-
progressors 
TWSG1 Twisted gastrulation protein homolog 1 2 5,68E-05 1,17E-03 0,63 
NEGR1 Neuronal growth regulator 1 3 5,93E-05 1,17E-03 0,44 
PVRL1 Nectin-1 1 6,12E-05 1,17E-03 0,18 
ACAN Aggrecan core protein 2 7,00E-05 1,27E-03 0,28 
RETN Resistin 2 9,34E-05 1,42E-03 0,51 
CNTFR Ciliary neurotrophic factor receptor subunit alpha 2 9,49E-05 1,42E-03 0,47 
NEU1 Sialidase-1 3 9,38E-05 1,42E-03 0,37 
AMY2A Pancreatic alpha-amylase 5 1,11E-04 1,49E-03 0,48 
CPN2 Carboxypeptidase N subunit 2 4 1,11E-04 1,49E-03 0,34 
LYNX1 Ly-6/neurotoxin-like protein 1 1 1,12E-04 1,49E-03 0,33 
QPCT Glutaminyl-peptide cyclotransferase 7 1,57E-04 1,64E-03 0,36 
CADM1 Cell adhesion molecule 1 2 1,57E-04 1,64E-03 0,34 
PRCP Lysosomal Pro-X carboxypeptidase 2 1,43E-04 1,64E-03 0,34 
AMY2B Alpha-amylase 2B 1 1,49E-04 1,64E-03 0,21 
ASGR2 Asialoglycoprotein receptor 2 1 1,75E-04 1,72E-03 0,14 
TINAGL1 Tubulointerstitial nephritis antigen-like 1 1,94E-04 1,86E-03 0,18 
SERPINA5 Plasma serine protease inhibitor 9 2,05E-04 1,91E-03 0,36 
SIRPB1 Signal-regulatory protein beta-1 4 2,14E-04 1,94E-03 0,58 
ISLR Immunoglobulin superfamily containing leucine-rich repeat protein 1 2,28E-04 1,96E-03 0,21 
CLEC3B Tetranectin 2 2,78E-04 2,28E-03 0,24 
CLEC4G C-type lectin domain family 4 member G 1 2,74E-04 2,28E-03 0,18 
MUC1 Mucin-1 3 3,09E-04 2,47E-03 0,32 
TNFRSF1B Tumor necrosis factor receptor superfamily member 1B 1 3,41E-04 2,50E-03 0,63 
VMO1 Vitelline membrane outer layer protein 1 homolog 2 3,41E-04 2,50E-03 0,37 
PEBP1 Phosphatidylethanolamine-binding protein 1 2 3,33E-04 2,50E-03 0,31 
APOD Apolipoprotein D 15 4,46E-04 3,20E-03 0,43 
EGF Pro-epidermal growth factor 19 4,59E-04 3,21E-03 0,36 
CPM Carboxypeptidase M 1 4,93E-04 3,26E-03 0,31 
CD9 CD9 antigen 1 5,38E-04 3,36E-03 0,65 
MCAM Cell surface glycoprotein MUC18 1 5,73E-04 3,52E-03 0,27 
NID1 Nidogen-1 3 5,86E-04 3,53E-03 0,55 
PVRL2 Nectin-2 3 6,57E-04 3,83E-03 0,56 
CLN5 Ceroid-lipofuscinosis neuronal protein 5 1 7,41E-04 4,18E-03 0,42 
HYAL1 Hyaluronidase-1 1 7,33E-04 4,18E-03 0,27 
TNFRSF14 Tumor necrosis factor receptor superfamily member 14 2 7,63E-04 4,23E-03 0,45 
SDC4 Syndecan-4 1 8,27E-04 4,52E-03 0,27 
PGLS 6-phosphogluconolactonase 5 9,71E-04 5,22E-03 0,60 
SPINT1 Kunitz-type protease inhibitor 1 1 1,01E-03 5,36E-03 0,31 
SPINT2 Kunitz-type protease inhibitor 2 1 1,08E-03 5,62E-03 0,44 
BHMT Betaine--homocysteine S-methyltransferase 1 2 1,16E-03 5,91E-03 0,41 
CDH2 Cadherin-2 1 1,24E-03 6,10E-03 0,37 
GGT3P Putative gamma-glutamyltranspeptidase 3 1 1,30E-03 6,30E-03 0,22 
CSPG4 Chondroitin sulfate proteoglycan 4 4 1,34E-03 6,42E-03 0,64 
EIF6 Eukaryotic translation initiation factor 6 2 1,50E-03 6,88E-03 0,49 
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Symbol Name 
Peptide 
occurences 
p-value Mann-
Whitney U-test 
Benjamini-Hochberg corrected p-value 
Mann-Whitney U-test 
ratio progressors/non-
progressors 
SCPEP1 Retinoid-inducible serine carboxypeptidase 1 1,49E-03 6,88E-03 0,23 
CD84 SLAM family member 5 2 1,79E-03 7,99E-03 0,55 
HEXA Beta-hexosaminidase subunit alpha 2 2,05E-03 8,85E-03 0,47 
PLD3 Phospholipase D3 1 2,06E-03 8,85E-03 0,22 
PRSS8 Prostasin 1 2,14E-03 8,93E-03 0,44 
ACP2 Lysosomal acid phosphatase 7 2,19E-03 8,98E-03 0,56 
PROCR Endothelial protein C receptor 4 2,26E-03 9,15E-03 0,47 
ABHD14B Alpha/beta hydrolase domain-containing protein 14B 1 2,31E-03 9,22E-03 0,33 
AXL Tyrosine-protein kinase receptor UFO 5 2,36E-03 9,28E-03 0,59 
CEL Bile salt-activated lipase 2 2,37E-03 9,28E-03 0,37 
KLK1 Kallikrein-1 2 2,42E-03 9,35E-03 0,52 
LDLR Low-density lipoprotein receptor 1 2,47E-03 9,44E-03 0,60 
NUCB1 Nucleobindin-1 1 2,63E-03 9,84E-03 0,58 
ALDOB Fructose-bisphosphate aldolase B 1 2,69E-03 9,95E-03 0,24 
OSCAR Osteoclast-associated immunoglobulin-like receptor 4 3,12E-03 1,13E-02 0,44 
COL6A1 Collagen alpha-1(VI) chain 9 3,20E-03 1,15E-02 0,49 
HEG1 Protein HEG homolog 1 3 3,28E-03 1,16E-02 0,61 
ZG16B Zymogen granule protein 16 homolog B 1 3,35E-03 1,17E-02 0,33 
PCOLCE Procollagen C-endopeptidase enhancer 1 3 3,40E-03 1,18E-02 0,62 
PGA4 Pepsin A-4 3 3,81E-03 1,23E-02 0,57 
FGA Fibrinogen alpha chain 4 3,81E-03 1,23E-02 0,57 
HAVCR2 Hepatitis A virus cellular receptor 2 6 3,65E-03 1,23E-02 0,54 
ICAM2 Intercellular adhesion molecule 2 1 3,76E-03 1,23E-02 0,32 
PROZ Vitamin K-dependent protein Z 3 3,81E-03 1,23E-02 0,27 
PTPRG Receptor-type tyrosine-protein phosphatase gamma 1 4,14E-03 1,31E-02 0,48 
COMP Cartilage oligomeric matrix protein 1 4,52E-03 1,40E-02 0,37 
APOE Apolipoprotein E 2 4,87E-03 1,48E-02 0,53 
COL18A1 Collagen alpha-1(XVIII) chain 1 4,91E-03 1,48E-02 0,36 
PEBP4 Phosphatidylethanolamine-binding protein 4 1 5,31E-03 1,56E-02 0,52 
CD248 Endosialin 11 5,56E-03 1,58E-02 0,64 
VASN Vasorin 6 5,56E-03 1,58E-02 0,61 
THBD Thrombomodulin 1 5,93E-03 1,67E-02 0,64 
OLFM4 Olfactomedin-4 4 6,52E-03 1,76E-02 0,59 
CD300A CMRF35-like molecule 8 3 6,41E-03 1,76E-02 0,56 
NHLRC3 NHL repeat-containing protein 3 3 6,41E-03 1,76E-02 0,50 
PDGFRB Platelet-derived growth factor receptor beta 1 6,68E-03 1,78E-02 0,52 
FZD2 Frizzled-2 1 6,79E-03 1,80E-02 0,63 
PVR Poliovirus receptor 3 7,00E-03 1,82E-02 0,44 
LDHB L-lactate dehydrogenase B chain 3 7,28E-03 1,88E-02 0,57 
MAN1A1 Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA 1 7,68E-03 1,90E-02 0,49 
ACVR1B Activin receptor type-1B 1 7,58E-03 1,90E-02 0,44 
EPHB6 Ephrin type-B receptor 6 1 7,69E-03 1,90E-02 0,43 
EPHB4 Ephrin type-B receptor 4 4 7,91E-03 1,92E-02 0,63 
IL18BP Interleukin-18-binding protein 1 7,88E-03 1,92E-02 0,55 
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Symbol Name 
Peptide 
occurences 
p-value Mann-
Whitney U-test 
Benjamini-Hochberg corrected p-value 
Mann-Whitney U-test 
ratio progressors/non-
progressors 
GLB1 Beta-galactosidase 4 1,01E-02 2,26E-02 0,62 
IL6ST Interleukin-6 receptor subunit beta 1 1,05E-02 2,32E-02 0,32 
MASP2 Mannan-binding lectin serine protease 2 6 1,32E-02 2,83E-02 0,62 
PSCA Prostate stem cell antigen 1 1,39E-02 2,95E-02 0,48 
SERPINF2 Alpha-2-antiplasmin 1 1,40E-02 2,96E-02 0,61 
GRN Granulins 4 1,65E-02 3,31E-02 0,45 
FOLR1 Folate receptor alpha 5 1,71E-02 3,37E-02 0,55 
IGFBP7 Insulin-like growth factor-binding protein 7 11 2,13E-02 3,94E-02 0,61 
COTL1 Coactosin-like protein 1 2,33E-02 4,17E-02 0,59 
NUTF2 Nuclear transport factor 2 2 2,55E-02 4,41E-02 0,64 
ACPP Prostatic acid phosphatase 7 2,72E-02 4,66E-02 0,40 
LCN2 Neutrophil gelatinase-associated lipocalin 1 2,81E-02 4,79E-02 0,38 
Ig kappa chain V-I region Roy Ig kappa chain V-I region Roy 1 2,91E-02 4,90E-02 0,63 
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Supplementary Table 4: The 7 miRNAs with the 15 predicted targets and molecular pathways involved. In bold the 4 miRNAs that were further validated. 
 
 
Symbol 
Exp Fold 
Change 
Confidence ID Symbol 
Exp Fold 
Change 
Pathway 
miR-
301b-
3p 
3.377 
High 
(predicted) 
P54760 EPHB4 -1.586 Axonal Guidance Signaling,Ephrin B Signaling,Ephrin Receptor Signaling 
High 
(predicted) 
P40189 IL6ST -3.173 
Acute Phase Response Signaling,CNTF Signaling, ERK5 Signaling,IL-6 
Signaling,Role of JAK family kinases in IL-6-type Cytokine Signaling,Role of 
Macrophages, T Helper Cell Differentiation 
High 
(predicted) 
P01130 LDLR -1.671 
Clathrin-mediated Endocytosis Signaling,LXR/RXR Activation,TR/RXR 
Activation 
High 
(predicted) 
P23470 PTPRG -2.078 Protein Kinase A Signaling 
High 
(predicted) 
P20333 TNFRSF1B -1.587 
Acute Phase Response Signaling,Apoptosis Signaling, Crosstalk between 
Dendritic Cells and Natural Killer Cells,Death Receptor Signaling,Dendritic 
Cell Maturation, IL-6 Signaling,LPS/IL-1 Mediated Inhibition of RXR 
Function,LXR/RXR Activation,NF-κB Signaling,p38 MAPK Signaling,PPAR 
Signaling,Production of Nitric Oxide and Reactive Oxygen Species in 
Macrophages,Role of Macrophages, T Helper Cell Differentiation,Tight 
Junction Signaling,TNFR2 Signaling,Type I Diabetes Mellitus 
Signaling,Type II Diabetes Mellitus Signaling 
miR-
145-5p 
4.850 
High 
(predicted) 
P36896 ACVR1B -2.278 
Epithelial Adherens Junction Signaling, PPARα/RXRα Activation,TGF-β 
Signaling,Wnt/β-catenin Signaling 
High 
(predicted) 
P19022 CDH2 -2.738 
Epithelial Adherens Junction Signaling,Germ Cell-Sertoli Cell Junction 
Signaling,Gα12/13 Signaling,Regulation of the Epithelial-Mesenchymal 
Transition Pathway,RhoGDI Signaling,Signaling by Rho Family 
GTPases,Wnt/β-catenin Signaling 
High 
(predicted) 
P01133 EGF -2.788 
Actin Cytoskeleton Signaling,EGF Signaling,Ephrin Receptor 
Signaling,Epithelial Adherens Junction Signaling,ErbB Signaling,ERK5 
Signaling,FAK Signaling,Gap Junction Signaling, Signaling,IL-8 
Signaling,,,NF-κB Signaling,Regulation of Cellular Mechanics by Calpain 
Protease,Regulation of the Epithelial-Mesenchymal Transition 
Pathway,Telomerase Signaling,Thrombin Signaling 
Experimentally 
Observed 
P15941 MUC1 -3.156 ILK Signaling 
High 
(predicted) 
Q15223 NECTIN1 -5.588 
Epithelial Adherens Junction Signaling,Sertoli Cell-Sertoli Cell Junction 
Signaling,Tight Junction Signaling 
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Symbol 
Exp Fold 
Change 
Confidence ID Symbol 
Exp Fold 
Change 
Pathway 
miR-
410-3p 
1.734 
High 
(predicted) 
Q14332 FZD2 -1.584 
Regulation of the Epithelial-Mesenchymal Transition Pathway,Role of 
Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis, 
Wnt/Ca+ pathway,Wnt/β-catenin Signaling 
High 
(predicted) 
P01130 LDLR -1.671 
Clathrin-mediated Endocytosis Signaling,LXR/RXR Activation,TR/RXR 
Activation 
miR-
34c-5p 
8.743 
High 
(predicted) 
Q15223 NECTIN1 -5.588 
Epithelial Adherens Junction Signaling,Sertoli Cell-Sertoli Cell Junction 
Signaling,Tight Junction Signaling 
High 
(predicted) 
P09619 PDGFRB -1.921 
3-phosphoinositide Biosynthesis, NF-κB Signaling,PAK Signaling,PDGF 
Signaling,PPAR Signaling,PTEN Signaling,Regulation of the Epithelial-
Mesenchymal Transition Pathway,Sphingosine-1-phosphate 
Signaling,STAT3 Pathway,Superpathway of Inositol Phosphate Compounds 
High 
(predicted) 
P08697 SERPINF2 -1.640 
Acute Phase Response Signaling,Coagulation System,FXR/RXR 
Activation,LXR/RXR Activation 
miR-
3150a-
3p 
38.655 
High 
(predicted) 
Q15223 NECTIN1 -5.588 
Epithelial Adherens Junction Signaling,Sertoli Cell-Sertoli Cell Junction 
Signaling,Tight Junction Signaling 
miR-
3928-
3p 
15.575 
High 
(predicted) 
P02790 HPX 8.296 Acute Phase Response Signaling,FXR/RXR Activation,LXR/RXR Activation 
miR-
708-5p 
-1.237 
High 
(predicted) 
P26992 CNTFR -2.110 CNTF Signaling 
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Supplementary Table 5: Disease and functions the selected miRNAs and their targets are predicted to be involved.  
 
 
Categories 
Diseases or Functions 
Annotation p-Value 
Predicted 
Activation State Molecules 
Cell Death and Survival apoptosis 4,64E-06 Increased 
IL6ST,EPHB4,CDH2,miR-34c-5p,LDLR,miR-145-
5p,CNTFR,MUC1,EGF,TNFRSF1B,FZD2,ACVR1B,PDGF
RB 
Cell Death and Survival cell death 1,26E-05 Increased 
IL6ST,EPHB4,MUC1,CNTFR,EGF,SERPINF2,ACVR1B,m
iR-34c-5p,CDH2,LDLR,miR-145-
5p,TNFRSF1B,FZD2,PDGFRB 
Renal Necrosis/Cell Death 
cell death of kidney cell 
lines 0,00531 Increased miR-34c-5p,EGF,TNFRSF1B 
Renal Necrosis/Cell Death 
apoptosis of kidney cell 
lines 0,0304 Increased miR-34c-5p,EGF 
Cell Death and Survival cell survival 3,81E-06 Decreased 
IL6ST,EPHB4,miR-34c-
5p,CDH2,PTPRG,CNTFR,EGF,TNFRSF1B,FZD2,PDGFR
B 
Cell Death and Survival cell viability 0,00002 Decreased 
IL6ST,EPHB4,miR-34c-
5p,CDH2,PTPRG,EGF,TNFRSF1B,FZD2,PDGFRB 
Cellular Growth and 
Proliferation, Tissue 
Development generation of cells 0,00013 Decreased 
IL6ST,EPHB4,HPX,miR-34c-
5p,CDH2,LDLR,EGF,NECTIN1,TNFRSF1B,PDGFRB 
Renal Inflammation, Renal 
Nephritis Nephritis 0,0538 
 
MUC1,miR-301b-3p 
Renal Inflammation, Renal 
Nephritis class II lupus nephritis 0,107 
 
miR-301b-3p 
 103 
 
 104 
 
6. SYSTEMS BIOLOGY COMBINING HUMAN- AND ANIMAL-DATA 
MIRNA AND MRNA DATA IDENTIFIES NEW TARGETS IN 
URETEROPELVIC JUNCTION OBSTRUCTION 
 
Theofilos Papadopoulos
1,2
, Audrey Casemayou
1,2
, Eric Neau
1,2
, Benjamin Breuil
1,2
, Cécile Caubet
1,2
, 
Denis Calise
2
, Barbara A. Thornhill
3,4
, Magdalena Bachvarova
4,5
, Julie Belliere
1,2
, Robert L 
Chevalier
3,4
, Panagiotis Moulos
6,7
, Dimcho Bachvarov
4,5
, Benedicte Buffin-Meyer
1,2
, Stéphane 
Decramer
1,2,8,9
, Françoise Conte Auriol
10
, Jean-Loup Bascands
2,11
, Joost P Schanstra
1, 2*
, Julie Klein
1, 2*
. 
 
1 
Institut National de la Santé et de la Recherche Médicale (INSERM), U1048, Institut of 
Cardiovascular and Metabolic Disease, Toulouse, France. 
2 
Université Toulouse III Paul-Sabatier, Toulouse,  France. 
3 
Department of Pediatrics, University of Virginia School of Medicine, Charlottesville, VA, USA
.  
4 
Department of Molecular Medicine, Université Laval, Québec, Canada. 
5 
Centre de recherche du CHU de Québec, L'Hôtel-Dieu de Québec, Québec, Canada. 
6 
HybridStat Predictive Analytics, Aiolou 19, 10551, Athens, Greece. 
7 
Institute of Molecular Biology and Genetics, Biomedical Sciences Research Center 'Alexander 
Fleming', Fleming 34, 16672, Vari, Greece. 
8 
CHU Toulouse, Hôpital des Enfants, Service de Néphrologie–Médecine Interne–Hypertension 
Pédiatrique, 31059 Toulouse, France. 
9 
Centre De Référence des Maladies Rénales Rares du Sud Ouest (SORARE), 31059 Toulouse, 
France. 
10
Unité de recherche clinique pédiatrique, Module plurithémathique pédiatrique du Centre 
d'Investigation Clinique Toulouse 1436 Hôpital des enfants 330 avenue de grande bretagne, 31059 
Toulouse, France 
11
 DéTROI - Inserm U1188 - Université de La Réunion, Diabète athérothrombose Thérapies Réunion 
Océan Indien, CYROI, 2, rue Maxime Rivière, 97490 Sainte Clotilde - La Réunion - France 
 
 
 
Papadopoulos et al., BMC systems biology.  
 
 
  
 105 
 
6.1. ABSTRACT 
 
Background  
Although renal fibrosis and inflammation have shown to be involved in the pathophysiology 
of obstructive nephropathies, molecular mechanisms underlying evolution of these processes remain 
undetermined. In an attempt towards improved understanding of obstructive nephropathy and 
improved translatability of the results to clinical practice we have developed a systems biology 
approach combining omics data of both human and mouse obstructive nephropathy.  
Results 
We have studied in parallel the urinary miRNome of infants with ureteropelvic junction 
obstruction and the kidney tissue miRNome and transcriptome of the corresponding neonatal partial 
unilateral ureteral obstruction (UUO) mouse model. Several hundreds of miRNAs and mRNAs 
displayed changed abundance during disease. Combination of miRNAs in both species and associated 
mRNAs let to the prioritization of 5 miRNAs and 35 mRNAs associated to disease. In vitro and in 
vivo validation identified consistent dysregulation of let-7a-5p and miR-29-3p and new potential 
targets, E3 ubiquitin-protein ligase (DTX4) and neuron navigator 1 (NAV1), potentially involved in 
fibrotic processes, in obstructive nephropathy in both human and mice that would not be identified 
otherwise.  
Conclusions  
Our study is the first to correlate a mouse model of neonatal partial UUO with human UPJ 
obstruction in a comprehensive systems biology analysis. Our data revealed let-7a and miR-29b as 
molecules potentially involved in the development of fibrosis in UPJ obstruction via the control of 
DTX4 in both man and mice that would not be identified otherwise.  
 
 
 
 
 
 
Keywords 
 Obstructive nephropathy 
 miRNAs / microRNAs 
 microarrays 
 let-7a-5p and miR-29b-3p 
 DTX4 and NAV1 
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6.2. Background 
Congenital obstructive nephropathy is the main cause of end stage renal disease (ESRD) in 
children (Warady and Chadha, 2007). This contrasts sharply with adult ESRD, which for the greater 
part originates from type II diabetes and hypertension (Chevalier, 2015a). The most frequent cause of 
congenital urinary tract obstruction is ureteropelvic junction (UPJ) obstruction with an estimated 
incidence of 1 in 1000–1500 (Chang et al., 2004). The spectrum of renal abnormalities varies greatly 
in UPJ obstruction ranging from subtle changes such as modified proximal or tubular size, chronic 
tubulointerstitial injury, glomerulosclerosis, fibrosis, aberration of nephron development and in severe 
cases (less than 1%) renal dysplasia (Klein et al., 2011). The gold standard in diagnosis of UPJ is by 
prenatal ultrasonography with subsequent evaluation in the postnatal period (Chevalier, 2015b). 
However, this method is not sensitive enough to accurately estimate renal function and functioning 
nephron number (Waikar et al., 2009). This has led to an urgent need for the development of 
biomarkers to assess the severity of UPJ obstruction and to help the clinicians to decide if and when 
pyeloplasty is required (Chevalier, 2015b, Chertin et al., 2006). 
Due to the fact that limited human kidney samples are available, almost all observations on the 
pathophysiology of UPJ obstruction are based on animal models, which potentially limit the 
transferability of the observations in the clinical context. As a consequence, the pathophysiological 
mechanisms of UPJ obstruction remain incompletely understood. Renal lesions in UPJ obstruction 
have been described including tubular proliferation/apoptosis, renin-angiotensin system activation, 
inflammation, and fibrosis (Klein et al., 2011, Chevalier, 2015b, Chevalier et al., 2014, Meiri et al., 
2012). Interstitial fibrosis is a late consequence of congenital UPJ obstruction, and can be attenuated 
by early release of obstruction, but not if nephron number is reduced (Sergio et al., 2015). It is 
becoming increasingly clear that patients with congenital urinary tract obstruction must be followed 
into adulthood, as the lesions can progress over the entire life (Chevalier, 2015a). 
MicroRNAs (miRNAs) are small non-coding RNAs (20 - 24 nt) that regulate gene expression 
by blocking the translation of proteins and are involved in multiple molecular pathways and 
pathologies. MiRNAs are now considered promising molecules for biomarkers and/or targeted therapy 
of disease (Hammond, 2015, Almeida et al., 2011, van Rooij and Kauppinen, 2014, Esteller, 
2011). While, kidney diseases are no exception (Schena et al., 2014, Papadopoulos et al., 2015b), to 
our knowledge no studies specifically report miRNAs related to UPJ obstruction. There is evidence 
connecting dysregulated miRNAs including miR-21 and miR-29 with kidney fibrosis (Zarjou et al., 
2011, Chau et al., 2012, Glowacki et al., 2013, He et al., 2013, Wang et al., 2012a, Qin et al., 
2011), an important feature in severe UPJ obstruction. Moreover, knock-down of DICER (the main 
protein involved in the biogenesis of miRNAs (Bartel, 2004, Denzler and Stoffel, 2015)) leads to 
congenital anomalies of the kidney and the urinary tract (CAKUT) in mice (Bartram et al., 2013). 
MiRNAs are very stable in urine, a biofluid which can be collected non-invasively and can be valuable 
source of molecules to monitor diseases of the kidney and urinary tract (Papadopoulos et al., 2015b). 
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These observations suggest that studying miRNAs in UPJ obstruction might help to understand the 
development of obstructive nephropathy and/or provide early markers of pathological obstruction. 
In this study we analysed the modification of urinary miRNAs in UPJ obstruction. To improve 
upon the clinical translatability of our results and compensate for the lack of tissue availability in 
human disease, we combined miRNA data obtained in human urine and miRNA and mRNA data in 
kidney tissue of a neonatal partial unilateral ureteral obstruction (UUO) mouse model. This combined 
systems biology-based approach followed by an in vitro validation pointed to the consistent 
dysregulation of specific miRNAs, let-7a-5p and miR-29-3p and to new potential targets, E3 
ubiquitin-protein ligase (DTX4) and neuron navigator 1 (NAV1) in UPJ obstruction that would not be 
identified otherwise.  
 108 
 
6.3. Results 
 
MiRNA abundance changes in urine of newborns with UPJ obstruction  
A total of 20 male UPJ obstruction patients and 8 male healthy age-matched (< 1 year-
old) individuals were studied (Table 1). The severity of the obstruction varied with 
hydronephrosis grades from 1-4 and pelvic dilatation sizes from 6 to 40 mm (Table 1). We 
compared the urinary miRNA abundance of UPJ obstruction patients to urine of healthy controls 
using microarray analysis. This yielded the identification of 227 miRNAs with changed urinary 
abundance between the two groups (unadjusted p<0.05, Additional file 1).  
 
Table 1: Clinical data of the human UPJ obstruction patients.  
 
N 
Age (days) at 
urine sampling 
median [range] 
HN grade 
median [range] 
Pelvic diameter mm 
median [range] 
Healthy controls 8 112 [20-201] n.a. n.a. 
UPJ obstruction 20 74 [3-269] 2 [1-4] 15 [6-40] 
HN: hydronephrosis; n.a.: not applicable 
 
    
MiRNA and mRNA expression changes in renal tissue of a neonatal partial UUO mouse 
model 
The renal miRNA and mRNA profiles of 9 neonatal mice with partial UUO 
(hydronephrosis grades 2 and 3) and 9 control sham operated mice were studied using microarray 
analysis (Table 2). This led to the identification of 79 differentially expressed miRNAs and 706 
differentially expressed mRNAs, respectively (unadjusted p<0.05, Additional file 2 and 3).  
 
Table 2: Experimental data of the partial UUO model animals. 
 
N 
(Male/Female) 
HN grade 
median [range] 
Pelvic diameter in mm 
median [range] 
Sham 9 (4/5) n.a. 1.2 [0.8-1.5] 
Partial UUO 9 (6/3) 2.5 [2-3] 1.5 [1-2.8] 
HN: hydronephrosis; n.a.: not applicable 
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Identification of most prominent dysregulated miRNAs commonly associated with 
obstructive nephropathy in humans and mice 
To prioritize the molecular features with potentially the highest impact on the 
development of kidney lesions, we next identified the miRNAs that could consistently reflect the 
human disease by comparing the similarity of the human (urine) and animal (kidney tissue) 
miRNA signature taking advantage from the fact that miRNAs are well conserved between 
species (Griffiths-Jones et al., 2006). The 227 differentially expressed human miRNAs and 79 
differentially expressed mouse miRNAs were combined. This led to the identification of 18 
common miRNAs (Additional file 4) that were reduced to five miRNAs when applying a fold 
change threshold of 2.5 in mice tissue. These five miRNAs were let-7a-5p miR-16-5p, miR-29b-
3p, miR-125b-5p and miR-26a-5p (Table 3).  
 
Table 3: Most prominent dysregulated miRNAs commonly associated to the partial UUO model and 
human UPJ obstruction. 
 
UPJ vs Healthy 
(urine) 
Partial UUO vs Sham (kidney) 
miRNA FC p-value FC p-value 
let-7a-5p -1,559 3,17E-03 -3,558 3,93E-03 
miR-16-5p -1,293 2,27E-03 -2,913 6,97E-04 
miR-29b-3p -1,153 2,93E-02 10,073 3,10E-08 
miR-125b-5p -1,18 3,03E-02 -3,219 3,15E-03 
miR-26a-5p -1,376 3,03E-02 -3,175 1,13E-03 
FC: fold change. 
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Correlation of the urinary abundance of the five miRNAs in UPJ patients with clinical 
parameters showed that miR-125-5p was inversely correlated with hydronephrosis grade 
(spearman r = -0,63, p = 0,003, Table 4). In addition, a slight but significant inverse correlation 
with pelvic diameter was also observed for miR-let-7a-5p and miR-125-5p and with 
hydronephrosis grade for miR-let-7a-5p and miR-26a-5p, and a slight but significant positive 
correlation with age for miR-let-7a-5p and miR-16-5p (Table 4). 
 
Table 4: Correlation of the urinary abundance of the five miRNAs in UPJ patients with clinical parameters 
 
Pelvic diameter (mm) Hydronephrosis grade Age (days) 
 
Spearman r p value Spearman r p value Spearman r p value 
hsa-let-7a-5p -0,47 0,04 -0,54 0,01 0,53 0,02 
hsa-miR-125b-5p -0,47 0,04 -0,63 0,003 0,26 n.s. 
hsa-miR-26a-5p -0,33 n.s. -0,50 0,02 0,07 n.s. 
hsa-miR-16-5p -0,20 n.s. -0,18 n.s. 0,49 0,03 
hsa-miR-29b-3p 0,40 n.s. 0,37 n.s. -0,29 n.s. 
 
 
Identification of most prominent dysregulated pathways and mRNA targets in obstructive 
nephropathy 
706 differentially expressed mRNAs were observed in kidneys of neonatal mice with 
partial UUO, including increased expression of markers of fibrosis such as Tgf-β1 and different 
forms of collagen (Additional file 3). To prioritize the mRNA targets, the five selected common 
miRNAs in mice and human obstructive nephropathy were combined with these 706 
differentially expressed mRNAs using Ingenuity Pathway Analysis (IPA).  
Then, we focused on the direct connections of the 5 miRNAs as generated from the 
predicted networks from IPA analysis. This led to the identification of 35 predicted target 
mRNAs for these 5 miRNAs (Additional file 5 and Additional file 6, 7, 8). Next, in order to 
focus on the most prominent molecular changes, only mRNAs predicted to be targeted by at least 
2 of the 5 miRNAs were kept for further analysis: E3 ubiquitin-protein ligase DXT4 (Dtx4), 
leiomodin-1 (Lmod1), a disintegrin-like and metallopeptidase (reprolysin type) with 
thrombospondin type 1 motif, 19 (Adamts19) and neuron navigator 1 (Nav1) (Table 5, 
Additional file 5).  
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Table 5: Most prominent dysregulated mRNA target in obstructive nephropathy. 
Gene Symbol 
Description 
FC p-value 
let-7a-
5p 
miR-
125b-5p 
miR-  
16-5p 
miR-
26a-5p 
miR- 
29b-3p 
Dtx4 
E3 ubiquitin-protein 
ligase or deltex 4 
homolog  
2,41 1,23E-03      
Lmod1 
leiomodin 1 (smooth 
muscle) 
1,57 1,48E-03      
Adamts19 
a disintegrin-like and 
metallopeptidase 
(reprolysin type) 
with 
thrombospondin type 
1 motif, 19 
2,97 5,67E-04 
   
  
Nav1 
neuron navigator 1 
1,57 1,64E-03      
FC: fold change. 
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MiRNA knockdown leads to dysregulated expression of the mRNA targets in renal cells in 
vitro  
 
To validate the results of the in silico analysis, we next assessed whether the predicted miRNA-
mRNA target pairs were directly associated in human renal cells. Human kidney cells (HK2) 
were treated for 48h with chemically modified molecules blocking the action of specific miRNA 
(antagomirs). In the presence of antagomirs, the detected signal of let-7a, miR-16-5p, miR-125b-
5p, miR-26a-5p and miR-29b-3p was significantly decreased (Figure 1).  
 
 
Figure 1. Selected miRNA expression in response to antagomirs in vitro. Expression of let-7a (A), miR-
125b-5p (B), miR-16-5p (C), miR-26a-5p (D) and miR-29b-3p (E) was assessed by RT-PCR in HK2 cells 
treated or not with antagomirs. Cont: control; Antag: antagomir. *p<0.05 versus Cont. 
  
 
 
 
 113 
 
MRNA expression of let-7a and miR-125b-3p target DTX4 was significantly increased in 
response to downregulation of let-7a but was unmodified by antagomir anti-miR-125b-3p 
(Figure 2A). Moreover, significant upregulation of neuron navigator 1 NAV1 was observed in 
HK2 cells treated with the miR-29b-3p antagomir (Figure 2D). Surprisingly, the use of 
antagomirs for miR-125b-5p and miR-26a-5p resulted in slight but significant downregulation of 
LMOD1, ADAMTS19 and NAV1 (Figures 2B-D), a result opposite than the predicted regulation, 
which possibly indicates an indirect mechanism of effect of these two miRNAs on these targets. 
Antagomirs for miR-125b-5p, miR-16-5p and miR-29b-3p showed no effect on DTX4, LMOD1 
and ADAMTS19, respectively (Figure 2A-C). 
 
 
Figure 2. Selected mRNA predicted target expression in response to antagomirs in vitro. Expression of 
E3 ubiquitin-protein ligase DXT4 (DTX4)(A), leiomodin-1 (LMOD1)(B), a disintegrin-like and 
metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 19 (ADAMTS19)(C) and neuron 
navigator 1 (NAV1)(D) was assessed by RT-PCR in HK2 cells treated or not with antagomirs against let-
7a, miR-125b-5p, miR-16-5p, miR-26a-5p or miR-29b-3p. Cont: control; Antag: antagomir. *p<0.05 
versus Cont. 
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Dtx4 and Nav1 are dysregulated during complete UUO in vivo 
Since obstructive nephropathy potentially induces different pathways in the developing and the 
adult kidney we also verified the expression of the mRNA targets in the adult mouse complete 
UUO model, using 8 male mice with complete UUO and 6 sham operated mice. We 
demonstrated that, similarly to what we observed in partial UUO in neonatal mice, Dtx4 and 
Nav1 expression was significantly increased in UUO mice compared to the sham (Figure 3A and 
3C), while Lmod1 was not modified (Figure 3B). The signal for Adamts19 was too weak to 
provide any reliable data. In addition to the targets, we also showed that the renal expression of 
Tgf-β and collagen 1, two markers of fibrosis, and IL-6, a marker of inflammation was 
significantly increased in UUO mice compared to the sham (Figure 3D-F), validating the 
pathological changes observed in this model. 
 
Figure 3. Selected mRNA predicted target expression in response to adult complete UUO in vivo. 
Renal expression of E3 ubiquitin-protein ligase DXT4 (Dtx4)(A), leiomodin-1 (Lmod1)(B), neuron 
navigator 1 (Nav1)(C), transforming growth factor beta (Tgfb)(D), collagen 1 (Col1a1)(E), and interleukin 
6 (Il6)(F) was assessed by RT-PCR in adult mice after 7 days UUO.*p<0.05 versus Sham. 
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6.4. Discussion 
Obstructive nephropathies, with UPJ obstruction as the prototypic obstructive 
nephropathy, are frequently encountered developmental anomalies in the pediatric population. 
Although renal fibrosis and inflammation are involved in the pathophysiology of severe UPJ 
obstruction, the molecular mechanisms underlying evolution of the lesions remain undetermined. 
In addition, most of this information has been obtained in animal models of disease. Recently 
discovered small non-coding RNAs called miRNAs are excreted and are stable in urine. Hence, 
urinary miRNAs could help to further decipher the pathophysiology of UPJ obstruction and 
generate the missing link between human and animal data. In this study we combined human 
urinary miRNA data and animal kidney tissue miRNA and mRNA data in a systems biology 
approach to obtain insight in the pathophysiology of the disease and improve upon the 
translatability of the results. The combined approach and independent validation pointed to the 
consistent dysregulation of specific miRNAs and to new potential targets in UPJ obstruction.  
MiRNAs let-7a-5p, miR-125b-5p, miR-16-5p, miR-26a-5p and miR-29b-3p were 
consistently modified in mice and humans. Among these, miR-29b is a well-known player in 
renal pathologies and especially fibrosis. Indeed, miR-29b targets specific fibrotic molecules 
including collagens or β-smooth muscle actin, and its abundance is reduced in many fibrotic 
pathologies as its expression is inhibited by TGFβ (Qin et al., 2011, Zhu et al., 2013). The 
protective role of miR-29b in fibrosis was further demonstrated in vivo since restoring miR-29b 
levels in a diabetic nephropathy animal model reversed accumulation of renal extracellular matrix 
(Chen et al., 2014). On the other hand, to our knowledge, this is the first time that miR-16 and 
let-7a are associated to the development of kidney disease, as these miRNAs were mostly 
characterized to be involved in cancer (Liu et al., 2012, Dong et al., 2010, Wang et al., 2013, 
Han et al., 2016, Chen et al., 2015a, Papadopoulos et al., 2015a). Downregulation of let-7a has 
also been observed in scleroderma, contributing to the excessive deposition of collagen and tissue 
fibrosis in the skin (Makino et al., 2013). Few data is available for miR-125b and kidney disease. 
Circulating miR-125b was found downregulated in chronic kidney disease (CKD) in hypertensive 
patients suffering from cardiovascular disease (Chen et al., 2015b). In another study upregulation 
of miR-125b protected against cisplatin-induced kidney injury via inhibition of Nuclear factor 
erythroid-2-related factor 2 (Joo et al., 2013). MiR-26a has previously been reported to be over 
expressed in lung epithelia during development and to be involved in glomerular and tubular 
injury related to podocyte damage and maintenance of glomerular filtration rate (Ho et al., 2008). 
A recent small-scale study (n=4 UPJ obstruction patients vs n=4 tumor-resection controls) 
identified in kidney tissue five miRNAs associated to UPJ obstruction. None of those overlapped 
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with the human urinary miRNAs in our study and one, hsa-miR-342-5p, was also found in kidney 
tissue to be associated to obstruction in the partial neonatal mouse model, however with an 
opposite regulation.  
A total of 35 mRNA targets for these differentially expressed miRNAs were predicted 
with the use of Ingenuity Pathway Analysis. In vitro validation of the predicted miRNA-mRNA 
pairs and in vivo assessment of the observed mRNA changes led to the sound confirmation of the 
regulation of E3 ubiquitin-protein ligase DTX4 by let-7a. Although E3 ubiquitin-protein ligase 
DTX4 has not yet been found associated to obstructive nephropathy, using the Kidney & Urinary 
Pathway Knowledge Base (KUPKB, (Klein et al., 2012) we observed that it has been found to be 
induced in models of polycystic kidney disease (Chen et al., 2008, Dweep et al., 2013) and in a 
lupus nephritis model (Teramoto et al., 2008). Furthermore, DTX4 is a member of Notch 
Signaling non-canonical pathway (Viatour et al., 2011). It has been described that activation of 
Notch signaling can lead to fibrosis (Sirin and Susztak, 2012, Lavoz et al., 2014, Djudjaj et al., 
2012, Sanchez-Nino and Ortiz, 2012, Sweetwyne et al., 2014). Hence one can hypothesize that 
downregulation of let-7a, activates DTX4 and the Notch signaling pathway, promoting the 
progression of fibrosis in UPJ obstruction.  
NAV1 is a protein mostly found in neurons and is reported to play a critical role in 
microtubule development (Martinez-Lopez et al., 2005), but has not yet been implicated in UPJ 
obstruction. Coinciding with DTX4, NAV1 expression is also induced in a model of polycystic 
kidney disease (Chen et al., 2008) and is induced in vitro by the major pro-fibrotic cytokine 
TGFβ (Brennan et al., 2012), potentially linking NAV1 induction to fibrosis. It is notable, 
though, that the regulation of NAV1 by miR-29b-3p did not follow the classical regulation 
pattern (up regulation of a miRNA causes down regulation of a target or vice versa) in the partial 
UUO model. In contrast, in the in vitro experiment NAV1 followed the predicted regulation and 
confirming that it may be a direct target of miR-29b. Previous reports have documented that some 
miRNAs may not target mRNAs directly, but only block the protein translation, leaving the 
mRNA intact (Nottrott et al., 2006, Petersen et al., 2006, Pillai et al., 2005, Pasquinelli, 2012). 
Furthermore, other reports point to the fact that miRNAs may induce the same direction of 
regulation of their mRNA targets depending on the timeframe and conditions (Vasudevan, 2012, 
Vasudevan and Steitz, 2007, Vasudevan et al., 2007, Orom et al., 2008, Valinezhad Orang et 
al., 2014), providing an explanation of a possible indirect mechanism of miR-29b-NAV1 
regulation. Nevertheless, further investigation is needed to determine if NAV1 is a direct target of 
miR-29b in vivo and if it is an interesting molecule in the context of UPJ obstruction.   
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Combination of the human urine miRNA data with the mouse tissue data increased the 
confidence in the human data and allowed selecting the most promising miRNAs in human 
disease. A downside of our approach is that this type of prioritization will only focus on part of 
the molecular mechanism of UPJ. If signals for specific mechanisms are absent in, for example, 
humans due to technical limitations or absence of shedding of miRNAs in urine but not in mouse 
tissue, this mechanism is not necessarily irrelevant in the pathophysiology of UPJ. Another 
shortcoming of our study is the fact that we used unadjusted p-values. Infants with UPJ 
obstruction included in the study displayed a wide range of hydronephrosis (grade 1-4, Table 1) 
and pelvic diameter (6-40 mm, Table 1) which generates considerable variability in the UPJ 
obstruction group. The mean fold change after comparison of healthy controls and UPJ 
obstruction patients was only 1.21 fold (± 0.27) in this data. This is probably due to the fact that 
during excretion/shedding of miRNAs in urine the in-situ miRNA changes are flattened out. 
Moreover, correction for multiple testing resulted in no significant miRNAs in humans. We 
therefore continued the prioritization with unadjusted pvalues but we compensated for this 
shortcoming by the independent validation of the selected targets.  
In addition, we cannot be sure that the urinary miRNAs origin is from the kidney and not 
from other organ e.g. bladder, of the urinary system, but the combination of the human urine data 
with the mice tissue data (allowed by the ability of the miRNAs to be conserved between species) 
gives us high confidence.  In our study, we did not observe enriched canonical pathways when 
studying the miRNAs of human or mouse UPJ obstruction separately even if around hundreds of 
miRNAs were found significantly different. Hence we have used both statistical selection, 
combination of different omics data (miRNA and mRNA data) and pathway enrichment analysis 
to identify miRNAs and their targets most likely involved in the etiology of UPJ obstruction.  
 
6.5. Conclusion 
Collectively this study is the first to correlate a mouse model of neonatal partial UUO 
with human UPJ obstruction in a comprehensive systems biology analysis. Our data revealed let-
7a and miR-29b as molecules potentially involved in the development of fibrosis in UPJ 
obstruction via the control of DTX4 in both man and mice that would not be identified otherwise.  
We believe that our approach of combining omics data is generally applicable. Many 
omics studies generate long lists of differentially expressed molecules that are difficult to 
prioritize and does not necessarily inform on the actual impact of these changes in disease. To 
further improve on the validity and clinical translatability of the data, and because urine is a rich 
source of biomarkers that can be collected easily and non-invasively, combination of human urine 
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and animal tissue data (e.g. miRNA, metabolites, proteins etc) could be of great help to better 
understand the molecular mechanisms involved in the development of many complex diseases.  
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6.6. Materials and Methods 
 
Human samples  
The studies were performed in accordance with the ethical principles in the Declaration of 
Helsinki and Good Clinical Practice and was approved by the CPP SOOM II (number DC-2008-
452). Written informed consent was obtained from all participants (parents). The UPJO group 
was composed of patients with grade 1 to 4 hydronephrosis and a renal pelvic diameter between 6 
and 40 mm (Table 1). Urine was collected from boys (<1 y). Urine from patients was collected in 
the morning during 30 min using a sterile pediatric urine collection pouch (B. Braun, Boulogne, 
France) during hospital consultation. Samples from healthy controls were both collected in a 
hospital setting (from newborns with heart murmur) and at home. Immediately after collection, 
all urines were frozen at -20°C and stored at -80°C.  
 
Mouse models  
All mouse experiments were conducted in accordance with the NIH guide for the care and use of 
laboratory animals and were approved by the University of Virginia Animal Care and Use 
Committee (for the neonatal partial obstruction model) and the animal care and use committee 
UMS US006/INSERM, Toulouse, France (protocol number CEEA-122 2014-06 / 02605.01) for 
the complete adult obstruction model. 
Both the partial neonatal and adult complete unilateral ureteral obstruction (UUO) mouse models 
have been previously described (Thornhill et al., 2007, Klein et al., 2009). Neonatal mice and 
adult mice were sacrificed after 5-7 and 7 days of obstruction, respectively. 
 
 Microarray analysis  
Microarray analysis was carried out as described previously (Bachvarov et al., 2006, Faddaoui 
et al., 2016). Briefly, total RNA was extracted from kidney tissues of 9 neonatal mice with partial 
UUO (hydronephrosis grades 2 and 3) and 9 control sham operated mice. Fluorescently labeled 
cRNA targets were generated using the Fluorescent Linear Amplification Kit (Agilent) and 10.0 
mM Cyanine 3- or 5-labeled CTP (PerkinElmer, Boston, MA), and following user's manual. 
Cyanine labeled cRNA from UUO kidneys was mixed with the same amount of reverse-color 
cyanine-labeled cRNA from the corresponding control kidney samples and hybridized on the 
Agilent 44K Mouse Whole Genome Oligonucleotide Microarray. Array hybridization, washing 
and scanning were performed as previously described (Bachvarov et al., 2006, Faddaoui et al., 
2016).  
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MicroRNA expression profiling was performed using the Mouse miRNA Microarray Release 
15.0 (8×15K, G4471A-029152, Agilent Technologies), and the Human miRNA V3 Microarray 
Release 12.0 (8×15K, G44710C-021827, Agilent Technologies). Briefly, 100 ng of total RNA 
was labeled and hybridized using the commercial miRNA Microarray System with miRNA 
Complete and Hybridization Kit (Agilent Technologies) following manufacturer's instructions. 
Array hybridization, washing, scanning, data extraction, and analyses were performed as 
described previously. 
 
Cell models and antagomir treatment  
Human HK-2 cells were grown in a DMEM/F-12 Nut Mix medium supplemented with 10% heat-
inactivated fetal calf serum (FCS; GIBCO, Grand Island, NY, USA), 10 µg/mL of EGF, 5 µg/mL 
of insulin, 4 pg/mL Triiodothyronine (T3), 36ng/mL of hydrocortisone. After 24 hours of FCS 
starvation, HK-2 cells were transfected with 5 nmol IDT

 miRNA inhibitor targeting 5 
miRNAs: hsa-let-7a-5p (ref. no 67488991), hsa-miR-125b-5p (ref. no 67488990) hsa-miR-16-5p 
(ref no. 67488992), hsa-miR-26a-5p (ref. no.  67488993) and hsa-miR-29b-3p (ref. no. 
67488994), or with scrambled siRNA (Integrated DNA Technologies, Leuven, Belgium), using 
the DharmaFECT Duo transfection reagent (Dharmacon, Lafayette, CO, USA).  
 
Gene expression analysis 
Total RNA was extracted from human kidney cells (HK2 cells) and complete UUO kidney 
samples using the Illumina’s Epicentre MasterPure Kit (Madison, WI, USA). Reverse 
transcription was performed for the miRNAs with MiRCURY LNA Universal RT Kit of Exiqon 
(Vedbaek, Denmark) and for the mRNA with High Capacity cDNA Reverse Transcription Kit of 
Thermo Scientific (Waltham, MA, USA) on a FlexCycler2 (Analytik Jena AG, Jena, Germany). 
Quantitative PCR amplification was performed on a StepOnePlus Real-Time PCR System 
(Thermo Scientific Waltham, MA, USA). Sybr Green technology was used for miRNAs 
according to Exiqon’s kit, while for the mRNA PCR the MESA BLUE qPCR MasterMix Plus kit 
from Eurogentec (Liege, Belgium). The primers used for the PCR are listed in Additional File 9.  
 
Bioinformatic analysis  
Network and pathway analysis of the microarray data were performed using Ingenuity Pathway 
Analysis (IPA) software version 18488943 (IPA

, QIAGEN Redwood City, see 
http://www.Ingenuity.com).  
 
 121 
 
Statistics  
For the microarrays statistical analysis the freely available software Gene ARMADA was used 
(Chatziioannou et al., 2009). A background correction was made for all arrays by loess 
correction and normalization was made by linear lowess followed by quantile normalization. The 
statistically different genes were the result of a t-test analysis (p-value < 0.05). The results of the 
qPCR for the cell cultures and the partial and complete UUO experiments were expressed in fold 
change units based on 2
-ΔΔCt 
method. The graphs and the statistical analysis (Mann - Whitney test 
between the groups with p-value < 0.05 as significant) were performed with GraphPad Prism 
v5.0. 
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6.8 Additional Data 
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Additional Table 1: Differentially expressed miRNAs in human UPJ. 
Symbol 
Exp Fold 
Change 
Exp p-value Symbol 
Exp Fold 
Change 
Exp p-value 
Down-regulated 
mir-638 -3,467 2,29E-02 mir-639 -1,118 7,93E-03 
miR-188-5p -3,161 4,21E-02 miR-142-3p -1,116 2,65E-03 
miR-574-5p -2,9 6,73E-03 miR-30a-3p -1,116 1,00E-02 
miR-574-3p -2,439 2,54E-03 miR-644a -1,115 9,16E-03 
miR-483-5p -2,203 4,66E-02 miR-432-3p -1,113 1,62E-02 
mir-21 -1,948 1,20E-02 miR-18a-3p -1,112 4,23E-04 
mir-572 -1,893 1,73E-02 mir-449 -1,112 4,05E-02 
mir-601 -1,842 8,93E-03 miR-550a-3p -1,112 3,86E-02 
miR-671-5p -1,698 3,01E-02 miR-92a-2-5p -1,112 6,25E-03 
mir-10 -1,645 1,08E-02 miR-941 -1,11 2,72E-02 
mir-765 -1,586 1,74E-03 mir-647 -1,107 2,48E-02 
let-7a-5p -1,559 3,17E-03 miR-7a-5p -1,107 1,09E-02 
MIR659 -1,545 2,09E-02 miR-31-3p -1,104 8,13E-03 
miR-135a-1-3p -1,443 2,78E-02 miR-194-3p -1,101 1,36E-02 
miR-26a-5p -1,376 3,03E-02 miR-34a-5p -1,101 8,55E-03 
mir-204 -1,348 1,68E-02 miR-140-5p -1,1 5,27E-03 
miR-483-3p -1,344 1,30E-02 miR-369-3p -1,1 3,71E-03 
miR-32-3p -1,343 7,61E-03 mir-612 -1,098 2,17E-02 
mir-708 -1,336 4,21E-03 miR-548f-3p -1,096 2,50E-02 
mir-596 -1,329 9,72E-05 miR-148b-5p -1,094 4,30E-03 
mir-8 -1,328 3,15E-02 miR-27a-5p -1,089 7,76E-03 
mir-22 -1,31 2,18E-02 mir-302 -1,089 3,12E-02 
miR-1228-5p -1,306 3,42E-02 miR-590-3p -1,089 4,73E-02 
miR-16-5p -1,293 2,27E-03 mir-652 -1,089 6,27E-03 
mir-34 -1,271 3,42E-03 miR-767 -1,089 1,47E-02 
miR-1224-3p -1,264 2,50E-02 miR-34c-3p -1,088 2,40E-02 
mir-26 -1,263 1,99E-03 miR-17-3p -1,087 2,75E-02 
mir-23 -1,257 1,39E-02 miR-485-5p -1,087 4,96E-02 
miR-518c-5p -1,256 4,20E-06 mir-373 -1,081 3,15E-02 
let-7 -1,255 3,92E-04 miR-505-5p -1,081 2,59E-02 
miR-10b-3p -1,246 5,22E-03 mir-609 -1,08 3,61E-02 
miR-509-3p -1,244 8,27E-03 mir-580 -1,078 2,40E-02 
mir-27 -1,241 5,70E-03 mir-675 -1,078 4,03E-02 
mir-322 -1,233 3,15E-03 miR-1273h-5p -1,074 4,41E-02 
mir-17 -1,218 2,72E-05 miR-885-3p -1,064 4,91E-02 
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Symbol 
Exp Fold 
Change 
Exp p-value Symbol 
Exp Fold 
Change 
Exp p-value 
mir-30 -1,214 2,43E-02 miR-337-5p -1,06 2,89E-02 
mir-328 -1,212 1,12E-02 mir-122 -1,059 4,26E-02 
mir-29 -1,205 1,10E-02 mir-619 -1,118 8,27E-03 
mir-146 -1,201 8,54E-04 miR-299a-3p -1,119 5,09E-03 
miR-195-3p -1,188 2,99E-02 miR-29b-3p -1,153 2,93E-02 
miR-19b-3p -1,188 4,13E-02 miR-27b-5p -1,151 3,18E-03 
mir-130 -1,186 1,24E-02 miR-194-5p -1,145 1,63E-02 
miR-203a-3p -1,186 1,17E-02 miR-135a-5p -1,14 2,85E-02 
miR-92a-3p -1,185 3,93E-03 miR-10a-3p -1,139 1,10E-02 
miR-125b-5p -1,18 3,03E-02 mir-210 -1,138 2,94E-02 
miR-628-3p -1,18 8,60E-05 mir-325 -1,138 1,37E-02 
mir-297 -1,177 3,75E-03 mir-561 -1,137 2,48E-02 
mir-187 -1,17 1,24E-03 miR-526a -1,136 7,87E-03 
miR-149-3p -1,167 3,53E-02 miR-103-3p -1,135 6,67E-03 
mir-103 -1,164 3,81E-03 mir-581 -1,134 1,38E-02 
mir-148 -1,162 4,35E-03 mir-221 -1,133 1,12E-03 
miR-151-5p -1,162 9,09E-03 mir-383 -1,132 5,93E-03 
mir-432 -1,16 8,83E-03 miR-101-3p -1,13 3,98E-03 
mir-15 -1,159 1,85E-02 mir-31 -1,13 3,83E-03 
mir-192 -1,159 6,06E-03 miR-138-5p -1,129 4,33E-03 
mir-571 -1,155 1,03E-02 mir-19 -1,128 1,14E-02 
miR-376a-5p -1,122 7,03E-03 miR-532-5p -1,128 2,49E-03 
miR-9-5p -1,121 3,47E-03 miR-219a-2-3p -1,127 7,56E-03 
mir-25 -1,119 7,90E-03 mir-626 -1,127 1,23E-03 
   
   
Up-regulated 
miR-18b-3p 1,051 4,35E-02 miR-187-5p 1,274 2,71E-02 
mir-183 1,056 4,06E-02 miR-425-3p 1,274 1,79E-02 
miR-146a-3p 1,058 2,64E-02 mir-627 1,291 2,91E-03 
miR-455-3p 1,066 4,69E-02 mir-634 1,311 4,03E-02 
mir-368 1,07 2,64E-02 miR-191-3p 1,345 7,21E-03 
miR-15b-3p 1,077 1,90E-02 miR-541-3p 1,415 2,80E-02 
miR-106b-3p 1,078 4,41E-02 miR-362-5p 1,478 2,88E-02 
miR-1231-3p 1,079 7,39E-03 mir-181 1,613 4,97E-02 
mir-217 1,081 4,11E-02 mir-631 1,945 4,91E-02 
miR-628 1,082 4,80E-02 mir-874 3,275 2,06E-02 
miR-624-5p 1,084 4,49E-02 mir-643 1,205 7,48E-03 
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Symbol 
Exp Fold 
Change 
Exp p-value Symbol 
Exp Fold 
Change 
Exp p-value 
miR-377-5p 1,085 3,67E-02 miR-193a-3p 1,211 1,42E-02 
mir-668 1,088 1,27E-02 mir-154 1,216 7,24E-03 
miR-450b-5p 1,089 1,41E-02 miR-129-1-3p 1,241 1,56E-03 
mir-191 1,092 1,37E-02 mir-887 1,249 4,31E-03 
miR-514a-3p 1,094 4,84E-03 miR-376a-3p 1,259 1,11E-03 
miR-100-3p 1,095 4,26E-02 miR-365-3p 1,27 2,22E-02 
miR-138-2-3p 1,095 4,89E-02 miR-7-1-3p 1,142 4,19E-02 
miR-501-3p 1,095 2,81E-02 miR-124-5p 1,144 4,57E-03 
miR-24-1-5p 1,096 8,30E-03 miR-133a-3p 1,144 2,32E-03 
mir-425 1,096 9,06E-03 mir-555 1,145 3,71E-02 
miR-144-5p 1,097 1,57E-03 mir-607 1,146 7,35E-03 
miR-127-5p 1,098 2,05E-02 mir-661 1,146 4,51E-02 
miR-593-5p 1,098 4,16E-02 mir-877 1,146 4,42E-02 
mir-379 1,101 3,60E-02 miR-532-3p 1,147 1,23E-02 
miR-875-5p 1,101 4,08E-02 miR-26b-3p 1,148 1,13E-02 
miR-182-3p 1,102 6,80E-03 mir-552 1,149 8,86E-03 
miR-488-5p 1,103 2,83E-03 miR-218-1-3p 1,15 1,15E-03 
miR-582-5p 1,103 1,40E-02 miR-223-5p 1,15 1,84E-02 
mir-133 1,105 7,67E-03 mir-566 1,152 1,70E-02 
miR-486-5p 1,106 8,87E-03 mir-551 1,154 3,55E-03 
miR-219a-5p 1,11 3,40E-02 mir-597 1,154 6,21E-03 
miR-34a-3p 1,113 8,73E-03 MIR1229 1,157 3,62E-02 
mir-548 1,113 1,26E-02 miR-218-2-3p 1,157 1,60E-02 
mir-635 1,113 1,44E-03 miR-192-3p 1,161 1,96E-02 
miR-202-5p 1,114 4,57E-02 miR-520a-5p 1,163 5,47E-03 
mir-412 1,116 3,68E-02 mir-891 1,163 4,24E-03 
mir-32 1,118 5,03E-03 mir-943 1,164 2,10E-03 
miR-515-5p 1,118 7,06E-03 mir-588 1,17 3,40E-03 
mir-489 1,121 7,94E-03 miR-4712-5p 1,175 2,47E-02 
mir-506 1,121 1,06E-02 mir-216 1,178 4,94E-02 
miR-153-3p 1,124 2,51E-02 mir-150 1,179 4,25E-02 
miR-509-5p 1,124 7,95E-03 miR-518a-3p 1,182 4,89E-02 
miR-642a-5p 1,127 3,73E-02 miR-329-3p 1,19 7,54E-03 
miR-1233-3p 1,128 2,06E-02 mir-515 1,191 2,34E-02 
mir-149 1,128 4,20E-02 miR-409-3p 1,193 3,57E-04 
miR-548c-3p 1,128 3,19E-03 miR-615-5p 1,194 1,08E-05 
miR-625-3p 1,128 4,09E-02 mir-126 1,197 3,38E-02 
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Symbol 
Exp Fold 
Change 
Exp p-value Symbol 
Exp Fold 
Change 
Exp p-value 
mir-567 1,129 4,42E-02 miR-361-5p 1,198 2,57E-02 
miR-542-3p 1,13 3,27E-02 miR-767-3p 1,2 4,52E-03 
mir-935 1,13 2,39E-03 mir-920 1,204 1,76E-03 
miR-138-1-3p 1,132 2,34E-02 mir-1231 1,142 2,36E-02 
miR-145-3p 1,134 4,68E-03 mir-653 1,142 3,32E-02 
miR-340-3p 1,134 3,86E-02    
miR-221-5p 1,137 3,51E-02    
miR-671-3p 1,139 1,45E-02    
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Additional Table 2: Differentially expressed miRNAs in mouse partial UUO. 
Symbol 
Exp Fold 
Change 
Exp p-value Symbol 
Exp Fold 
Change 
Exp p-value 
Down-regulated 
miR-690 -5,186 3,80E-03 miR-148a-3p -1,702 2,11E-02 
miR-466b-5p -4,151 7,82E-03 miR-140-5p -1,69 4,05E-03 
miR-1827 -4,035 1,30E-02 miR-378a-3p -1,687 5,88E-03 
let-7a-5p -3,558 3,93E-03 miR-342-3p -1,673 3,01E-03 
miR-143-3p -3,332 3,72E-04 miR-146a-5p -1,671 3,30E-03 
miR-125b-5p -3,219 3,15E-03 miR-126a-5p -1,649 1,11E-02 
miR-26a-5p -3,175 1,13E-03 miR-708-5p -1,609 4,41E-03 
miR-199a-5p -3,087 2,18E-03 miR-139-5p -1,431 2,50E-02 
miR-466f-3p -3,079 2,13E-02 miR-101b-3p -1,39 1,68E-02 
miR-10a-5p -3,052 4,39E-03 miR-296-5p -1,305 7,39E-04 
miR-181a-5p -3,028 1,54E-02 miR-344a-5p -1,286 1,37E-02 
miR-16-5p -2,913 6,97E-04 let-7d-3p -1,28 2,83E-05 
miR-3941 -2,901 8,56E-03 miR-330-5p -1,277 4,20E-02 
miR-466g -2,815 1,42E-02 miR-615-3p -1,274 3,37E-05 
miR-467a-3p -2,737 1,35E-02 miR-328-3p -1,228 3,35E-04 
miR-196a-5p -2,729 1,25E-03 miR-186-5p -1,222 1,80E-03 
miR-23a-3p -2,674 8,97E-05 miR-193a-3p -1,221 2,70E-03 
miR-214-3p -2,655 1,04E-02 miR-203a-3p -1,198 1,21E-02 
miR-17-5p -2,508 4,05E-03 miR-149-5p -1,186 1,11E-02 
miR-19b-3p -2,448 1,89E-03 miR-425-5p -1,183 1,48E-02 
miR-130a-3p -2,363 4,00E-03 miR-10a-3p -1,174 4,67E-03 
miR-103-3p -2,179 6,54E-03 miR-181a-1-3p -1,172 6,81E-03 
miR-141-3p -2,167 3,48E-03 miR-744-5p -1,165 3,13E-03 
miR-27a-3p -2,155 2,10E-03 miR-669a-5p -1,15 1,41E-02 
miR-30c-5p -2,151 1,35E-02 miR-320b -1,149 7,42E-03 
miR-218-5p -2,146 3,27E-03 miR-132-3p -1,108 2,30E-02 
miR-151-5p -2,144 8,04E-03 miR-338-5p -1,069 1,01E-05 
miR-652-3p -2,111 1,02E-02 miR-3909 -1,066 6,45E-04 
miR-92a-3p -2,076 8,14E-03 miR-487b-3p -1,041 3,56E-14 
miR-145-5p -2,056 1,73E-03 miR-106b-3p -1,04 8,56E-05 
miR-1895 -2,046 4,82E-03 miR-467b-5p -1,028 2,66E-04 
miR-24-3p -1,96 6,50E-03 miR-151-3p -1,005 6,31E-04 
miR-100-5p -1,952 1,32E-02 miR-331-3p -1,9 1,35E-02 
miR-455-3p -1,933 1,34E-02 miR-126a-3p -1,846 1,63E-02 
miR-221-3p -1,931 3,96E-03 miR-200b-3p -1,841 1,12E-02 
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miR-142-3p -1,93 3,03E-03 miR-345-5p -1,809 2,80E-03 
miR-365-3p -1,928 1,45E-02    
   
   
Up-regulated 
miR-9-3p 1,006 1,32E-03 miR-452-5p 1,131 2,59E-05 
miR-20a-3p 1,035 3,55E-04 miR-29b-3p 10,073 3,10E-08 
miR-24-1-5p 1,05 8,59E-04 miR-224-5p 1,08 1,73E-06 
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Additional Table 3: Differentially expressed mRNAs in mouse partial UUO. 
Gene Symbol Description 
Exp Fold 
Change 
Exp p-value 
Down-regulated 
Aqp4 aquaporin 4 -3,45 0,00111702 
Egf epidermal growth factor -3,23 0,00002300 
Cfd complement factor D (adipsin) -3,03 0,00171642 
Cidea cell death-inducing DNA fragmentation factor, alpha subunit-like effector A -2,78 0,00061255 
Cox8b cytochrome c oxidase, subunit VIIIb -2,63 0,00358692 
Ptger3 prostaglandin E receptor 3 (subtype EP3) -2,63 0,00003000 
Aadat aminoadipate aminotransferase -2,50 0,00560964 
F13b coagulation factor XIII, beta subunit -2,44 0,00000551 
Abca13 ATP-binding cassette, sub-family A (ABC1), member 13 -2,38 0,00214086 
Slc14a2 solute carrier family 14 (urea transporter), member 2 -2,38 0,00100433 
C11orf54 chromosome 11 open reading frame 54 -2,27 0,00080400 
Efhd1 EF hand domain containing 1 -2,22 0,00228723 
HLA-A major histocompatibility complex, class I, A -2,17 0,00000121 
Mthfd1 
methylenetetrahydrofolate dehydrogenase (NADP+ dependent), 
methenyltetrahydrofolate cyclohydrolase, formyltetrahydrofolate synthase 
-2,17 0,00005360 
Pah phenylalanine hydroxylase -2,17 0,00001400 
Glod5 glyoxalase domain containing 5 -2,17 0,00000855 
Ppp1r1a protein phosphatase 1, regulatory (inhibitor) subunit 1A -2,13 0,00629651 
Slc16a7 solute carrier family 16 (monocarboxylic acid transporters), member 7 -2,13 0,00544090 
Acsl1 acyl-CoA synthetase long-chain family member 1 -2,13 0,00174555 
Slc6a19 solute carrier family 6 (neurotransmitter transporter), member 19 -2,13 0,00193457 
Slc34a3 solute carrier family 34 (sodium phosphate), member 3 -2,13 0,00012044 
Cldn8 claudin 8 -2,08 0,00377068 
Calb1 calbindin 1 -2,08 0,00262563 
Klf15 Kruppel-like factor 15 -2,08 0,00242003 
Kcnj10 potassium inwardly-rectifying channel, subfamily J, member 10 -2,08 0,00116043 
Slco1a6 solute carrier organic anion transporter family, member 1a6 -2,08 0,00127739 
Sult1d1 sulfotransferase family 1D, member 1 -2,08 0,00092928 
Dnase1 deoxyribonuclease I -2,08 0,00056505 
Apoo apolipoprotein O -2,08 0,00003190 
Fut9 fucosyltransferase 9 -2,08 0,00000160 
NAT8B N-acetyltransferase 8B (GCN5-related, putative, gene/pseudogene) -2,08 0,00134000 
KLK3 kallikrein-related peptidase 3 -2,08 0,00077500 
DEFB119 defensin, beta 119 -2,08 0,00001250 
Atp6v0a4 ATPase, H+ transporting, lysosomal V0 subunit A4 -2,04 0,00876550 
Slc5a8 solute carrier family 5 (iodide transporter), member 8 -2,04 0,00528178 
Gm13111 predicted gene 13111 -2,04 0,00217481 
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Slc16a4 solute carrier family 16 (monocarboxylic acid transporters), member 4 -2,04 0,00051605 
Slc26a4 solute carrier family 26, member 4 -2,04 0,00016218 
Slc5a3 solute carrier family 5 (inositol transporters), member 3 -2,04 0,00018154 
Slc9a3 solute carrier family 9 (sodium/hydrogen exchanger), member 3 -2,04 0,00005490 
S100g S100 calcium binding protein G -2,00 0,00586946 
Slco1a1 solute carrier organic anion transporter family, member 1a1 -2,00 0,00234929 
Adhfe1 alcohol dehydrogenase, iron containing, 1 -2,00 0,00155576 
Acy1 aminoacylase 1 -2,00 0,00087079 
ACSM2A acyl-CoA synthetase medium-chain family member 2A -2,00 0,00015300 
MPC1 mitochondrial pyruvate carrier 1 -2,00 0,00010700 
KIAA1919 KIAA1919 -1,96 0,00320000 
Clec2e/Clec2h C-type lectin domain family 2, member h -1,96 0,00168000 
Gk glycerol kinase -1,96 0,00175000 
Slc22a7 solute carrier family 22 (organic anion transporter), member 7 -1,96 0,00389173 
Ass1 argininosuccinate synthetase 1 -1,96 0,00228847 
Fam151a family with sequence simliarity 151, member A -1,96 0,00215228 
Igsf11 immunoglobulin superfamily, member 11 -1,96 0,00101758 
Pla1a phospholipase A1 member A -1,96 0,00078673 
Mccc1 methylcrotonoyl-Coenzyme A carboxylase 1 (alpha) -1,96 0,00034670 
Mpv17l Mpv17 transgene, kidney disease mutant-like -1,96 0,00027342 
Slc2a5 solute carrier family 2 (facilitated glucose transporter), member 5 -1,96 0,00005880 
4931408D14Rik RIKEN cDNA 4931408D14 gene -1,92 0,00352076 
Acox2 acyl-Coenzyme A oxidase 2, branched chain -1,92 0,00317214 
Hao2 hydroxyacid oxidase 2 -1,92 0,00128253 
Bdh1 3-hydroxybutyrate dehydrogenase, type 1 -1,92 0,00013154 
Hgd homogentisate 1, 2-dioxygenase -1,92 0,00080256 
Smpx small muscle protein, X-linked -1,92 0,00055296 
Cav2 caveolin 2 -1,92 0,00019344 
Lrrc19 leucine rich repeat containing 19 -1,92 0,00012931 
CYP4A11 cytochrome P450, family 4, subfamily A, polypeptide 11 -1,89 0,00427000 
TMEM52B transmembrane protein 52B -1,89 0,00011400 
Col4a3 collagen, type IV, alpha 3 -1,89 0,00739556 
Slc2a9 solute carrier family 2 (facilitated glucose transporter), member 9 -1,89 0,00446636 
Slc37a4 solute carrier family 37 (glucose-6-phosphate transporter), member 4 -1,89 0,00387738 
Slc22a8 solute carrier family 22 (organic anion transporter), member 8 -1,89 0,00368034 
Acot4 acyl-CoA thioesterase 4 -1,89 0,00314130 
Cth cystathionase (cystathionine gamma-lyase) -1,89 0,00266431 
Lactb2 lactamase, beta 2 -1,89 0,00256119 
Mep1a meprin 1 alpha -1,89 0,00243824 
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Sult1b1 sulfotransferase family 1B, member 1 -1,89 0,00268569 
Lypla1 lysophospholipase 1 -1,89 0,00136623 
Dmgdh dimethylglycine dehydrogenase precursor -1,89 0,00097338 
Aldh6a1 aldehyde dehydrogenase family 6, subfamily A1 -1,89 0,00049530 
Slc12a3 solute carrier family 12, member 3 -1,89 0,00045364 
Tcn2 transcobalamin 2 -1,89 0,00035310 
Kcnj15 potassium inwardly-rectifying channel, subfamily J, member 15 -1,89 0,00016787 
Slc16a12 solute carrier family 16 (monocarboxylic acid transporters), member 12 -1,89 0,00018462 
Slc5a12 solute carrier family 5 (sodium/glucose cotransporter), member 12 -1,89 0,00023751 
FAM195A family with sequence similarity 195, member A -1,85 0,00722000 
CFAP52 cilia and flagella associated protein 52 -1,85 0,00037700 
CYP2A6 (includes 
others) 
cytochrome P450, family 2, subfamily A, polypeptide 6 -1,85 0,00031100 
Igfbp2 insulin-like growth factor binding protein 2 -1,85 0,00391132 
Retsat retinol saturase (all trans retinol 13,14 reductase) -1,85 0,00527904 
Exoc6 exocyst complex component 6 -1,85 0,00392703 
Cox7a1 cytochrome c oxidase, subunit VIIa 1 -1,85 0,00020395 
Dio1 deiodinase, iodothyronine, type I -1,85 0,00101572 
Npnt nephronectin -1,85 0,00068332 
Acaa2 
acetyl-Coenzyme A acyltransferase 2 (mitochondrial 3-oxoacyl-Coenzyme A 
thiolase) 
-1,85 0,00001060 
Folh1 folate hydrolase -1,82 0,00633490 
Cldn10 claudin 10 -1,82 0,00409089 
Bckdhb branched chain ketoacid dehydrogenase E1, beta polypeptide -1,82 0,00341395 
Slc4a1 solute carrier family 4 (anion exchanger), member 1 -1,82 0,00293392 
Slc5a2 solute carrier family 5 (sodium/glucose cotransporter), member 2 -1,82 0,00197650 
Tmed6 transmembrane emp24 protein transport domain containing 6 -1,82 0,00232168 
Agxt2 alanine-glyoxylate aminotransferase 2 -1,82 0,00113143 
Ttc36 tetratricopeptide repeat domain 36 -1,82 0,00011848 
Fam13a family with sequence similarity 13, member A -1,82 0,00054200 
PC pyruvate carboxylase -1,82 0,00020700 
LRP2 low density lipoprotein receptor-related protein 2 -1,82 0,00004590 
CA14 carbonic anhydrase XIV -1,79 0,00290000 
ACOT1 acyl-CoA thioesterase 1 -1,79 0,00218000 
Hnf4aos hepatic nuclear factor 4 alpha, opposite strand -1,79 0,00007630 
Nepn nephrocan -1,79 0,00438063 
Slc27a2 solute carrier family 27 (fatty acid transporter), member 2 -1,79 0,00487881 
Wscd2 WSC domain containing 2 -1,79 0,00449274 
Atp6v1c2 ATPase, H+ transporting, lysosomal V1 subunit C2 -1,79 0,00290917 
Dynll2 dynein light chain LC8-type 2 -1,79 0,00097154 
Hif1a hypoxia inducible factor 1, alpha subunit -1,79 0,00115289 
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Proz protein Z, vitamin K-dependent plasma glycoprotein -1,79 0,00124629 
Ednrb endothelin receptor type B -1,79 0,00063445 
Tfrc transferrin receptor -1,79 0,00074885 
Tpk1 thiamine pyrophosphokinase -1,79 0,00027421 
Chpt1 choline phosphotransferase 1 -1,79 0,00025737 
Spp2 secreted phosphoprotein 2 -1,79 0,00007470 
Acss1 acyl-CoA synthetase short-chain family member 1 -1,79 0,00002130 
Scel sciellin -1,75 0,00650457 
Mro maestro -1,75 0,00319368 
Susd2 sushi domain containing 2 -1,75 0,00417487 
Slc25a13 
solute carrier family 25 (mitochondrial carrier, adenine nucleotide 
translocator), member 13 
-1,75 0,00320486 
Slc5a11 solute carrier family 5 (sodium/glucose cotransporter), member 11 -1,75 0,00114186 
Lrrc66 leucine rich repeat containing 66 -1,75 0,00089267 
Slc39a8 solute carrier family 39 (metal ion transporter), member 8 -1,75 0,00101403 
Fn3k fructosamine 3 kinase -1,75 0,00007400 
Angpt1 angiopoietin 1 -1,75 0,00051827 
Kcnt1 potassium channel, subfamily T, member 1 -1,75 0,00032549 
Cgref1 cell growth regulator with EF hand domain 1 -1,75 0,00008990 
Cycs cytochrome c, somatic -1,75 0,00010120 
Grhpr glyoxylate reductase/hydroxypyruvate reductase -1,75 0,00015128 
Pdzk1 PDZ domain containing 1 -1,75 0,00013139 
Gas2 growth arrest specific 2 -1,75 0,00002360 
Gcsh glycine cleavage system protein H (aminomethyl carrier) -1,75 0,00001720 
Atp6v1e1 ATPase, H+ transporting, lysosomal V1 subunit E1 -1,75 0,00000466 
TMEM242 transmembrane protein 242 -1,75 0,00374000 
MTFP1 mitochondrial fission process 1 -1,75 0,00081700 
Col4a5 collagen, type IV, alpha 5 -1,72 0,00726260 
Dnajc12 DnaJ (Hsp40) homolog, subfamily C, member 12 -1,72 0,00339041 
Mogat2 monoacylglycerol O-acyltransferase 2 -1,72 0,00353556 
Hspa4 heat shock protein 4 -1,72 0,00146002 
Npl N-acetylneuraminate pyruvate lyase -1,72 0,00255782 
Miox myo-inositol oxygenase -1,72 0,00029527 
Tpd52l1 tumor protein D52-like 1 -1,72 0,00073787 
Serpina6 serine (or cysteine) peptidase inhibitor, clade A, member 6 -1,72 0,00053010 
Slc2a2 solute carrier family 2 (facilitated glucose transporter), member 2 -1,72 0,00058582 
Hnf4a hepatic nuclear factor 4, alpha -1,72 0,00035201 
Arhgap24 Rho GTPase activating protein 24 -1,72 0,00020558 
Sdhb succinate dehydrogenase complex, subunit B, iron sulfur (Ip) -1,72 0,00018012 
Mdh1 malate dehydrogenase 1, NAD (soluble) -1,72 0,00010605 
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Aga aspartylglucosaminidase -1,72 0,00000847 
SLC22A25 solute carrier family 22, member 25 -1,70 0,00158000 
MT-ATP6 ATP synthase F0 subunit 6 -1,70 0,00035000 
Atp5b ATP synthase, H+ transporting mitochondrial F1 complex, beta subunit -1,69 0,00432072 
Ppargc1a peroxisome proliferative activated receptor, gamma, coactivator 1 alpha -1,69 0,00317024 
Slc6a12 
solute carrier family 6 (neurotransmitter transporter, betaine/GABA), member 
12 
-1,69 0,00311852 
Crim1 cysteine rich transmembrane BMP regulator 1 (chordin like) -1,69 0,00033293 
Dlst 
dihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-glutarate 
complex) 
-1,69 0,00127817 
Sgk1 serum/glucocorticoid regulated kinase 1 -1,69 0,00113983 
Grpel1 GrpE-like 1, mitochondrial -1,69 0,00094813 
Rmnd1 required for meiotic nuclear division 1 homolog (S, cerevisiae) -1,69 0,00088226 
Eaf2 ELL associated factor 2 -1,69 0,00070345 
Pou3f3 POU domain, class 3, transcription factor 3 -1,69 0,00051809 
Fxyd4 FXYD domain-containing ion transport regulator 4 -1,69 0,00019303 
Aifm1 apoptosis-inducing factor, mitochondrion-associated 1 -1,69 0,00003160 
Ankib1 ankyrin repeat and IBR domain containing 1 -1,69 0,00002840 
Chchd10 coiled-coil-helix-coiled-coil-helix domain containing 10 -1,69 0,00004000 
Olfr784/Olfr801 olfactory receptor 784 -1,67 0,00680000 
MCUR1 mitochondrial calcium uniporter regulator 1 -1,67 0,00075300 
Bhmt2 betaine-homocysteine methyltransferase 2 -1,67 0,00465821 
Tal2 T-cell acute lymphocytic leukemia 2 -1,67 0,00606718 
Afp alpha fetoprotein -1,67 0,00532478 
Cd36 CD36 antigen -1,67 0,00531177 
Itga8 integrin alpha 8 -1,67 0,00510390 
Fabp4 fatty acid binding protein 4, adipocyte -1,67 0,00469567 
Itgb6 integrin beta 6 -1,67 0,00279674 
Abhd3 abhydrolase domain containing 3 -1,67 0,00427509 
Dusp9 dual specificity phosphatase 9 -1,67 0,00211848 
Rab3ip RAB3A interacting protein -1,67 0,00349749 
Dld dihydrolipoamide dehydrogenase -1,67 0,00327237 
Sectm1b secreted and transmembrane 1B -1,67 0,00325139 
Habp2 hyaluronic acid binding protein 2 -1,67 0,00260458 
Mal myelin and lymphocyte protein, T-cell differentiation protein -1,67 0,00290473 
Tspan1 tetraspanin 1 -1,67 0,00082139 
Aldob aldolase B, fructose-bisphosphate -1,67 0,00241812 
Fitm1 fat storage-inducing transmembrane protein 1 -1,67 0,00038601 
Kcnn2 
potassium intermediate/small conductance calcium-activated channel, 
subfamily N, member 2 
-1,67 0,00066358 
Slc22a2 solute carrier family 22 (organic cation transporter), member 2 -1,67 0,00078398 
Dpep1 dipeptidase 1 (renal) -1,67 0,00048015 
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Aadac arylacetamide deacetylase (esterase) -1,67 0,00017005 
B830017H08Rik RIKEN cDNA B830017H08 gene -1,67 0,00026470 
Cyp2d26 cytochrome P450, family 2, subfamily d, polypeptide 26 -1,67 0,00010853 
Mgst3 microsomal glutathione S-transferase 3 -1,64 0,00942431 
Pcca propionyl-Coenzyme A carboxylase, alpha polypeptide -1,64 0,00535324 
Scnn1a sodium channel, nonvoltage-gated 1 alpha -1,64 0,00547112 
Lrrc58 leucine rich repeat containing 58 -1,64 0,00380238 
Gchfr GTP cyclohydrolase I feedback regulator -1,64 0,00130043 
Galnt14 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 14 
-1,64 0,00061836 
Trim63 tripartite motif-containing 63 -1,64 0,00201115 
Ndufs2 NADH dehydrogenase (ubiquinone) Fe-S protein 2 -1,64 0,00152016 
Suclg1 succinate-CoA ligase, GDP-forming, alpha subunit -1,64 0,00119485 
Ndufab1 NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex, 1 -1,64 0,00062359 
Sucnr1 succinate receptor 1 -1,64 0,00076425 
A1cf APOBEC1 complementation factor -1,64 0,00003200 
Cab39l calcium binding protein 39-like -1,64 0,00039268 
Abhd14a abhydrolase domain containing 14A -1,64 0,00011949 
Tmem27 transmembrane protein 27 -1,64 0,00005060 
Gcnt1 glucosaminyl (N-acetyl) transferase 1, core 2 -1,64 0,00000930 
LOC102634389 uncharacterized LOC102634389 -1,64 0,00485000 
CYP2F1 cytochrome P450, family 2, subfamily F, polypeptide 1 -1,64 0,00203000 
KIAA1191 KIAA1191 -1,64 0,00023900 
Gm4013 predicted gene 4013 -1,61 0,00063000 
COLGALT2 collagen beta(1-O)galactosyltransferase 2 -1,61 0,00130000 
Aldh9a1 aldehyde dehydrogenase 9, subfamily A1 -1,61 0,00702787 
Klf9 Kruppel-like factor 9 -1,61 0,00738868 
Sfxn2 sideroflexin 2 -1,61 0,00685846 
Tmem37 transmembrane protein 37 -1,61 0,00708295 
Npb neuropeptide B -1,61 0,00531441 
Lrba LPS-responsive beige-like anchor -1,61 0,00464128 
Spag5 sperm associated antigen 5 -1,61 0,00388354 
Cdkal1 CDK5 regulatory subunit associated protein 1-like 1 -1,61 0,00205178 
Iqgap2 IQ motif containing GTPase activating protein 2 -1,61 0,00114383 
Ect2 ect2 oncogene -1,61 0,00078848 
Clybl citrate lyase beta like -1,61 0,00029066 
Snhg11 small nucleolar RNA host gene 11 (non-protein coding) -1,61 0,00039544 
Nnt nicotinamide nucleotide transhydrogenase -1,61 0,00017317 
Aqp11 aquaporin 11 -1,61 0,00013192 
Cyc1 cytochrome c-1 -1,61 0,00013885 
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Tfpi2 tissue factor pathway inhibitor 2 -1,59 0,00725041 
Nudt4 nudix (nucleoside diphosphate linked moiety X)-type motif 4 -1,59 0,00387031 
Idh3a isocitrate dehydrogenase 3 (NAD+) alpha -1,59 0,00597849 
Ttc32 tetratricopeptide repeat domain 32 -1,59 0,00589992 
Tmem116 transmembrane protein 116 -1,59 0,00298010 
BC026585 cDNA sequence BC026585 -1,59 0,00424543 
Slc6a20b solute carrier family 6 (neurotransmitter transporter), member 20B -1,59 0,00226240 
Iqcg IQ motif containing G -1,59 0,00167877 
Med14 mediator complex subunit 14 -1,59 0,00086897 
Ndufs8 NADH dehydrogenase (ubiquinone) Fe-S protein 8 -1,59 0,00248945 
Oxct1 3-oxoacid CoA transferase 1 -1,59 0,00115044 
Slc16a9 solute carrier family 16 (monocarboxylic acid transporters), member 9 -1,59 0,00273549 
Vwce von Willebrand factor C and EGF domains -1,59 0,00294521 
Vpreb1 pre-B lymphocyte gene 1 -1,59 0,00069106 
Slc4a4 solute carrier family 4 (anion exchanger), member 4 -1,59 0,00108217 
Fars2 phenylalanine-tRNA synthetase 2 (mitochondrial) -1,59 0,00071588 
Aoah acyloxyacyl hydrolase -1,59 0,00024277 
Dlat 
dihydrolipoamide S-acetyltransferase (E2 component of pyruvate 
dehydrogenase complex) 
-1,59 0,00003280 
SLC51B solute carrier family 51, beta subunit -1,59 0,00702000 
Gapdh-ps14 glyceraldehyde-3-phosphate dehydrogenase, pseudogene 14 -1,59 0,00072800 
HIST2H2AA3/HI
ST2H2AA4 
histone cluster 2, H2aa3 -1,59 0,00057800 
Ifi44 interferon-induced protein 44 -1,56 0,00607329 
Sar1b SAR1 gene homolog B (S, cerevisiae) -1,56 0,00518175 
Esd esterase D/formylglutathione hydrolase -1,56 0,00293989 
Slc22a23 solute carrier family 22, member 23 -1,56 0,00117172 
Cryl1 crystallin, lambda 1 -1,56 0,00211500 
Osbpl1a oxysterol binding protein-like 1A -1,56 0,00070092 
Amacr alpha-methylacyl-CoA racemase -1,56 0,00026397 
Bmp7 bone morphogenetic protein 7 -1,56 0,00011306 
Agps alkylglycerone phosphate synthase -1,56 0,00000856 
HSD3B1 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 -1,56 0,00349000 
FUOM fucose mutarotase -1,56 0,00220000 
SUGCT succinyl-CoA:glutarate-CoA transferase -1,56 0,00092800 
TTC7A tetratricopeptide repeat domain 7A -1,56 0,00017300 
PLPPR4 phospholipid phosphatase related 4 -1,56 0,00074700 
NXPE3 neurexophilin and PC-esterase domain family, member 3 -1,56 0,00054100 
Cyp2d22 cytochrome P450, family 2, subfamily d, polypeptide 22 -1,54 0,00444173 
Depdc1b DEP domain containing 1B -1,54 0,00678738 
Hspa8 heat shock protein 8 -1,54 0,00488649 
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Mrpl46 mitochondrial ribosomal protein L46 -1,54 0,00668229 
Ptgr2 prostaglandin reductase 2 -1,54 0,00331605 
Acadvl acyl-Coenzyme A dehydrogenase, very long chain -1,54 0,00420651 
Pla2g5 phospholipase A2, group V -1,54 0,00154006 
Nus1 nuclear undecaprenyl pyrophosphate synthase 1 homolog (S, cerevisiae) -1,54 0,00130058 
Ak7 adenylate kinase 7 -1,54 0,00085965 
Gabarapl1 gamma-aminobutyric acid (GABA) A receptor-associated protein-like 1 -1,54 0,00281588 
Glyat glycine-N-acyltransferase -1,54 0,00201235 
Bpnt1 bisphosphate 3'-nucleotidase 1 -1,54 0,00168723 
Slc25a39 solute carrier family 25, member 39 -1,54 0,00193822 
Iah1 isoamyl acetate-hydrolyzing esterase 1 homolog (S, cerevisiae) -1,54 0,00122843 
Atp6v1a ATPase, H+ transporting, lysosomal V1 subunit A -1,54 0,00076280 
Slc23a3 solute carrier family 23 (nucleobase transporters), member 3 -1,54 0,00005470 
Gjb2 gap junction protein, beta 2 -1,54 0,00036640 
Slc25a17 
solute carrier family 25 (mitochondrial carrier, peroxisomal membrane 
protein), member 17 
-1,54 0,00029170 
Sfxn1 sideroflexin 1 -1,54 0,00025563 
Rb1 retinoblastoma 1 -1,54 0,00002730 
Uqcrfs1 ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 -1,54 0,00002390 
Adk adenosine kinase -1,54 0,00000995 
Cisd1 CDGSH iron sulfur domain 1 -1,54 0,00000259 
TMEM229A transmembrane protein 229A -1,54 0,00197000 
4930481A15Rik RIKEN cDNA 4930481A15 gene -1,54 0,00048100 
MAP7 microtubule-associated protein 7 -1,54 0,00035500 
DNAH12 dynein, axonemal, heavy chain 12 -1,54 0,00015200 
Ndufb2 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2 -1,39 0,00140315 
    
Up-regulated 
Cxcl2 chemokine (C-X-C motif) ligand 2 1,32 0,00395815 
Actb actin, beta 1,35 0,00997899 
Dtx3 deltex 3 homolog (Drosophila) 1,51 0,00184538 
PEA15 phosphoprotein enriched in astrocytes 15 1,51 0,00119000 
Spon1 spondin 1, (f-spondin) extracellular matrix protein 1,51 0,00002450 
TENM3 teneurin transmembrane protein 3 1,52 0,00746000 
Thsd1 thrombospondin, type I, domain 1 1,52 0,00433737 
POU2F2 POU class 2 homeobox 2 1,52 0,00270000 
CCDC184 coiled-coil domain containing 184 1,52 0,00315000 
Cd200r1 CD200 receptor 1 1,52 0,00135133 
Crym crystallin, mu 1,52 0,00226392 
Zfp740 zinc finger protein 740 1,52 0,00037731 
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Tmeff1 transmembrane protein with EGF-like and two follistatin-like domains 1 1,52 0,00027038 
Inhbb inhibin beta-B 1,53 0,00524078 
B2m beta-2 microglobulin 1,53 0,00265061 
1600029O15Rik RIKEN cDNA 1600029O15 gene 1,53 0,00094096 
MFSD2A major facilitator superfamily domain containing 2A 1,53 0,00234000 
2310035P21Rik RIKEN cDNA 2310035P21 gene 1,53 0,00008070 
Postn periostin, osteoblast specific factor 1,53 0,00027639 
Procr protein C receptor, endothelial 1,54 0,00700356 
Tnip2 TNFAIP3 interacting protein 2 1,54 0,00690884 
Kcnk3 potassium channel, subfamily K, member 3 1,54 0,00569228 
Tro trophinin 1,54 0,00481998 
Col23a1 collagen, type XXIII, alpha 1 1,54 0,00181177 
Ifngr1 interferon gamma receptor 1 1,54 0,00140742 
Gsdmd gasdermin D 1,54 0,00037279 
MAP7D1 MAP7 domain containing 1 1,54 0,00034100 
PCDHB14 protocadherin beta 14 1,54 0,00005410 
Ehbp1l1 EH domain binding protein 1-like 1 1,55 0,00678198 
E330032C10Rik RIKEN cDNA E330032C10 gene 1,55 0,00568000 
Fam105a family with sequence similarity 105, member A 1,55 0,00324852 
Synpo synaptopodin 1,55 0,00473111 
FAM3D family with sequence similarity 3, member D 1,55 0,00195000 
Pot1b protection of telomeres 1B 1,55 0,00132454 
BEAN1 brain expressed, associated with NEDD4, 1 1,56 0,00282000 
C1qtnf7 C1q and tumor necrosis factor related protein 7 1,56 0,00470089 
Ifitm7 interferon induced transmembrane protein 7 1,56 0,00455554 
C1qb complement component 1, q subcomponent, beta polypeptide 1,56 0,00256316 
Arid5a AT rich interactive domain 5A (MRF1-like) 1,56 0,00105630 
Itgb4 integrin beta 4 1,56 0,00001760 
Nav1 neuron navigator 1 1,57 0,00163736 
Gpm6b glycoprotein m6b 1,57 0,00330637 
C7 complement component 7 1,57 0,00078200 
Gria4 glutamate receptor, ionotropic, AMPA4 (alpha 4) 1,57 0,00087762 
Runx2 runt related transcription factor 2 1,57 0,00108565 
Hs6st2 heparan sulfate 6-O-sulfotransferase 2 1,57 0,00151680 
Lmod1 leiomodin 1 (smooth muscle) 1,57 0,00148332 
Myh9 myosin, heavy polypeptide 9, non-muscle 1,57 0,00002880 
PLEC plectin 1,57 0,00001490 
Duxbl1 (includes 
others) 
double homeobox B-like 1 1,58 0,00498000 
Zyx zyxin 1,58 0,00686626 
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Pdgfra platelet derived growth factor receptor, alpha polypeptide 1,58 0,00241345 
Mmp7 matrix metallopeptidase 7 1,58 0,00284682 
Plekhg2 
pleckstrin homology domain containing, family G (with RhoGef domain) 
member 2 
1,58 0,00127753 
Hbegf heparin-binding EGF-like growth factor 1,58 0,00011449 
Rras Harvey rat sarcoma oncogene, subgroup R 1,58 0,00000544 
Mmp2 matrix metallopeptidase 2 1,59 0,00724283 
Slamf9 SLAM family member 9 1,59 0,00685326 
Hmcn1 hemicentin 1 1,59 0,00380406 
KIAA0895L KIAA0895-like 1,59 0,00611000 
Cebpb CCAAT/enhancer binding protein (C/EBP), beta 1,59 0,00177273 
Il6st interleukin 6 signal transducer 1,59 0,00005560 
Gm29790 predicted gene, 29790 1,60 0,00484000 
Cntn6 contactin 6 1,60 0,00126061 
Gng8 guanine nucleotide binding protein (G protein), gamma 8 1,60 0,00123813 
Myadm myeloid-associated differentiation marker 1,60 0,00079076 
S1pr2 sphingosine-1-phosphate receptor 2 1,60 0,00054251 
Cbarp calcium channel, voltage-dependent, beta subunit associated regulatory protein 1,60 0,00006380 
Tc2n tandem C2 domains, nuclear 1,61 0,00714254 
Inpp5d inositol polyphosphate-5-phosphatase D 1,61 0,00629272 
Camk2b calcium/calmodulin-dependent protein kinase II, beta 1,61 0,00576891 
Adh7 alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide 1,61 0,00489196 
Tlr1 toll-like receptor 1 1,61 0,00192742 
Tgfb1 transforming growth factor, beta 1 1,61 0,00185473 
Crip1 cysteine-rich protein 1 (intestinal) 1,61 0,00098435 
Stat4 signal transducer and activator of transcription 4 1,62 0,00502516 
Zc3h6 zinc finger CCCH type containing 6 1,62 0,00448020 
Gpsm3 G-protein signalling modulator 3 (AGS3-like, C, elegans) 1,62 0,00641185 
ADGRA2 adhesion G protein-coupled receptor A2 1,62 0,00554000 
Efs embryonal Fyn-associated substrate 1,62 0,00416027 
Fkbp10 FK506 binding protein 10 1,62 0,00378981 
Meis3 Meis homeobox 3 1,62 0,00184210 
Muc4 mucin 4 1,62 0,00297751 
Nkain4 Na+/K+ transporting ATPase interacting 4 1,62 0,00174388 
Sparc secreted acidic cysteine rich glycoprotein 1,62 0,00060352 
Col12a1 collagen, type XII, alpha 1 1,62 0,00000021 
Sorbs2 sorbin and SH3 domain containing 2 1,63 0,00062293 
Unc5a unc-5 homolog A (C, elegans) 1,63 0,00209716 
Ugcg UDP-glucose ceramide glucosyltransferase 1,63 0,00133485 
Tnnt2 troponin T2, cardiac 1,64 0,00328438 
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Lox lysyl oxidase 1,64 0,00518796 
Stx1a syntaxin 1A (brain) 1,65 0,00320208 
Lyl1 lymphoblastomic leukemia 1 1,65 0,00424853 
Slc11a1 
solute carrier family 11 (proton-coupled divalent metal ion transporters), 
member 1 
1,65 0,00372550 
Mmrn1 multimerin 1 1,65 0,00302821 
Crlf2 cytokine receptor-like factor 2 1,65 0,00289161 
Bok BCL2-related ovarian killer protein 1,65 0,00028961 
Rtn4 reticulon 4 1,66 0,00461938 
Pamr1 peptidase domain containing associated with muscle regeneration 1 1,66 0,00389178 
Tmem158 transmembrane protein 158 1,66 0,00406425 
Pik3r5 phosphoinositide-3-kinase, regulatory subunit 5, p101 1,66 0,00282719 
Gdf9 growth differentiation factor 9 1,66 0,00125671 
Pdlim1 PDZ and LIM domain 1 (elfin) 1,66 0,00048683 
C1orf198 chromosome 1 open reading frame 198 1,67 0,00739000 
Col2a1 collagen, type II, alpha 1 1,67 0,00526899 
Dock10 dedicator of cytokinesis 10 1,67 0,00117190 
Synj2 synaptojanin 2 1,67 0,00072451 
Adamtsl5 ADAMTS-like 5 1,67 0,00001990 
Cx3cr1 chemokine (C-X3-C) receptor 1 1,68 0,00480877 
Pik3cd phosphatidylinositol 3-kinase catalytic delta polypeptide 1,68 0,00443714 
Hivep3 human immunodeficiency virus type I enhancer binding protein 3 1,68 0,00605928 
Tnik TRAF2 and NCK interacting kinase 1,68 0,00217911 
Egflam EGF-like, fibronectin type III and laminin G domains 1,68 0,00069338 
Hcls1 hematopoietic cell specific Lyn substrate 1 1,68 0,00053185 
MKRN2OS MKRN2 opposite strand 1,68 0,00011700 
Stra6l STRA6-like 1,69 0,00355000 
Col5a2 collagen, type V, alpha 2 1,69 0,00313506 
Col15a1 collagen, type XV, alpha 1 1,69 0,00029020 
Ptrf polymerase I and transcript release factor 1,69 0,00097095 
Rbp1 retinol binding protein 1, cellular 1,69 0,00032857 
Irak3 interleukin-1 receptor-associated kinase 3 1,69 0,00000927 
Lpxn leupaxin 1,70 0,00545926 
ZNF616 zinc finger protein 616 1,70 0,00386000 
Ciita class II transactivator 1,70 0,00091141 
Frmd3 FERM domain containing 3 1,70 0,00052296 
Vim vimentin 1,70 0,00051564 
Esyt1 extended synaptotagmin-like protein 1 1,70 0,00001590 
Cd300lf CD300 antigen like family member F 1,71 0,00359009 
Rasgef1a RasGEF domain family, member 1A 1,71 0,00402791 
 141 
 
Igf2bp2 insulin-like growth factor 2 mRNA binding protein 2 1,71 0,00054944 
Lmna lamin A 1,71 0,00216762 
P3H3 prolyl 3-hydroxylase 3 1,71 0,00178000 
Antxr1 anthrax toxin receptor 1 1,72 0,00440600 
Rhoc ras homolog gene family, member C 1,72 0,00481923 
Garnl3 GTPase activating RANGAP domain-like 3 1,72 0,00159376 
A730008I21Rik RIKEN cDNA A730008I21 gene 1,73 0,00342284 
Nek6 NIMA (never in mitosis gene a)-related expressed kinase 6 1,73 0,00015588 
Dst dystonin 1,74 0,00696501 
PAK3 p21 protein (Cdc42/Rac)-activated kinase 3 1,74 0,00530000 
C1orf100 chromosome 1 open reading frame 100 1,74 0,00273000 
Lair1 leukocyte-associated Ig-like receptor 1 1,74 0,00238892 
Olfml2b olfactomedin-like 2B 1,74 0,00227414 
Csf1 colony stimulating factor 1 (macrophage) 1,74 0,00099039 
Pltp phospholipid transfer protein 1,74 0,00110555 
Arpc1b actin related protein 2/3 complex, subunit 1B 1,74 0,00054525 
Cd248 CD248 antigen, endosialin 1,74 0,00045621 
Timp2 tissue inhibitor of metalloproteinase 2 1,74 0,00038810 
Emp3 epithelial membrane protein 3 1,74 0,00000156 
CLEC10A C-type lectin domain family 10, member A 1,75 0,00515000 
Csdc2 cold shock domain containing C2, RNA binding 1,75 0,00379612 
Cxcl13 chemokine (C-X-C motif) ligand 13 1,75 0,00052198 
Gm39680 predicted gene, 39680 1,75 0,00000818 
Actc1 actin, alpha, cardiac muscle 1 1,76 0,00172284 
Fbn1 fibrillin 1 1,76 0,00128103 
Sepn1 selenoprotein N, 1 1,77 0,00608359 
Wbscr17 Williams-Beuren syndrome chromosome region 17 homolog (human) 1,77 0,00578499 
Ddr2 discoidin domain receptor family, member 2 1,78 0,00149479 
Wt1 Wilms tumor 1 homolog 1,79 0,00263757 
Pcdh10 protocadherin 10 1,79 0,00222523 
Dpysl4 dihydropyrimidinase-like 4 1,79 0,00059011 
Cybb cytochrome b-245, beta polypeptide 1,80 0,00111453 
Gm33298 predicted gene, 33298 1,80 0,00148000 
Efemp2 epidermal growth factor-containing fibulin-like extracellular matrix protein 2 1,80 0,00009270 
Stat3 signal transducer and activator of transcription 3 1,80 0,00007710 
Chst12 carbohydrate sulfotransferase 12 1,81 0,00281312 
Lum lumican 1,81 0,00071985 
Ckap4 cytoskeleton-associated protein 4 1,81 0,00159650 
Krt8 keratin 8 1,81 0,00000212 
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Tlr2 toll-like receptor 2 1,83 0,00710037 
Nfkb2 nuclear factor of kappa light polypeptide gene enhancer in B-cells 2, p49/p100 1,84 0,00550569 
Pglyrp1 peptidoglycan recognition protein 1 1,84 0,00271478 
Ccl11 chemokine (C-C motif) ligand 11 1,84 0,00330891 
Plek pleckstrin 1,84 0,00219709 
LOC728392 uncharacterized LOC728392 1,84 0,00178000 
MMP23B matrix metallopeptidase 23B 1,84 0,00009830 
Mfi2 
antigen p97 (melanoma associated) identified by monoclonal antibodies 133,2 
and 96,5 
1,85 0,00492744 
Mfap2 microfibrillar-associated protein 2 1,85 0,00268228 
Col6a2 collagen, type VI, alpha 2 1,85 0,00050407 
Tnfrsf12a tumor necrosis factor receptor superfamily, member 12a 1,85 0,00053480 
Myof myoferlin 1,85 0,00024512 
Areg amphiregulin 1,85 0,00007950 
Akap12 A kinase (PRKA) anchor protein (gravin) 12 1,85 0,00004360 
Irf8 interferon regulatory factor 8 1,85 0,00002760 
Tmsb4x (includes 
others) 
thymosin, beta 4, X chromosome 1,85 0,00003200 
Pcdh9 protocadherin 9 1,86 0,00946012 
ZBTB8B zinc finger and BTB domain containing 8B 1,86 0,00585000 
Fam155a family with sequence similarity 155, member A 1,86 0,00448713 
Fyb FYN binding protein 1,86 0,00453929 
Il1b interleukin 1 beta 1,86 0,00270017 
Sdc1 syndecan 1 1,86 0,00033755 
Trpv6 transient receptor potential cation channel, subfamily V, member 6 1,86 0,00004920 
Fam171b family with sequence similarity 171, member B 1,87 0,00044044 
Tgfb1i1 transforming growth factor beta 1 induced transcript 1 1,87 0,00114505 
Hspb1 heat shock protein 1 1,87 0,00096796 
Vgll3 vestigial like 3 (Drosophila) 1,87 0,00010022 
Vav1 vav 1 oncogene 1,88 0,00499737 
Myo1f myosin IF 1,88 0,00158189 
Flna filamin, alpha 1,88 0,00010633 
CXCL6 chemokine (C-X-C motif) ligand 6 1,90 0,00457000 
Gm5067 predicted gene 5067 1,90 0,00528791 
Cdkn2b cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) 1,90 0,00433846 
Fap fibroblast activation protein 1,90 0,00047633 
Tuba1a tubulin, alpha 1A 1,90 0,00074464 
Ifi27l2a/Ifi27l2b interferon, alpha-inducible protein 27 like 2A 1,91 0,00209000 
Dnm3os dynamin 3, opposite strand 1,91 0,00173453 
Tmem173 transmembrane protein 173 1,91 0,00185531 
Lbh limb-bud and heart 1,91 0,00013459 
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Ccl20 chemokine (C-C motif) ligand 20 1,92 0,00757383 
Slc15a3 solute carrier family 15, member 3 1,92 0,00491781 
CLEC4A C-type lectin domain family 4, member A 1,92 0,00157000 
Mst1r macrophage stimulating 1 receptor (c-met-related tyrosine kinase) 1,92 0,00044329 
Vwc2 von Willebrand factor C domain containing 2 1,93 0,00404572 
Col6a1 collagen, type VI, alpha 1 1,93 0,00519340 
Ptch2 patched homolog 2 1,93 0,00325673 
Hpgds hematopoietic prostaglandin D synthase 1,93 0,00087700 
Vipr2 vasoactive intestinal peptide receptor 2 1,93 0,00105498 
Thbs3 thrombospondin 3 1,93 0,00130123 
Bcl2a1c B-cell leukemia/lymphoma 2 related protein A1c 1,94 0,00758314 
HLA-DQA1 major histocompatibility complex, class II, DQ alpha 1 1,94 0,00480000 
SERPINA3 
serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), 
member 3 
1,94 0,00446000 
2310043M15Rik RIKEN cDNA 2310043M15 gene 1,94 0,00324145 
Lrp1 low density lipoprotein receptor-related protein 1 1,94 0,00066749 
Tpm1 tropomyosin 1, alpha 1,94 0,00000868 
AW112010 expressed sequence AW112010 1,95 0,00411484 
Edn1 endothelin 1 1,95 0,00122156 
F3 coagulation factor III 1,96 0,00470628 
UGT2B7 UDP glucuronosyltransferase 2 family, polypeptide B7 1,96 0,00341000 
C1qtnf5 C1q and tumor necrosis factor related protein 5 1,96 0,00380955 
Arsj arylsulfatase J 1,96 0,00077534 
4930588G05Rik RIKEN cDNA 4930588G05 gene 1,96 0,00209884 
Ncf1 neutrophil cytosolic factor 1 1,96 0,00038228 
Il1r2 interleukin 1 receptor, type II 1,96 0,00003490 
Lrrc25 leucine rich repeat containing 25 1,97 0,00130160 
Col16a1 collagen, type XVI, alpha 1 1,97 0,00033561 
Shisa3 shisa homolog 3 (Xenopus laevis) 1,98 0,00441042 
Pf4 platelet factor 4 1,98 0,00661321 
Ankrd1 ankyrin repeat domain 1 (cardiac muscle) 1,98 0,00079822 
Thbs2 thrombospondin 2 1,98 0,00058586 
Glipr1 GLI pathogenesis-related 1 (glioma) 1,98 0,00005260 
Kif1a kinesin family member 1A 1,99 0,00425129 
Jun Jun oncogene 1,99 0,00000003 
Hk2 hexokinase 2 2,00 0,00214794 
Apobec1 apolipoprotein B mRNA editing enzyme, catalytic polypeptide 1 2,00 0,00152598 
Gpnmb glycoprotein (transmembrane) nmb 2,01 0,00268795 
Clec5a C-type lectin domain family 5, member a 2,01 0,00115478 
Fign fidgetin 2,02 0,00826869 
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2210016H18Rik RIKEN cDNA 2210016H18 gene 2,02 0,00654241 
Wnt4 wingless-related MMTV integration site 4 2,02 0,00000164 
Clec7a C-type lectin domain family 7, member a 2,03 0,00359371 
Eno2 enolase 2, gamma neuronal 2,03 0,00325402 
Csf2rb 
colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-
macrophage) 
2,04 0,00348451 
Nudt6 nudix (nucleoside diphosphate linked moiety X)-type motif 6 2,04 0,00159545 
Itga4 integrin alpha 4 2,05 0,00226084 
Trbv1 T cell receptor beta, variable 1 2,05 0,00227000 
Col1a2 collagen, type I, alpha 2 2,05 0,00000769 
Twist2 twist homolog 2 (Drosophila) 2,06 0,00208382 
CSTA cystatin A (stefin A) 2,07 0,00550000 
Efhd2 EF hand domain containing 2 2,07 0,00000000 
Socs2 suppressor of cytokine signaling 2 2,08 0,00125522 
Laptm5 lysosomal-associated protein transmembrane 5 2,08 0,00136304 
Inhba inhibin beta-A 2,08 0,00013431 
Lsp1 lymphocyte specific 1 2,08 0,00011626 
Birc3 baculoviral IAP repeat-containing 3 2,09 0,00483301 
Relb avian reticuloendotheliosis viral (v-rel) oncogene related B 2,09 0,00665853 
Psmb8 
proteasome (prosome, macropain) subunit, beta type 8 (large multifunctional 
peptidase 7) 
2,09 0,00137712 
Serping1 serine (or cysteine) peptidase inhibitor, clade G, member 1 2,09 0,00022201 
Tnni2 troponin I, skeletal, fast 2 2,09 0,00002140 
Cyth4 cytohesin 4 2,11 0,00154584 
Cpne7 copine VII 2,12 0,00370499 
ADGRE1 adhesion G protein-coupled receptor E1 2,14 0,00285000 
Adamts2 
a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin 
type 1 motif, 2 
2,16 0,00548476 
Maff v-maf musculoaponeurotic fibrosarcoma oncogene family, protein F (avian) 2,16 0,00070706 
Acta1 actin, alpha 1, skeletal muscle 2,16 0,00006830 
Mirg miRNA containing gene 2,16 0,00010286 
Ccl9 chemokine (C-C motif) ligand 9 2,16 0,00005090 
Sox9 SRY-box containing gene 9 2,18 0,00559392 
Sntg2 syntrophin, gamma 2 2,18 0,00072400 
C1s complement component 1, s subcomponent 2,19 0,00023879 
Ccdc80 coiled-coil domain containing 80 2,19 0,00003740 
Klf6 Kruppel-like factor 6 2,20 0,00283277 
Mrc1 mannose receptor, C type 1 2,21 0,00110458 
Myocd myocardin 2,21 0,00074337 
Parp3 poly (ADP-ribose) polymerase family, member 3 2,21 0,00006810 
CLEC4C C-type lectin domain family 4, member C 2,22 0,00699000 
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Ms4a4b (includes 
others) 
membrane-spanning 4-domains, subfamily A, member 4B 2,22 0,00572000 
Gdf10 growth differentiation factor 10 2,24 0,00138785 
Ms4a6b membrane-spanning 4-domains, subfamily A, member 6B 2,25 0,00642459 
Trim29 tripartite motif-containing 29 2,26 0,00576890 
C1qa complement component 1, q subcomponent, alpha polypeptide 2,26 0,00328903 
Meg3 maternally expressed 3 2,26 0,00002080 
Rhou ras homolog gene family, member U 2,29 0,00138383 
Serpinb5 serine (or cysteine) peptidase inhibitor, clade B, member 5 2,29 0,00297478 
Creb5 cAMP responsive element binding protein 5 2,30 0,00512008 
Il34 interleukin 34 2,30 0,00126166 
Cyr61 cysteine rich protein 61 2,30 0,00048726 
Phlda3 pleckstrin homology-like domain, family A, member 3 2,30 0,00006450 
Acta2 actin, alpha 2, smooth muscle, aorta 2,30 0,00000188 
Ubd ubiquitin D 2,31 0,00073263 
Tubb6 tubulin, beta 6 2,31 0,00000675 
Ndp Norrie disease (pseudoglioma) (human) 2,34 0,00230022 
Cx3cl1 chemokine (C-X3-C motif) ligand 1 2,34 0,00001120 
Ednra endothelin receptor type A 2,35 0,00344960 
Ccl19 chemokine (C-C motif) ligand 19 2,35 0,00124702 
Clca3a1/Clca3a2 chloride channel accessory 3A1 2,35 0,00000836 
Foxj1 forkhead box J1 2,36 0,00276918 
Dpysl3 dihydropyrimidinase-like 3 2,36 0,00142205 
Fmo5 flavin containing monooxygenase 5 2,36 0,00048053 
FCGR2A Fc fragment of IgG, low affinity IIa, receptor (CD32) 2,36 0,00028100 
Ccl17 chemokine (C-C motif) ligand 17 2,37 0,00465528 
Spon2 spondin 2, extracellular matrix protein 2,37 0,00098260 
Ccdc88b coiled-coil domain containing 88B 2,38 0,00590947 
Iqsec3 IQ motif and Sec7 domain 3 2,38 0,00254086 
Cd14 CD14 antigen 2,38 0,00002010 
Nfkbiz 
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, 
zeta 
2,39 0,00167531 
HLA-DRB5 major histocompatibility complex, class II, DR beta 5 2,41 0,00499000 
Dtx4 deltex 4 homolog (Drosophila) 2,41 0,00122821 
Plac8 placenta-specific 8 2,41 0,00092193 
Mmp14 matrix metallopeptidase 14 (membrane-inserted) 2,41 0,00025483 
Ms4a7 membrane-spanning 4-domains, subfamily A, member 7 2,44 0,00156870 
AKR1B10 aldo-keto reductase family 1, member B10 (aldose reductase) 2,44 0,00109000 
Pdlim7 PDZ and LIM domain 7 2,44 0,00005310 
Cpxm2 carboxypeptidase X 2 (M14 family) 2,45 0,00000363 
Scara3 scavenger receptor class A, member 3 2,46 0,00089339 
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Fcer1g Fc receptor, IgE, high affinity I, gamma polypeptide 2,47 0,00012336 
2200002D01Rik RIKEN cDNA 2200002D01 gene 2,47 0,00005410 
Socs3 suppressor of cytokine signaling 3 2,48 0,00430235 
Fbln1 fibulin 1 2,48 0,00340385 
Fcrls Fc receptor-like S, scavenger receptor 2,48 0,00055090 
Wdfy4 WD repeat and FYVE domain containing 4 2,49 0,00641305 
Icam1 intercellular adhesion molecule 1 2,50 0,00013089 
Cygb cytoglobin 2,51 0,00212215 
Spp1 secreted phosphoprotein 1 2,52 0,00005040 
Col1a1 collagen, type I, alpha 1 2,53 0,00033859 
Loxl1 lysyl oxidase-like 1 2,54 0,00082523 
Tpm2 tropomyosin 2, beta 2,54 0,00074746 
Anxa13 annexin A13 2,55 0,00254006 
MS4A6A membrane-spanning 4-domains, subfamily A, member 6A 2,57 0,00232000 
CCL21 chemokine (C-C motif) ligand 21 2,58 0,00065500 
Coro1a coronin, actin binding protein 1A 2,58 0,00011610 
GXYLT2 glucoside xylosyltransferase 2 2,59 0,00086900 
ANXA8/ANXA8L
1 
annexin A8-like 1 2,59 0,00005990 
Fos FBJ osteosarcoma oncogene 2,59 0,00000881 
Nckap1l NCK associated protein 1 like 2,60 0,00116803 
Runx1 runt related transcription factor 1 2,60 0,00079936 
Mfap4 microfibrillar-associated protein 4 2,62 0,00694925 
Atf3 activating transcription factor 3 2,62 0,00000046 
Tnfsf13b tumor necrosis factor (ligand) superfamily, member 13b 2,63 0,00285740 
Serpine1 serine (or cysteine) peptidase inhibitor, clade E, member 1 2,66 0,00126704 
Serpinf1 serine (or cysteine) peptidase inhibitor, clade F, member 1 2,69 0,00078037 
Timp1 tissue inhibitor of metalloproteinase 1 2,74 0,00023804 
Penk preproenkephalin 2,75 0,00129473 
Upk3a uroplakin 3A 2,76 0,00342461 
Lgi2 leucine-rich repeat LGI family, member 2 2,77 0,00110409 
Uchl1 ubiquitin carboxy-terminal hydrolase L1 2,77 0,00000199 
Tagln transgelin 2,78 0,00009010 
Lcn2 lipocalin 2 2,79 0,00000929 
Krt18 keratin 18 2,79 0,00000089 
Clu clusterin 2,81 0,00000199 
Adam23 a disintegrin and metallopeptidase domain 23 2,82 0,00274975 
Cp ceruloplasmin 2,83 0,00036127 
Apbb1ip 
amyloid beta (A4) precursor protein-binding, family B, member 1 interacting 
protein 
2,83 0,00017779 
Aif1 allograft inflammatory factor 1 2,84 0,00428890 
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Aldh3b2 aldehyde dehydrogenase 3 family, member B2 2,84 0,00279623 
FCGR1A Fc fragment of IgG, high affinity Ia, receptor (CD64) 2,84 0,00278000 
Il33 interleukin 33 2,89 0,00129850 
Junb Jun-B oncogene 2,89 0,00023563 
Ptn pleiotrophin 2,90 0,00027148 
C1qc complement component 1, q subcomponent, C chain 2,91 0,00020037 
Gjb6 gap junction protein, beta 6 2,91 0,00018117 
Il18r1 interleukin 18 receptor 1 2,92 0,00007490 
Adamts19 
a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin 
type 1 motif, 19 
2,97 0,00056703 
Mfap5 microfibrillar associated protein 5 2,99 0,00215019 
Slit3 slit homolog 3 (Drosophila) 3,00 0,00083177 
Hp haptoglobin 3,00 0,00005760 
HLA-DQB1 major histocompatibility complex, class II, DQ beta 1 3,02 0,00078700 
Pdlim3 PDZ and LIM domain 3 3,02 0,00062099 
Lrrn2 leucine rich repeat protein 2, neuronal 3,02 0,00005380 
Tgfbi transforming growth factor, beta induced 3,11 0,00038365 
Thy1 thymus cell antigen 1, theta 3,12 0,00036506 
Mgp matrix Gla protein 3,25 0,00001510 
S100a6 S100 calcium binding protein A6 (calcyclin) 3,28 0,00000094 
Ccl7 chemokine (C-C motif) ligand 7 3,29 0,00025846 
Trem2 triggering receptor expressed on myeloid cells 2 3,53 0,00130911 
Cd44 CD44 antigen 3,56 0,00148334 
Ltbp2 latent transforming growth factor beta binding protein 2 3,58 0,00036313 
RAB7B RAB7B, member RAS oncogene family 3,59 0,00066900 
Vcam1 vascular cell adhesion molecule 1 3,66 0,00225302 
BCL2A1 BCL2-related protein A1 3,67 0,00234000 
Cyp2j13 cytochrome P450, family 2, subfamily j, polypeptide 13 3,73 0,00206565 
Sulf1 sulfatase 1 3,80 0,00053808 
Serpina3g 
(includes others) 
serine (or cysteine) peptidase inhibitor, clade A, member 3G 3,81 0,00035700 
Adcy7 adenylate cyclase 7 3,85 0,00018827 
Osmr oncostatin M receptor 3,91 0,00066072 
Ctss cathepsin S 3,92 0,00141361 
Upk1b uroplakin 1B 3,92 0,00020614 
Ccl5 chemokine (C-C motif) ligand 5 3,92 0,00000733 
Sprr2f small proline-rich protein 2F 4,04 0,00237408 
Egr1 early growth response 1 4,06 0,00000855 
Krt19 keratin 19 4,08 0,00004330 
LYZ lysozyme 4,10 0,00028000 
Cnn1 calponin 1 4,17 0,00000077 
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E330037M01Rik RIKEN cDNA E330037M01 gene 4,33 0,00278427 
Pmaip1 phorbol-12-myristate-13-acetate-induced protein 1 4,74 0,00014600 
Sprr1a small proline-rich protein 1A 4,87 0,00012525 
Fam25c family with sequence similarity 25, member C 4,96 0,00041500 
Egr2 early growth response 2 5,02 0,00000933 
Ccl2 chemokine (C-C motif) ligand 2 5,28 0,00028207 
AOC1 amine oxidase, copper containing 1 5,32 0,00038400 
Cxcl10 chemokine (C-X-C motif) ligand 10 6,99 0,00071279 
Krt20 keratin 20 9,35 0,00000438 
C3 complement component 3 12,24 0,00005770 
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Additional Table 4: Common deregulated miRNAs between human UPJ (urine) and mouse 
partial UUO (kidney tissue). 
 
 
Human UPJ Mouse partial UUO 
Symbol 
Exp Fold 
Change 
Exp p-value 
Exp Fold 
Change 
Exp p-value 
let-7a-5p -1,559 3,17E-03 -3,558 3,93E-03 
miR-125b-5p -1,18 3,03E-02 -3,219 3,15E-03 
miR-26a-5p -1,376 3,03E-02 -3,175 1,13E-03 
miR-16-5p -1,293 2,27E-03 -2,913 6,97E-04 
miR-29b-3p -1,153 2,93E-02 10,073 3,10E-08 
miR-19b-3p -1,188 4,13E-02 -2,448 1,89E-03 
miR-103-3p -1,135 6,67E-03 -2,179 6,54E-03 
miR-151-5p -1,162 9,09E-03 -2,144 8,04E-03 
miR-92a-3p -1,185 3,93E-03 -2,076 8,14E-03 
miR-455-3p 1,066 4,69E-02 -1,933 1,34E-02 
miR-142-3p -1,116 2,65E-03 -1,93 3,03E-03 
miR-365-3p 1,27 2,22E-02 -1,928 1,45E-02 
miR-140-5p -1,1 5,27E-03 -1,69 4,05E-03 
miR-193a-3p 1,211 1,42E-02 -1,221 2,70E-03 
miR-203a-3p -1,186 1,17E-02 -1,198 1,21E-02 
miR-10a-3p -1,139 1,10E-02 -1,174 4,67E-03 
miR-106b-3p 1,078 4,41E-02 -1,04 8,56E-05 
miR-24-1-5p 1,096 8,30E-03 1,05 8,59E-04 
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Additional Table 5: miRNAs and their respective mRNA targets. 
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Additional file 6: Molecular network predicted by IPA including let-7a-5p, miR-125b-5p and miR-16-5p 
and possibly related to hematological and immunological disease. Red= up regulated green= down 
regulated; all colored genes were identified in the partial UUO mouse mRNA dataset.  
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Additional file 7: Molecular network predicted by IPA including miR-26a-5p and miR-29b-3p and 
possibly related to organismal Injury and abnormalities. Red= up regulated green= down regulated; all 
colored genes were identified in the partial UUO mouse mRNA dataset. 
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Additional file 8: Molecular network predicted by IPA including miR-29b-3p and possibly related to cell 
death and survival and connective tissue development and function. Red= up regulated green= down 
regulated; all colored genes were identified in the partial UUO mouse mRNA dataset. 
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Additional file 9: Sequences of primers used. 
Primer sequences for miRNAs were obtained for hsa-let-7a-5p (ref.no. 205727), hsa-miR-125b-
5p (ref. no. 205713), hsa-miR-16-5p (ref. no. 205702), hsa-miR-26a-5p (ref.no. 206023) and hsa-
miR-29b-3p (ref. no. 204679) from Exiqon (Vedbaek, Denmark).  
Primers for mRNAs quantification were obtained from Integrated DNA Technologies (Leuven, 
Belgium): 
mouse DTX4: 
m-DTX4-F: ACATCTACTGCCTGGTGGCTATG  
m-DTX4-R: GGGCACTGTAAACTCCCATCCTTG  
mouse Nav1: 
m-Nav1-F: ACCCAAGGGAATGATTCGGTCAG  
m-NAV1-R: ACAGCACCGAGCCATGAACATC  
mouse LMOD1: 
m-LMOD-F: AGATGTCTGTGGATGAAAGCAAGC  
m-LMOD1-R: TCCTCTCCATTCTTGGCATCTGTC  
mouseADAMTS19: 
m-ADAMTS19-F: GCGAGTAGGTGACTGGTCTAAGTG  
m-ADAMTS19-R: ACACGAGACTGCATGCCTTTGC  
mouse LRRC58: 
m-LRRC58-F: TCCAAACCCAAAGTGTGGTGGA  
m-LRRC58-R: GGAGAGCACAGATAGTGCATGAGG  
mouse-GAPDH: 
m-GAPDH-F: CTTTGTCAAGCTCATTTCCTGG 
m-GAPDH-R: TCTTGCTCAGTGTCCTTGC 
mouse TGFb1: 
m-TGFb1-F: CCTGAGTGGCTGTCTTTTGA 
m-TGFb1-R: CGTGGAGTTTGTTATCTTTGCTG 
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7. Conclusions – Outlook 
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miRNAs have now a place among molecules of great interest to be explored in 
physiology and disease. The augmentation in the number of reports on miRNAs shows this 
interest. MiRNAs have been shown to be involved in pathologies as diverse as cancer, 
neurodegenerative diseases, vascular aging, atherosclerosis and kidney disease. MiRNAs might 
be useful in explaining (patho)physiological mechanisms, in being potential biomarkers and as 
therapeutics targets. This wide range of applications, especially as potential biomarkers or 
therapeutics, derives from their ubiquitous presence and their extreme stability under different 
biological and storage conditions. Technological solutions (PCR, microarrays, NGS etc.) to study 
miRNAs are similar to those to study mRNAs and thus have been in place for at least a decade. 
 
7.1 Technological considerations 
The observation of the presence of miRNAs in urine has triggered its research in kidney 
disease and lead to the identification of the number of urinary miRNAs potentially associated to 
different kidney diseases. Though, there are still obstacles that need to overcome to produce 
reliable clinically usable results with urinary miRNAs. One of the major problems in miRNA 
research is the normalization method. Up to now there is no good endogenous control that can be 
used for normalization. U6, a small non coding RNA was used in most studies in the early years, 
but recent reports showed its instability between different samples, tissue or biofluids in different 
species. We observed the same issue for U6 in the CKD progression validation study where the 
variability of U6 was the highest among the tested endogenous controls. RNU48, another 
endogenous control, showed a more stable pattern but was not detected in all samples. 
Fortunately we had developed another approach to select for a stable endogenous control by 
selecting in the discovery cohort the miRNA with the highest frequency (in all 70 samples) and 
displaying highest stability (smallest fold change between the groups). This miRNA, hsa-miR-
30a-5p, turned out to be remarkably stable compared to U6 and RNU48 and was hence used for 
normalization. We believe that this approach could be developed for individual diseases. 
Nowadays, the majority of the studies use as normalization controls either those miRNAs that are 
detected relatively stable in all samples or exogenous controls (eg the spike-in of a known 
exogenous miRNA sequence such as cel-miR-39 from Caenorhabditis elegans for human 
samples). The drawback of the use of exogenous controls is that dilution of miRNAs (especially 
urine in for example in diabetic nephropathy) is not normalized. A combination of spiked- in to 
determine extraction efficiency and internal miRNA normalization might currently be the best 
choice.  
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Although urine clearly contains miRNAs, they are extremely diluted, hence difficult to 
detect. These difficulties in urinary miRNA analyses are exacerbated by the methods used for the 
extraction of miRNAs which yield total RNA where miRNAs represent only 0.1% of the total 
RNA extracted making it extremely difficult to calculate the amount of miRNA in the extract to 
be equivalent in all samples. Hence normalization is critical in determining urinary miRNAs. 
Even with the developed endogenous normalization procedure, within the same group of patients 
analyzed with the same technology, we observe a large variation in urinary abundance of 
miRNAs. This pending issue with normalization and variability most likely hampers quick 
evolution of the use of urinary miRNAs as biomarkers of (kidney) disease.  
The use of different technologies for discovery and validation might be another cause of 
the low number of miRNAs validated in the CKD progression study. Next Generation 
Sequencing (NGS) uses a standardized method for normalization based on global signal 
normalization (less variability) and is currently significantly more sensitive than Taqman Low 
Density Arrays (TLDA) technology. For this reason it is possible that we were not able to 
validate a number of candidates using the TLDA approach. Increased patient numbers and 
technologies mimicking single cell PCR analysis might solve these issues.  
 
7.2 miRNAs in kidney disease 
Chronic kidney disease (CKD) is a complex pathology, especially in our study where we 
included CKD derived from different etiologies, with still unknown mechanisms leading to 
progression of disease. We tried in this study to determine the role of miRNAs in CKD 
progression and possibly provide novel biomarkers of progressive disease and therapeutic targets. 
In our retrospective study, urine samples from patients with progressive CKD vs non progressive 
CKD were used to investigate miRNAs in relation to CKD. The miRNA that was significant in 
both the discovery and validation study using two different technologies was miR-145-5p. Using 
in vitro knockdown studies the most likely mechanism linking mir-145-5p to CKD progression is 
necrosis.  
The ureteropelvic junction (UPJ) obstruction project proposed a novel study plan to 
examine pathologies with difficulty to collect samples. UPJ is mainly a condition affecting 
newborn children and still it is not clear when the condition of the obstruction is severe and needs 
a surgery or can be dealt with caution. It is logical that obtaining kidney samples from newborn 
children, healthy and with UPJ, is not easy. Thus, taking into advantage the conservation ability 
of the miRNAs between the species we could combine the miRNA results from human urine 
samples (control and with UPJ obstruction) with mice tissue samples of the neonatal partial 
 158 
 
unilateral ureteral obstruction (UUO) model. Our data revealed let-7a and miR-29b as molecules 
potentially involved in the development of fibrosis in UPJ obstruction via the control of DTX4 in 
both man and mice that would not be identified otherwise. The logical question in the design of 
this project is “how someone can be sure that the miRNAs in mice kidney are the same with the 
human in urine?”. This is a question which could be answered only if we had available human 
tissue samples, but the bibliography on the 2 strongest candidates, (let-7a-5p and miR-29b-3p) is 
in favour of their presence in human kidney tissue as well in the pathological condition.  
In both projects we faced the aforementioned drawbacks of normalization and putative 
miRNA quantity in the extracted RNA. To deal with the quantity of the miRNAs in the extracted 
total RNA, exosomal miRNAs could have been targeted, since exosomes can be isolated and 
include higher amount of “clean” miRNAs which can be measured with higher accuracy than in 
total RNA extract.  
 
7.3 Conclusion and outlook 
To conclude, urinary miRNAs are strong candidates to find use in diagnosis, prognosis, 
monitoring and therapy for kidney diseases. However, the majority of the available studies only 
show association between the urinary miRNA levels (increase or decrease) and renal disease 
clinical parameters without the verification of whether urinary miRNAs can be used to improve 
the diagnosis and/or prognosis. A correct workflow to promote the use of urinary miRNAs as 
biomarkers of kidney disease includes some well-defined steps taken from proteomics biomarker 
research: 1. Define the clinical question, 2. Choose carefully the sample set best associated to the 
clinical question, 3. Set up the experimental methodology, 4. Use appropriate statistics, 5. 
Confirm the findings in an independent test set (validation) and 6. Implement to clinical practice. 
To reach this goal, miRNA research needs to include larger cohorts compared to the previous 
studies (including ours) with clear definition of the pathology/etiology and prolonged disease 
follow-ups, expand/optimize the use of the technological tools available, establish a method for 
normalization and develop fast, reliable and reproducible protocols for the detection and 
validation of the miRNAs starting from smaller volumes of urine (less than 1 ml). A closer co-
operation with bioinformatics is also suggested that will contribute significantly in identifying 
new miRNAs as well as definition of their potential targets, leading to optimized computation of 
the pathways controlled by specific miRNAs and ultimately to optimized selection of miRNAs 
for potential intervention. 
miRNAs are here to stay and change the future on how we see and face pathologies and 
use them as biomarkers and as therapeutic targets now that many strategies against diseases, 
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including CKD, have reached a plateau. miRNAs have opened a new world in science and 
clinical practice. We just need to unlock their secrets. 
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miRNAs are short non-coding RNAs that control post-transcriptional regulation of gene
expression. They are found ubiquitously in tissue and body fluids and participate in the
pathogenesis of many diseases. Due to these characteristics and their stability, miRNAs could
serve as biomarkers of different pathologies of the kidney. Urine is a non-invasive reservoir of
molecules, especially indicative of the urinary system. In this review, we focus on urinary
miRNAs and their potential to serve as biomarkers in kidney disease. Past studies show that
urinary miRNAs correlate with renal dysfunctions and with processes involved in the
pathophysiology. However, these studies also stress the need for future research focusing on
large-scale studies to confirm the usability of urinary miRNAs as diagnostic and/or prognostic
markers of different kidney diseases in clinical practice.
KEYWORDS: biomarker . canonical pathways . computational analysis . kidney . kidney disease . miRNA . urine
The year 1993 will remain in history as the
beginning of a new research field in biological
sciences. In that year, the teams of Ambros
and Ruvkun independently published their
discoveries on lin-4 [1–3]. The lin-4 gene pro-
duces a small transcript that does not encode a
protein but negatively regulates the level of the
LIN-14 protein involved in the development
of Caenorhabditis elegans [1–3]. Since these first
publications, 7 years passed until a second
small non-coding RNA, let-7, was discovered
with a similar function to lin-4 [4]. Since then,
the now known microRNAs or miRNAs have
stimulated a growing scientific interest and
research has evolved significantly towards
detecting and identifying these small molecules
since miRNAs have been shown to be involved
in a variety of physiological functions and
diseases [5].
miRNA biogenesis, function &
annotation
miRNAs are short (20–23 nucleotides in
length), non-coding, endogenous, single-
stranded RNA molecules. The biogenesis and
the function of miRNAs have been extensively
reviewed elsewhere [6,7]. In brief, miRNAs
inhibit protein synthesis of protein-coding
genes, either by inhibition of translation
(if there is little complementarity with
3¢-untranslated region of the mRNA) or by
mRNA degradation (if there is extensive
complementarity with the mRNA target) [5,7,8].
miRNA precursors (pre-miRNA) are tran-
scribed from their specific non-coding gene or
from introns of coding genes in the form of a
cistronic or polycistronic transcript (pri-
miRNA). After a first cleavage by the Drosha–
DiGeorge syndrome critical region 8 complex,
the pre-miRNA is produced and adopts a
characteristic hairpin loop structure (FIGURE 1).
Alternatively, the pre-miRNA is generated by
splicing the host mRNA transcript. This non-
canonical biogenesis pathway bypasses the
cleavage by Drosha. In brief, the transcript is
spliced in a complex called spliceosome, pro-
ducing the ‘mirtron’ and next, the mirtron
refolds to the typical pre-miRNA hairpin
form [9].
In the next step, the pre-miRNA is trans-
ferred through exportin-5 from the nucleus to
the cytoplasm. Subsequently, the DICER com-
plex binds and cleaves the double-stranded
pre-miRNA, and releases the mature single-
stranded miRNA. From this point, the mature
miRNA is ready to perform its biological func-
tion. Together with other proteins (the most
important of them is Ago2), it forms the
RNA-induced silencing complex (RISC),
which guides the miRNA to the mRNA tar-
get, helps to connect to the 3¢-untranslated
region and blocks the translation of the
mRNA [6–8,10]. Interestingly, one miRNA gene
can lead to the generation of more than one
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mature miRNA, and on the other hand, different miRNA
genes can be clustered into the so-called miRNA families based
on the miRNA sequence [11].
The continuously increasing number of reports on miRNAs,
starting from some hundreds per year until 2007 and reaching
approximately 7000 in 2013 and 2014, points to their potential
role in the control of gene expression. This increase can be justi-
fied by the use of next-generation sequencing technologies com-
bined with easy-to-use methods for extraction, quantification
and expression of miRNAs. The number of newly identified
miRNAs has been also rising at a fast pace, as shown by the
number of entries in miRBase, which in the last update of June
2014 (version 21.0) reached 28,645 miRNA entries when con-
sidering all species, and 2588 entries for human miRNAs [12].
Advantages of urine miRNA measurement for kidney
function
It has been shown that miRNAs are significantly more stable
than mRNA, suggesting the potential suitability of miRNAs as
biomarkers [13]. Among the different body fluids, miRNAs are
present in urine, making the urinary miRNA pool potentially
suitable to monitor kidney function and detect both renal and
non-renal diseases [14,15]. Kidney diseases are a major and con-
stantly rising worldwide health problem. The main obstacle in
treating kidney diseases is the absence of early clinical signs or
biomarkers before the kidney enters an irreversible dysfunc-
tion [16]. Nowadays, renal biopsy is the gold standard diagnos-
tic tool but this is an invasive procedure that is associated with
significant hemorrhagic risk [16]. Alternatively, urine can be
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Figure 1. Biogenesis and function of the miRNA. (A) Canonical pathway: In the first step of miRNA biogenesis, miRNA is transcribed
in a primary form (pri-miRNA with a hairpin loop). The Drosha–DGCR8 complex splices the pri-miRNA to form the precursor miRNA (pre-
miRNA). (B) Non-canonical pathway: the miRNA is spliced from mRNA by a complex called spliceosome creating the mirtron. Next, the
mirtron reforms to the shape of pre-miRNA, avoiding cleavage by Drosha. (C) The pre-miRNA is transferred from the nucleus to the cyto-
plasm with the help of Exportin-5. (D) In the cytoplasm the protein DICER cleaves the hairpin loop and releases the two strands. One
strand will serve as the mature miRNA (18–22 nt length), while the other will be degraded. (E) The mature miRNA then binds to a pro-
tein complex including Ago2, forming the so-called RISC complex. Ago2 then connects the miRNA with the mRNA target: (F) if the
miRNA sequence is partially complementary to the mRNA’s 3¢-UTR, it binds to it and represses translation. (G) If the miRNA sequence is
completely complementary to the 3¢-UTR of the mRNA, it binds and Ago2 cleaves the mRNA, stopping the translation of the protein.
The picture was designed using Servier Medical Art.
3¢-UTR: 3¢-untranslated region; Ago2: Argonaute 2; DGCR8: DiGeorge syndrome critical region 8; RISC: RNA-induced silencing complex.
Review Papadopoulos, Belliere, Bascands, Neau, Klein & Schanstra
doi: 10.1586/14737159.2015.1009449 Expert Rev. Mol. Diagn.
Ex
pe
rt 
Re
vi
ew
 o
f M
ol
ec
ul
ar
 D
ia
gn
os
tic
s D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
N
yu
 M
ed
ic
al
 C
en
te
r o
n 
02
/1
6/
15
Fo
r p
er
so
na
l u
se
 o
nl
y.
collected easily, non-invasively and with low cost [15]. In addi-
tion, miRNAs in urine have been shown to be relatively stable
under different storage conditions and resistant to repeated
freeze–thaw cycles [17–19].
Although the origin of the urinary miRNAs has not been
thoroughly studied, it has been hypothesized that they are likely
both shed from along the urinary pathway and filtered from
plasma (FIGURE 2A) [20–22]. miRNAs have been found to be
secreted from the cells in which they are produced and packed
in microparticles, such as microvesicles, exosomes and apoptotic
bodies, and also bound to RNA-binding proteins or lipoprotein
complexes (FIGURE 2B) [23]. Among those, exosomes are the best-
studied miRNA vehicles. Exosomes are multi-vesicular vacuoles
that transfer cellular components between cells and promote
cell-to-cell communication and interactions [24,25]. Exosomes are
also the ‘bodyguards’ of miRNAs by protecting them from the
RNAse activity and the unfriendly urine environment.
Cheng et al. reported that miRNAs enriched in exosomes from
urine are protected from degradation and are capable of trans-
ferring the genetic information more efficiently than cell-free
miRNAs, which are probably degraded by RNAse [15,26]. The
protective role of other miRNA binding proteins has been
studied in less detail but these few reports support the theory
of protective transfer by these binding proteins of miRNAs in
body fluids and in cell-to-cell communication. In particular,
RNA-binding protein Ago2, in addition to being part of the
RISC silencing complex (FIGURE 1), has been described to be
involved in miRNA transport in the circulation, potentially
leading to the transport of a functional miRNA-induced silenc-
ing complex [27]. In the same category of RNA-binding pro-
teins, nucleophosmin 1 was also found to carry miRNA in
serum in humans and possibly serve in cell-to-cell communica-
tion [28]. Finally, Vickers et al. revealed the surprising role of
HDL lipoproteins in the transport of miRNAs in a similar way
to these RNA-binding proteins [29]. Interestingly, apoptotic cells
seem to signal using miRNAs. Upon apoptosis and cell injury,
it has been shown that miRNAs bound to these previously
mentioned RNA-binding proteins are released in the circulation
(FIGURE 2C) [21,30].
Extraction of urinary miRNAs is quite straightforward and
the majority of the past studies follow protocols based on the
same principle as for the extraction of urinary mRNAs. Ini-
tially, protocols used tens of milliliters of urine, but currently
this can be as little as 200 l using commercially available kits.
miRNAs can be extracted from total urine, including the uri-
nary cells, exosomes and miRNAs bound to RNA-binding pro-
teins. This is the most used method (SUPPLEMENTARY TABLE 1
[Supplementary material can be found online at www.informa-
healthcare.com/10.1586/14737159.2015.1009449_Suppl.pdf]).
The currently available commercial kits provide rapid extraction
of total miRNAs from urine based on binding of small RNAs
to specific material packed in columns. Other studies have
exclusively focused on the urinary exosome content. The two
classical ways to isolate exosomes were by cumbersome sucrose
gradient ultracentrifugation or by isolation using antibodies
specific for one of the surface proteins typically found on exo-
somes. The last method is very specific but might exclude
some subfractions of exosomes. Currently, specific commercial
kits, based on precipitation, allow easy and rapid exosomal
miRNA isolation. A drawback of these kits compared to ultra-
centrifugation at ~200,000 g is that any precipitated material
will be included in the ‘exosomal’ fraction and thus potentially
less pure than the exosomal fraction obtained by ultracentrifu-
gation. For the detection of isolated miRNAs, the most popular
method is (semi)quantitative RT-PCR. For screening purposes,
microarrays were popular in the past but are being slowly
replaced by next-generation sequencing that allows the identifi-
cation of truly novel miRNAs and has in general a higher sen-
sitivity than the microarrays.
Altogether, these observations strongly suggest that urinary
miRNAs could be a promising pool of non-invasive bio-
markers, especially for diseases of the kidney and the urinary
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Figure 2. Possible origin of urinary miRNAs and miRNA transporting molecules. (A) It has been hypothesized that miRNAs are
likely both shed from along the urinary pathway (1) and filtered from plasma (2). (B) miRNAs are produced by exocytosis and thus
secreted in urine are most likely protected from degradation by existing in exosomes or lipoproteins (e.g., HDL) or bound with
RNA-binding proteins (e.g., Ago2). (C) miRNAs (free or in/or attached to the RNA-binding proteins) can also be released in urine after
cell injury or apoptosis. The figures were designed using Servier Medical Art.
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tract and thus mirror kidney (dys)function. Research in urinary
miRNAs produces continuously new identifications and corre-
lations of miRNAs with clinical features of kidney diseases.
Modification of urinary miRNA abundance in kidney
diseases
Alterations in the expression of miRNAs affect kidney develop-
ment and function [31–34]. This was exemplified by the report
by Nagalakshmi et al. where knocking down DICER in mice
caused nephron maldevelopment [35]. Also, the abundance of
human kidney biopsy miRNAs has been reported as being
modified in different kidney diseases [36–39]. In contrast, reports
on human urinary miRNAs related to kidney diseases are lim-
ited (SUPPLEMENTARY TABLE 1). We discuss below the major discoveries
recently made in this domain.
Chronic kidney disease
Chronic kidney disease (CKD) is a general term for progressive
kidney failure from different causes and is classified into five
stages defined by the decline in the glomerular filtration
rate [40]. The final stage of CKD progression is called end-stage
renal disease (ESRD), where the kidney stops functioning, a
condition with increasing incidence worldwide [41]. At this
stage, hemodialysis and transplantation are the only replace-
ment therapies. A main issue in CKD is the early detection of
disease in patients at risk (i.e., in individuals with diabetes,
hypertension, etc.) and identify those patients with already
established CKD that rapidly progress to ESRD [42,43].
A number of studies reported association of significant varia-
tions in urinary miRNA abundance in CKD. One of the first
reports on urinary miRNAs in CKD described significantly
increased levels of miR-638 in urine samples from patients
with stage 3, 4 and 5 (ESRD) compared to samples from
healthy volunteers [44]. MiR-638 has been shown to be associ-
ated with the maintenance of the epithelial cell phenotype [45].
In another report, differential urinary miRNA abundance was
found to be associated with different CKD etiologies: reduced
levels of urinary miR-15 were observed in diabetic glomerulo-
sclerosis, increased levels of miR-17 in IgA nephropathy
(IgAN) and increased miR-216a and miR-21 levels in hyper-
tensive nephrosclerosis [46]. More importantly, urinary
miR-21 and miR-216a abundance was correlated with the rate
of renal function decline [46]. Among these miRNAs, a decrease
in plasma miR-15b has been reported to be associated with
hyperphosphatemia in patients with ESRD [47] and miR-21 is
known to participate in the development of kidney fibrosis, a
key mechanism leading to CKD [48–51].
Finally, reduced urinary abundance of miR-29a, miR-29b,
miR-29c and miR-200a, miR-200b and miR-200c has been
observed in CKD patients originating from a variety of etiolo-
gies, including diabetic nephropathy (DN), focal segmental glo-
merulosclerosis (FSGS), IgAN, membranous nephropathy and
mesangial proliferative glomerulonephritis [52–56]. As miR-21,
these miRNAs are known to be associated with the develop-
ment of kidney fibrosis. miR-29 is reported to control the
expression of tropomyosin 1, a protein involved in the epithe-
lial to mesenchymal transition (EMT) mechanism, and collagen
isoform COL2A1 (collagen is a well-documented protein that
causes fibrosis) [57,58]. The mir-8 family (miR-200a, miR-200c,
miR-141, miR-429) is found to target ZEB1, ZEB2 and
SIP1 known to be involved in the EMT process, fibrosis and
maintenance of the cell phenotype [59,60].
Diabetic nephropathy
About 25–40% of patients suffering from diabetes, either
Type 1 (T1D) or Type 2 (T2D), will be diagnosed later with
DN [61]. The pathophysiology of DN involves progressive
thickening of the glomerular basement membrane, podocyte
loss and mesangial proliferation in the glomerulus, and tubu-
lointerstitial fibrosis characterized by uncontrolled deposition of
extracellular matrix and low-grade inflammation [61–63].
Argyropoulos et al. studied urinary miRNA abundance in
either normo-, micro- or macroalbuminuric T1D patients and in
patients with overt DN. They observed that urinary levels of
miR-323b-5p, miR-429 and miR-17-5p were associated with
persistent microalbuminuria in patients with long-standing
T1D [64]. After predicting the targets of these miRNAs, it was
hypothesized that miR-323b-5p may regulate Claudin-16, which
is a vital component of the tight junction in the thick ascending
limb of Henle in the tubular section of the kidney [65] and that
miR-17-5p targets fibronectin [66], an extracellular matrix protein
increased in DN [67]. In addition, miR-429 belongs to the same
fibrosis-related mir-8 family mentioned above [68].
Another study analyzed the abundance of urinary miRNAs
in urine of T1D patients with microalbuminuria as well [69].
The authors observed decreased urinary levels of exosomal
miR-155 and miR-424 and increased levels of miR-145 in
T1D patients with microalbuminuria compared to T1D
patients with normoalbuminuria or non-diabetic controls [69].
Interestingly, in vivo and in vitro studies suggest that glomeru-
lar miR-145 overexpression might be triggered by hyperglyce-
mia, potentially stimulating mesangial cell hypertrophy and
cytoskeleton remodeling, key early features of DN [70,71].
miR-424 was found to be involved in the regulation of angio-
genesis [72,73] and miR-155 has been shown to regulate angio-
tensin 2 [74] and SMAD proteins related to fibrosis [75,76].
Besides glomerular and interstitial damage, DN is also char-
acterized by vascular lesions. Liu et al. found that
miR-126 abundance was increased in urine of T2D patients
suffering from DN compared to diabetic patients without DN
and healthy volunteers. miR-126 is a miRNA highly enriched
in endothelial cells and is a key player in maintaining endothe-
lial homeostasis and vascular integrity. The authors, therefore,
suggested that urinary miR-126 originates from endothelial
cells-derived exosomes and propose that urinary miR-126 could
serve as a biomarker to identify T2D patients with DN and
monitor progression of the disease [77], although this remains to
be confirmed in independent studies.
Diabetes is the number one cause of DN. The reports on
the connection of diabetes and DN with urinary miRNAs are
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promising, but further investigation is needed to determine if
urinary miRNAs can be used as biomarkers to predict the initi-
ation of DN because of diabetes.
Glomerulopathies
Primary glomerulopathies, such as minimal change disease,
FSGS, membranous glomerulonephritis, IgAN and membrano-
proliferative glomerulonephritis, are disorders affecting the glo-
merular structure and function and are considered as a leading
cause of ESRD and major cause of CKD worldwide [78,79].
IgA nephropathy (Berger’s disease)
IgAN is the most frequent glomerular disease and is character-
ized by mesangioproliferative changes in glomeruli with deposi-
tion of immunoglobulin A in the mesangium [80].
Research on miRNAs in urine of IgAN patients detected
decreased abundance of miR-200a, miR-200b and
miR-429 (mir-8 family) and correlated with disease severity
and rate of progression. Decreased urinary levels of
miR-429 were also found to be correlated with an increased
rate of renal function decline [81]. Furthermore, it has been
shown that increased levels of miR-146a and miR-155 in urine
and tissue are associated with reduced production of pro-
inflammatory cytokines, IL-1b, IL-6 and tumor necrosis factor
(TNF-a), molecules involved in the pathogenesis of
IgAN [82–84]. Finally, urinary levels of miR-21, miR-29b,
miR-29c and miR-93, mostly fibrosis-related miRNAs, corre-
lated with urinary SMAD3 (but not with TGF-1, SMAD2,
SMAD4 or SMAD7) in IgAN patients [52]. This observation
supports the involvement of the TGF-b1/SMAD mechanism
in the progression of renal fibrosis during IgAN [57].
Other glomerulopathies
Wang et al. demonstrated that the levels of urinary miR-10a
and miR-30d were elevated in patients suffering from FSGS
compared to healthy donors [85]. miR-10a and miR-30d are
reported as kidney-specific miRNAs serving a protective role
against kidney tissue injuries by targeting IL-12/IL-23p40 [86],
the pro-apoptotic protein Bim [87], apoptotic caspase CASP3
[88] and tumor suppressor gene p53 [89].
In another report, urinary miR-155, miR-196a, miR-30a-5p
and miR-490 levels have been shown to increase in FSGS
patients compared to healthy controls, and moreover
miR-196a, miR-30a-5p and miR-490 levels significantly
decreased in FSGS patients under treatment with steroids, a
common immunosuppressive therapy employed in FSGS
patients leading to remission [90], suggesting a potentially pre-
dictive use for the response on steroid therapy [91].
Renal allograft monitoring
Up to now, the most effective renal therapy for ESRD is renal
transplantation [92]. However, even though renal transplantation
is a very successful short-term therapy, up to 50% of the grafts
lose function after 10 years. The most common features
reported in rejection of grafts are interstitial fibrosis, tubular
atrophy and kidney dysfunction, appearing after the first year
of transplantation [39,93].
Urinary miRNA miR-210 is a possible candidate to monitor
acute allograft rejection since its urinary abundance decreased
after rejection compared to stable transplant [94]. miR-210 is
involved in the endothelial cell response to hypoxia [95] and
was found to be an indicator of cellular damage in acute kid-
ney injury (AKI) [96].
Urinary abundance of miR-200b, miR-125b, miR-203,
miR-211, mir-30 family and miR-20 is decreased, while the
abundance of miR-142-3p is increased in chronic kidney allo-
graft rejection [97,98] The functions of these miRNAs have been
related to pathological processes in chronic kidney allograft rejec-
tion. miR-200b, as mentioned previously, is related to fibrosis, a
mechanism present in allograft rejection and miR-125b is
involved in B-lymphocyte development [99], in macrophage acti-
vation [100] and involved in the maintenance of the smooth mus-
cle phenotype of the juxtaglomerular cells [101]. miR-203 was
shown to regulate the innate immune response [102] and
miR-142 is proposed to be a key element of the regulation of
T cells and macrophages [103,104]. Finally, miR-204 is reported to
be involved in apoptosis and cell growth [105] and the
mir-30 family was proposed to be involved in the maintenance of
podocytes and glomerular function [106].
Renal allograft monitoring is still a major issue in renal
transplantation and these studies suggest that specific urinary
miRNAs are associated with rejection. It, however, remains to
be determined whether these urinary miRNAs can be predictive
markers.
Acute kidney injury
AKI represents a sudden dysfunction of the kidney leading to
disruption of electrolyte, fluid and metabolic homeostasis for a
few hours and up to a few weeks [107]. Risk factors for AKI
include non-modifiable factors like age (more frequent in the
elderly), pre-existing proteinuria and CKD, co-morbid diseases
and modifiable factors such as exposure to nephrotoxins, con-
trast media, sepsis and major surgery [107].
Three studies examined modified urinary miRNA abundance
in AKI. Among the miRNAs detected at significantly different
levels compared to healthy individuals, miR-155 (decreased)
and miR-21 (increased) stand out in relation to the develop-
ment of AKI [108,109]. miR-21 has been shown to be involved
in many pathological conditions, including inflammation, pro-
liferation, fibrosis and apoptosis [110–112], while miR-155 is
involved in the regulation of the inflammatory response [108].
Finally, the elevated level of miR-494 after ischemia/reperfusion
injury was correlated with inflammation by inhibiting its direct
target, activating transcription factor 3 [113].
Lupus nephritis
Lupus nephritis (LN) is one of the most severe manifestations
of systemic lupus erythematosus, an autoimmune disease with
the ability to affect any organ or tissue. The pathogenesis of
LN is a combination of various pathological processes resulting
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in tubular damage, tubulointerstitial inflammation and fibrosis.
All processes involve modification of miRNA expression [114]
and consequently miRNAs have been scrutinized for their
involvement in the development of LN [115], mostly in blood
cells and renal biopsies [116–118]. However, only a few reports
are available on LN and urinary miRNA.
The available publications are referring to experiments using
urine samples from patients with LN and healthy volunteers.
miR-146a and miR-155 are proposed as potential markers for
diagnosis, disease activity and therapeutic response for
LN [119,120]. miR-146a and miR-155 have been extensively
studied and their role in innate immune response has been
shown repeatedly [111,121,122]. miR-146a has been reported to
regulate the Type I interferon pathway, a pathway involved in
LN pathogenesis [123] and miR-155 is a regulator of T and B
cell activation [83,124], cells with a key role in development and
progression of LN [125].
Polycystic kidney disease
Polycystic kidney disease (PKD) either autosomal dominant
(ADPKD) or autosomal recessive is characterized by the forma-
tion of multiple benign cysts causing the kidney to enlarge and
to progressively loose structure and function [126]. Fifty percent
of patients diagnosed with ADPKD will progress to ESRD
around the fifth decade of their life [127,128].
To our knowledge, only one study has investigated the
abundance of miRNA in urine of ADPKD patients. Urinary
miR-1 and miR-133a were found with lower abundance in
ADPKD patients compared to patients with CKD originating
from other etiologies [129]. These miRNAs have been identified
in renal cell carcinoma as tumor suppressors controlling cell
proliferation and apoptosis [130]. Also, the significantly
increased urinary levels of miR-223, miR-199a and miR-199b
were found to be associated with monocyte infiltration and
EMT, features of the pathogenesis of ADPKD [129,131–134].
Table 1. The top canonical pathways as generated from the miRNA data set lists for each disease by
ingenuity pathway analysis.
Canonical pathways Sum of
diseases
ADPKD AKI CKD DN FSGS_MCD_MGN IgAN LN RAR
Role of macrophages, fibroblasts and
endothelial cells
3 1 1 1
Regulation of the epithelial–mesenchymal
transition pathway
3 1 1 1
PI3K/AKT signaling 3 1 1 1
Cell cycle G1/S checkpoint regulation 3 1 1 1
IL-6 signaling 2 1 1
Dendritic cell maturation 2 1 1
Fibrosis 2 1 1
Aryl hydrocarbon receptor signaling 1 1
Integrin-linked kinase signaling 1 1
Toll-like receptor signaling 1 1
PTEN signaling 1 1
Tec kinase signaling 1 1
IL-10 signaling 1 1
Pathways with a clear reference to cancer were omitted.
ADPKD: Autosomal dominant polycystic kidney disease; AKI: Acute kidney injury; CKD: Chronic kidney disease; DN: Diabetic nephropathy; FSGS: Focal segmental
glomerulosclerosis; IgAN: IgA nephropathy; LN: Lupus nephritis; MCD: Minimal change disease; MGN: Membranous glomerulonephritis; PTEN: Phosphate and tensin
homolog; RAR: Renal allograft rejection.
Table 2. Top nine of most frequently found urinary
miRNAs in studies related to kidney disease
(>3 studies).
miRNA Mentioned in number of studies
hsa-mir-8 7
hsa-mir-155 5
hsa-mir-30 4
hsa-mir-638 4
hsa-mir-10 3
hsa-mir-146 4
hsa-mir-29 3
hsa-mir-21 3
hsa-mir-423 3
The miRNAs are presented as families. Total number of studies reviewed, n = 22.
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Computational analysis
In an attempt to examine in depth the urinary miRNAs and
their potential links to disease pathways in kidney disease, we
performed a computational analysis through the use of
QIAGEN’s Ingenuity Pathway Analysis (IPA, QIAGEN
Redwood City, [135]) using all reported miRNAs with signifi-
cantly changed urinary abundance in kidney disease (SUPPLEMENTARY
TABLE 1). These miRNAs were uploaded in data sets according to
the kidney disease in which they were detected, followed by
miRNA target filtering analysis under strict filters (only experi-
mentally observed miRNA–mRNA pairs were accepted and we
excluded any association with cancer-related pathways). This
produced information on the pathways most frequently
observed and revealed that the targets of the miRNAs are
involved in mechanisms that control major processes in kidney
disease (TABLE 1).
Indeed, macrophages and fibroblasts have been observed in
renal injury and fibrosis [136–138]. In addition, macrophages are
known vehicles of miRNAs [139]. EMT is a well-known,
although debated, mechanism involved in the development of
renal fibrosis [140] and the PI3K/AKT signaling pathway was
recently linked to the EMT process [141]. Finally, deregulation
of the cell cycle also promotes fibrosis and renal injuries [142].
Given the distribution of these pathways over the different
pathologies, these modified pathways do not appear to be asso-
ciated with a specific kidney disease. This suggests that the
miRNAs found in urine and their targets are involved in the
general kidney (dys)function. Hence, the urinary miRNAs asso-
ciated with these pathways might not be good biomarkers to
distinguish between different renal diseases.
In contrast, some canonical pathways were only found
enriched in specific kidney disease. For example, IL-6 and
IL-10 signaling along with Toll-like receptor signaling were
uniquely linked to IgAN and LN, diseases related to the
immune response and inflammation, and miR-29, miR-146a
and miR-155 are reported to regulate these pathways [143–147].
Figure 3. Network analysis of the most frequently observed urinary miRNAs associated with renal disease (TABLE 2, miR-21,
mir-8 and miR-29 family). The purple arrows indicate the experimental observed direct targets of the miRNAs. Among the targets pres-
ent are TGF-b and SMAD isoforms, collagen isoforms, ACVR2A, ERK1/2, TNF-a and BMPR2 reported to be involved in fibrotic mecha-
nisms, a hallmark of renal disease. Figure generated with ingenuity pathway analysis.
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Another example is Tec kinase signaling, enriched in glomeru-
lopathies. Tec kinase is shown to interact with SOCS-1 in glo-
merulopathies [148]. Finally, in ADPKD the integrin-linked
kinase signaling and phosphate and tensin homolog (PTEN)
signaling pathways were uniquely modified that appear to be
involved in the pathogenesis of ADPKD. Integrin-linked kinase
signaling has been reported to be involved in fibrogenesis.
PTEN has been shown to enhance angiogenesis and supports
proliferation, migration and adhesion [149,150] and is identified
in a mechanism for Akt activation by TGF-b via PTEN down-
regulation by miR-216a/217 [151].
Overall, this computational analysis supports the link of uri-
nary miRNAs to processes ongoing in situ in kidney disease.
Expert commentary
The biological function of miRNAs, their involvement in regu-
lation of gene expression, their ubiquitous presence and their
stability have set miRNAs as the new ‘hot trend’ in biological
research. According to Friedlander et al. nearly 2000 human
miRNAs genes have been identified and it is more than likely
that in the future this number will increase even more. In their
very recent report they predicted more than 1000 additional
miRNAs by using computational methods [152], suggesting that
the potential pool of miRNAs as biomarkers of disease will be
even larger in the near future and will expand their potential
application.
The observations of involvement of miRNAs in the etiology
of pathologies as diverse as cancer, neurodegenerative diseases,
vascular aging and atherosclerosis are increasing [153–156]. The
same tendency is observed for kidney diseases and urine might
be a valuable source of miRNA-based biomarkers of kidney
disease in addition to a source for other molecules of kidney
disease including proteins, peptides and metabolites [157].
The overview of the recent literature and the computational
analysis also show that the urinary miRNAs correlate overall
well with knowledge on the ongoing kidney disease processes.
The most frequently observed urinary miRNAs associated with
renal disease currently are from the mir-8 and mir-29 family
and miR-21 (observed in 7/22, 3/22 and 3/22 of the reviewed
studies, TABLE 2). In an additional computational analysis, we
focused on networks based on these miRNAs and their experi-
mentally observed targets (FIGURE 3). The canonical pathway
related to fibrosis had the lowest p-value (7.45  1014) and
confirmed the relevance of these miRNAs in fibrosis, a hall-
mark in many kidney diseases. Furthermore, the network
pointed to important validated fibrotic targets, which are
directly connected to these miRNAs including TGF-b and
SMAD isoforms, collagen isoforms, ACVR2A [158], ERK1/2
[159], TNF-a [160] and BMPR2 [161,162].
Additional urinary miRNAs that were frequently found with
differential abundance in urine in a significant number of papers
are miR-155 (5/22 studies), miR-638 (4/22 studies) and
miR-30 (4/22 studies). Changes in expression of these miRNAs
are also observed in kidney tissue during kidney development
and kidney diseases, including DN, IgAN, LN and AKI [32] and
linked to processes in these diseases as described above. The fam-
ily members of mir-8 (miR-200 and miR-428) also appear asso-
ciated with the majority of the kidney diseases (6/9 diseases)
Table 3. The top 13 family miRNAs that appear in most kidney diseases (complete list in Supplementary
Table 3).
miRNA No. of diseases
observed
ADPKD AKI CKD DN FSGS/MCD IgAN LN MGN RAR
hsa-mir-8 7       
hsa-mir-638 5     
hsa-mir-155 4    
hsa-mir-17 4    
hsa-let-7 3   
hsa-mir-154 3   
hsa-mir-1260 3   
hsa-mir-21 3   
hsa-mir-29 3   
hsa-mir-30 3   
hsa-mir-423 3   
hsa-mir-574 3   
hsa-mir-92 3   
The members of the families are presented in SUPPLEMENTARY TABLE 4.
ADPKD: Autosomal dominant polycystic kidney disease; AKI: Acute kidney injury; CKD: Chronic kidney disease; DN: Diabetic nephropathy; FSGS: Focal segmental
glomerulosclerosis; IgAN: IgA nephropathy; LN: Lupus nephritis; MCD: Minimal change disease; MGN: Membranous glomerulonephritis; RAR: Renal allograft rejection.
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enhancing the potential importance (e.g., known to be involved
in AKI, DN, IgAN and LN) of this miRNA family in kidney
physiology and disease (TABLE 3). The subsequently most fre-
quently found miRNAs (in 5/9 diseases) are miR-638 (related to
the function of the epithelial cell and found in DN and glomer-
ulopathies) and miR-155 (known to interact with immune sys-
tem cells and thus found mostly in IgAN and LN). These
observations should be strengthened in the near future by the
increasing knowledge of the targets of these different miRNAs.
A complete list of the urinary miRNAs detected in different kid-
ney diseases can be found in SUPPLEMENTARY TABLE 2.
It must be noted, however, that the direction in change of
abundance of urinary miRNAs differs between renal diseases.
For example, urinary miR-141 abundance was found to decrease
in DN and increase in minimal change disease and LN. Con-
versely, miR-155 was observed with reduced abundance in urine
of patients in DN and AKI but with increased abundance in
IgAN and LN. Furthermore, it is interesting to point to the fact
that although being modified in the largest number of different
kidney diseases, the direction of change of the urinary abun-
dance of miR-200 is variable among the kidney diseases studied.
Similar observations hold for the key miRNAs, miR-29,
miR-429 and miR-638. Although to date this behavior seems
somewhat erratic, this observation is calling for further investiga-
tion but is in favor for the use of urinary miRNAs as potential
markers of disease. To that direction, Konta et al. presented in
their study that it is possible to record a pattern of urinary
miRNAs in different kidney diseases [163] showing the potential
of these molecules for diagnostic purposes.
Five-year view
The apparent ability of miRNAs to mirror biological function
in body fluids during disease opens up a potential wide range
of uses for urinary miRNAs in diagnosis, prognosis, monitoring
and therapy for kidney diseases. However, most of the studies
only show association between the urinary miRNA levels
(increase or decrease) and renal disease clinical parameters with-
out the verification of whether urinary miRNAs can be used to
improve the diagnosis and/or prognosis. In order to improve
upon urinary miRNA studies and promote the use of urinary
miRNAs as biomarkers of kidney disease, miRNA research
could ‘borrow’ a well-established workflow from clinical prote-
omics biomarker research. This workflow includes specific and
well-defined steps: Define the clinical question, choose carefully
the sample set best associated with the clinical question, set up
the experimental methodology, use appropriate statistics, con-
firm the findings in an independent test set (validation) and
implement to clinical practice (FIGURE 4) [164]. To reach this goal,
research in the next years should focus on studies involving
larger cohorts compared to the previous studies with clear defi-
nition of the pathology/etiology and prolonged disease follow-
up. Furthermore, we need to expand/optimize the use of the
Clinical question
Choosing samples
Setup the
experimental
methodology
Confirmation in
independent
test setsDefine a clear
clinical
question to
address and
set the future
clinical
outcome
Choose representative
case samples paired
with appropriate
controls. All samples
must include sufficient
demographical and
clinical data and
sampling
methodology should
be described in detail
Appropriate
statistics–
Implementation
The correct
statistic analysis
must be chosen
wisely
depending on
the statistical
needs of the
experiment
(number of
samples,
variability etc.)
Bring the
results to
clinical
practice
Well defined
protocols and
techniques
should be used to
secure reliability
and
reproducibility
Choose a new
and
independent
sample set to
validate the
findings
Figure 4. A possible workflow of how research on urinary miRNAs could lead to clinically useful urinary miRNAs.
Adapted from [164].
Reprinted with permission from AAAS.
miRNAs in urine Review
informahealthcare.com doi: 10.1586/14737159.2015.1009449
Ex
pe
rt 
Re
vi
ew
 o
f M
ol
ec
ul
ar
 D
ia
gn
os
tic
s D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
N
yu
 M
ed
ic
al
 C
en
te
r o
n 
02
/1
6/
15
Fo
r p
er
so
na
l u
se
 o
nl
y.
technological tools available (RT-PCR is used in the majority
of the available studies).
Finally, it appears that bioinformatics will contribute signifi-
cantly to the field in the coming years both in identifying new
miRNAs as well as definition of their potential targets, leading
to optimized computation of the pathways controlled by spe-
cific miRNAs and ultimately to optimized selection of miRNAs
for potential intervention.
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Key issues
. miRNAs are short (20–23 nucleotides length), non-coding, endogenous, single-stranded RNA molecules that inhibit protein synthesis of
protein-coding genes.
. miRNAs are produced in all cells and can be found in almost all body fluids, either free or bound to proteins, microvesicles, exosomes
and apoptotic bodies.
. The involvement of miRNAs in a large variety of biological functions combined with their great stability potentially makes them suitable
molecules for diagnosis, prognosis and monitoring of disease.
. Urine is a biofluid which is collected non-invasively and might be a valuable source of miRNA-based biomarkers of kidney disease in
addition to a source for other molecules of kidney disease, including proteins, peptides and metabolites.
. Although the reports on urinary miRNA and kidney disease are limited, the available information both in the literature and obtained
using a specific computational pathway analysis carried out for the review suggest that urinary miRNAs reflect on-going known disease
processes in the kidney and hence can potentially serve as non-invasive biomarkers of kidney disease.
. The majority of the urinary miRNAs were linked to one of the hallmarks of kidney disease which is fibrosis.
. Future research should focus on large-scale studies to confirm the usability of urinary miRNAs as diagnostic and/or prognostic markers
of different kidney diseases.
References
1. Lee RC, Feinbaum RL, Ambros V. The C.
elegans heterochronic gene lin-4 encodes
small RNAs with antisense complementarity
to lin-14. Cell 1993;75(5):843-54
2. Wightman B, Ha I, Ruvkun G.
Posttranscriptional regulation of the
heterochronic gene lin-14 by lin-4 mediates
temporal pattern formation in C. elegans.
Cell 1993;75(5):855-62
3. Lee R, Feinbaum R, Ambros V. A short
history of a short RNA. Cell 2004;
116(2 Suppl):S89-92
4. Reinhart BJ, Slack FJ, Basson M, et al. The
21-nucleotide let-7 RNA regulates
developmental timing in Caenorhabditis
elegans. Nature 2000;403(6772):901-6
5. Almeida MI, Reis RM, Calin GA.
MicroRNA history: discovery, recent
applications, and next frontiers. Mutat Res
2011;717(1-2):1-8
6. Kim VN. MicroRNA biogenesis:
coordinated cropping and dicing. Nat Rev
Mol Cell Biol 2005;6(5):376-85
7. Winter J, Jung S, Keller S, et al. Many
roads to maturity: microRNA biogenesis
pathways and their regulation. Nat Cell Biol
2009;11(3):228-34
8. Bartel DP. MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell
2004;116(2):281-97
9. Ha M, Kim VN. Regulation of
microRNA biogenesis. Nat Rev Mol Cell
Biol 2014;15(8):509-24
10. von Brandenstein M, Richter C, Fries JW.
MicroRNAs: small but amazing, and their
association with endothelin. Life Sci 2012;
91(13-14):475-89
11. Ambros V, Bartel B, Bartel DP, et al.
A uniform system for
microRNA annotation. Rna 2003;9(3):
277-9
12. Kozomara A, Griffiths-Jones S. miRBase:
annotating high confidence microRNAs
using deep sequencing data. Nucleic Acids
Res 2014;42(Database issue):D68-73
13. Jung M, Schaefer A, Steiner I, et al. Robust
microRNA stability in degraded
RNA preparations from human tissue and
cell samples. Clin Chem 2010;56(6):
998-1006
14. Lorenzen JM, Thum T. Circulating and
urinary microRNAs in kidney disease. Clin
J Am Soc Nephrol 2012;7(9):1528-33
15. Cheng L, Sun X, Scicluna BJ, et al.
Characterization and deep sequencing
analysis of exosomal and non-exosomal
miRNA in human urine. Kidney Int 2014;
86(2):433-44
16. Haase M, Mertens PR. Biomarkers: more
than just markers!. Nephrol Dial Transplant
2015;30(1):33-8
17. Yun SJ, Jeong P, Kim WT, et al. Cell-free
microRNAs in urine as diagnostic and
prognostic biomarkers of bladder cancer. Int
J Oncol 2012;41(5):1871-8
18. Mall C, Rocke DM, Durbin-Johnson B,
Weiss RH. Stability of miRNA in human
urine supports its biomarker potential.
Biomarkers Med 2013;7(4):623-31
19. Lv LL, Cao Y, Liu D, et al. Isolation and
quantification of microRNAs from urinary
Review Papadopoulos, Belliere, Bascands, Neau, Klein & Schanstra
doi: 10.1586/14737159.2015.1009449 Expert Rev. Mol. Diagn.
Ex
pe
rt 
Re
vi
ew
 o
f M
ol
ec
ul
ar
 D
ia
gn
os
tic
s D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
N
yu
 M
ed
ic
al
 C
en
te
r o
n 
02
/1
6/
15
Fo
r p
er
so
na
l u
se
 o
nl
y.
exosomes/microvesicles for biomarker
discovery. Int J Biol Sci 2013;9(10):1021-31
20. Fang DY, King HW, Li JY, Gleadle JM.
Exosomes and the kidney: blaming the
messenger. Nephrology (Carlton) 2013;
18(1):1-10
21. Mlcochova H, Hezova R, Stanik M,
Slaby O. Urine microRNAs as potential
noninvasive biomarkers in urologic cancers.
Urol Oncol 2014;32(1):41.e41-9
22. van Balkom BW, Pisitkun T, Verhaar MC,
Knepper MA. Exosomes and the kidney:
prospects for diagnosis and therapy of renal
diseases. Kidney Int 2011;80(11):1138-45
23. Beltrami C, Clayton A, Phillips AO, et al.
Analysis of urinary microRNAs in chronic
kidney disease. Biochem Soc Trans 2012;
40(4):875-9
24. Camussi G, Deregibus MC, Bruno S, et al.
Exosomes/microvesicles as a mechanism of
cell-to-cell communication. Kidney Int
2010;78(9):838-48
25. Ramachandran S, Palanisamy V. Horizontal
transfer of RNAs: exosomes as mediators of
intercellular communication. Wiley
Interdiscip Rev RNA 2012;3(2):286-93
26. Cheng L, Sharples RA, Scicluna BJ, Hill AF.
Exosomes provide a protective and enriched
source of miRNA for biomarker profiling
compared to intracellular and cell-free blood.
J Extracell Vesicles 2014;3:23743
27. Arroyo JD, Chevillet JR, Kroh EM, et al.
Argonaute2 complexes carry a population of
circulating microRNAs independent of
vesicles in human plasma. Proc Natl Acad
Sci USA 2011;108(12):5003-8
28. Wang K, Zhang S, Weber J, et al. Export
of microRNAs and microRNA-protective
protein by mammalian cells. Nucleic Acids
Res 2010;38(20):7248-59
29. Vickers KC, Palmisano BT, Shoucri BM,
et al. MicroRNAs are transported in plasma
and delivered to recipient cells by
high-density lipoproteins. Nat Cell Biol
2011;13(4):423-33
30. Turchinovich A, Weiz L, Langheinz A,
Burwinkel B. Characterization of
extracellular circulating microRNA. Nucleic
Acids Res 2011;39(16):7223-33
31. Aguilar AL, Piskol R, Beitzinger M, et al.
The small RNA expression profile of the
developing murine urinary and reproductive
systems. FEBS Lett 2010;584(21):4426-34
32. Ma L, Qu L. The function of microRNAs
in renal development and pathophysiology.
J Genet Genomics 2013;40(4):143-52
33. Agrawal R, Tran U, Wessely O. The
miR-30 miRNA family regulates Xenopus
pronephros development and targets the
transcription factor Xlim1/Lhx1.
Development 2009;136(23):3927-36
34. Wessely O, Agrawal R, Tran U.
MicroRNAs in kidney development: lessons
from the frog. RNA Biol 2010;7(3):296-9
35. Nagalakshmi VK, Ren Q, Pugh MM, et al.
Dicer regulates the development of
nephrogenic and ureteric compartments in
the mammalian kidney. Kidney Int 2011;
79(3):317-30
36. Wu J, Zheng C, Fan Y, et al.
Downregulation of microRNA-30 facilitates
podocyte injury and is prevented by
glucocorticoids. J Am Soc Nephrol 2014;
25(1):92-104
37. Krupa A, Jenkins R, Luo DD, et al. Loss of
MicroRNA-192 promotes fibrogenesis in
diabetic nephropathy. J Am Soc Nephrol
2010;21(3):438-47
38. Lu J, Kwan BC, Lai FM, et al. Glomerular
and tubulointerstitial miR-638,
miR-198 and miR-146a expression in lupus
nephritis. Nephrology (Carlton) 2012;17(4):
346-51
39. Ben-Dov IZ, Muthukumar T, Morozov P,
et al. MicroRNA sequence profiles of
human kidney allografts with or without
tubulointerstitial fibrosis. Transplantation
2012;94(11):1086-94
40. Levin A, Stevens PE. Summary of KDIGO
2012 CKD Guideline: behind the scenes,
need for guidance, and a framework for
moving forward. Kidney Int 2014;85(1):
49-61
41. Kottgen A, Glazer NL, Dehghan A, et al.
Multiple loci associated with indices of renal
function and chronic kidney disease. Nat
Genet 2009;41(6):712-17
42. Ecder T. Early diagnosis saves lives: focus
on patients with chronic kidney disease.
Kidney Int Suppl (2011) 2013;3(4):335-6
43. Lutz J, Menke J, Sollinger D, et al.
Haemostasis in chronic kidney disease.
Nephrol Dial Transplant 2014;29(1):29-40
44. Neal CS, Michael MZ, Pimlott LK, et al.
Circulating microRNA expression is reduced
in chronic kidney disease. Nephrol Dial
Transplant 2011;26(11):3794-802
45. Ma K, Pan X, Fan P, et al. Loss of
miR-638 in vitro promotes cell invasion and
a mesenchymal-like transition by influencing
SOX2 expression in colorectal carcinoma
cells. Mol Cancer 2014;13:118
46. Szeto CC, Ching-Ha KB, Ka-Bik L, et al.
Micro-RNA expression in the urinary
sediment of patients with chronic kidney
diseases. Dis Markers 2012;33(3):137-44
47. Wang H, Peng W, Ouyang X, Dai Y.
Reduced circulating miR-15b is correlated
with phosphate metabolism in patients with
end-stage renal disease on maintenance
hemodialysis. Ren Fail 2012;34(6):685-90
48. Patel V, Noureddine L. MicroRNAs and
fibrosis. Curr Opin Nephrol Hypertens
2012;21(4):410-16
49. Chau BN, Xin C, Hartner J, et al.
MicroRNA-21 promotes fibrosis of the
kidney by silencing metabolic pathways. Sci
Transl Med 2012;4(121):121ra118
50. Glowacki F, Savary G, Gnemmi V, et al.
Increased circulating miR-21 levels are
associated with kidney fibrosis. PLoS One
2013;8(2):e58014
51. Wang G, Kwan BC, Lai FM, et al. Urinary
miR-21, miR-29, and miR-93: novel
biomarkers of fibrosis. Am J Nephrol 2012;
36(5):412-18
52. Lv LL, Cao YH, Ni HF, et al.
MicroRNA-29c in urinary exosome/
microvesicle as a biomarker of renal fibrosis.
Am J Physiol Renal Physiol 2013;305(8):
F1220-7
53. Wang B, Koh P, Winbanks C, et al.
miR-200a Prevents renal fibrogenesis
through repression of TGF-beta2 expression.
Diabetes 2011;60(1):280-7
54. Oba S, Kumano S, Suzuki E, et al.
miR-200b precursor can ameliorate renal
tubulointerstitial fibrosis. PLoS One 2010;
5(10):e13614
55. Qin W, Chung AC, Huang XR, et al.
TGF-beta/Smad3 signaling promotes renal
fibrosis by inhibiting miR-29. J Am Soc
Nephrol 2011;22(8):1462-74
56. Tang O, Chen XM, Shen S, et al.
MiRNA-200b represses transforming growth
factor-beta1-induced EMT and fibronectin
expression in kidney proximal tubular cells.
Am J Physiol Renal Physiol 2013;304(10):
F1266-73
57. Fang Y, Yu X, Liu Y, et al. miR-29c is
downregulated in renal interstitial fibrosis in
humans and rats and restored by HIF-alpha
activation. Am J Physiol Renal Physiol
2013;304(10):F1274-82
58. Wang B, Komers R, Carew R, et al.
Suppression of microRNA-29 expression by
TGF-beta1 promotes collagen expression
and renal fibrosis. J Am Soc Nephrol 2012;
23(2):252-65
59. Gregory PA, Bert AG, Paterson EL, et al.
The miR-200 family and miR-205 regulate
epithelial to mesenchymal transition by
targeting ZEB1 and SIP1. Nat Cell Biol
2008;10(5):593-601
miRNAs in urine Review
informahealthcare.com doi: 10.1586/14737159.2015.1009449
Ex
pe
rt 
Re
vi
ew
 o
f M
ol
ec
ul
ar
 D
ia
gn
os
tic
s D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
N
yu
 M
ed
ic
al
 C
en
te
r o
n 
02
/1
6/
15
Fo
r p
er
so
na
l u
se
 o
nl
y.
60. Xiong M, Jiang L, Zhou Y, et al. The
miR-200 family regulates
TGF-beta1-induced renal tubular epithelial
to mesenchymal transition through Smad
pathway by targeting ZEB1 and
ZEB2 expression. Am J Physiol Renal
Physiol 2012;302(3):F369-79
61. Conserva F, Pontrelli P, Accetturo M,
Gesualdo L. The pathogenesis of diabetic
nephropathy: focus on microRNAs and
proteomics. J Nephrol 2013;26(5):811-20
62. Brosius FC 3rd. New insights into the
mechanisms of fibrosis and sclerosis in
diabetic nephropathy. Rev Endocr Metab
Disord 2008;9(4):245-54
63. Lan HY. Transforming growth factor-beta/
Smad signalling in diabetic nephropathy.
Clin Exp Pharmacol Physiol 2012;39(8):
731-8
64. Argyropoulos C, Wang K, McClarty S,
et al. Urinary microRNA profiling in the
nephropathy of type 1 diabetes. PLoS One
2013;8(1):e54662
65. Hou J, Shan Q, Wang T, et al. Transgenic
RNAi depletion of claudin-16 and the renal
handling of magnesium. J Biol Chem 2007;
282(23):17114-22
66. Shan SW, Lee DY, Deng Z, et al.
MicroRNA MiR-17 retards tissue growth
and represses fibronectin expression. Nat
Cell Biol 2009;11(8):1031-8
67. Miller CG, Pozzi A, Zent R,
Schwarzbauer JE. Effects of high glucose on
integrin activity and fibronectin matrix
assembly by mesangial cells. Mol Biol Cell
2014;25(16):2342-50
68. Padmashree DG, Swamy NR. Molecular
signaling cascade of miRNAs in causing
Diabetes Nephropathy. Bioinformation
2013;9(8):401-8
69. Barutta F, Tricarico M, Corbelli A, et al.
Urinary exosomal microRNAs in incipient
diabetic nephropathy. PLoS One 2013;
8(11):e73798
70. Rangrez AY, Massy ZA,
Metzinger-Le Meuth V, Metzinger L.
miR-143 and miR-145: molecular keys to
switch the phenotype of vascular smooth
muscle cells. Circ Cardiovasc Genet 2011;
4(2):197-205
71. Cordes KR, Sheehy NT, White MP, et al.
miR-145 and miR-143 regulate smooth
muscle cell fate and plasticity. Nature 2009;
460(7256):705-10
72. Ghosh G, Subramanian IV, Adhikari N,
et al. Hypoxia-induced
microRNA-424 expression in human
endothelial cells regulates HIF-alpha
isoforms and promotes angiogenesis. J Clin
Invest 2010;120(11):4141-54
73. Chamorro-Jorganes A, Araldi E, Penalva LO,
et al. MicroRNA-16 and
microRNA-424 regulate cell-autonomous
angiogenic functions in endothelial cells via
targeting vascular endothelial growth factor
receptor-2 and fibroblast growth factor
receptor-1. Arterioscler Thromb Vasc Biol
2011;31(11):2595-606
74. Martin MM, Lee EJ, Buckenberger JA,
et al. MicroRNA-155 regulates human
angiotensin II type 1 receptor expression in
fibroblasts. J Biol Chem 2006;281(27):
18277-84
75. Louafi F, Martinez-Nunez RT,
Sanchez-Elsner T. MicroRNA-155 targets
SMAD2 and modulates the response of
macrophages to transforming growth factor-
{beta}. J Biol Chem 2010;285(53):41328-36
76. Rai D, Kim SW, McKeller MR, et al.
Targeting of SMAD5 links
microRNA-155 to the TGF-beta pathway
and lymphomagenesis. Proc Natl Acad Sci
USA 2010;107(7):3111-16
77. Liu Y, Gao G, Yang C, et al. Stability of
miR-126 in Urine and Its Potential as a
Biomarker for Renal Endothelial Injury with
Diabetic Nephropathy. Int J Endocrinol
2014;2014:393109
78. Jiang S, Chuang PY, Liu ZH, He JC. The
primary glomerulonephritides: a systems
biology approach. Nat Rev Nephrol 2013;
9(9):500-12
79. Glassock RJ, Cohen AH. The primary
glomerulopathies. Disease-a-month : DM.
Mosby-Year Book; 1996;42(6):329-83
80. Szeto CC, Li PK. MicroRNAs in
IgA nephropathy. Nat Rev Nephrol 2014;
10(5):249-56
81. Wang G, Kwan BC, Lai FM, et al.
Expression of microRNAs in the urinary
sediment of patients with IgA nephropathy.
Dis Markers 2010;28(2):79-86
82. Wang G, Kwan BC, Lai FM, et al. Elevated
levels of miR-146a and miR-155 in kidney
biopsy and urine from patients with
IgA nephropathy. Dis Markers 2011;30(4):
171-9
83. Faraoni I, Antonetti FR, Cardone J,
Bonmassar E. miR-155 gene: a typical
multifunctional microRNA. Biochim
Biophys Acta 2009;1792(6):497-505
84. Qu Z, Li W, Fu B. MicroRNAs in
autoimmune diseases. BioMed Res Int
2014;2014:527895
85. Wang N, Zhou Y, Jiang L, et al. Urinary
microRNA-10a and microRNA-30d serve as
novel, sensitive and specific biomarkers for
kidney injury. PLoS One 2012;7(12):
e51140
86. Xue X, Feng T, Yao S, et al. Microbiota
downregulates dendritic cell expression of
miR-10a, which targets IL-12/IL-23p40. J
Immunol 2011;187(11):5879-86
87. Chu JY, Sims-Lucas S, Bushnell DS, et al.
Dicer function is required in the
metanephric mesenchyme for early kidney
development. Am J Physiol Renal Physiol
2014;306(7):F764-72
88. Li N, Kaur S, Greshock J, et al.
A combined array-based comparative
genomic hybridization and functional library
screening approach identifies mir-30d as an
oncomir in cancer. Cancer Res 2012;72(1):
154-64
89. Kumar M, Lu Z, Takwi AA, et al. Negative
regulation of the tumor suppressor p53 gene
by microRNAs. Oncogene 2011;30(7):
843-53
90. Ren H, Shen P, Li X, et al. Treatment and
prognosis of primary focal segmental
glomerulosclerosis. Contrib Nephrol
2013;181:109-18
91. Zhang W, Zhang C, Chen H, et al.
Evaluation of MicroRNAs miR-196a, miR-
30a-5P, and miR-490 as Biomarkers of
Disease Activity among Patients with FSGS.
Clin J Am Soc Nephrol 2014;9(9):1545-52
92. Sui W, Dai Y, Huang Y, et al. Microarray
analysis of MicroRNA expression in acute
rejection after renal transplantation. Transpl
Immunol 2008;19(1):81-5
93. Zununi S, Ardalan M. MicroRNA and
renal allograft monitoring. Nephrourol Mon
2013;5(3):783-6
94. Lorenzen JM, Volkmann I, Fiedler J, et al.
Urinary miR-210 as a mediator of acute
T-cell mediated rejection in renal allograft
recipients. Am J Transplant 2011;11(10):
2221-7
95. Fasanaro P, D’Alessandra Y, Di Stefano V,
et al. MicroRNA-210 modulates endothelial
cell response to hypoxia and inhibits the
receptor tyrosine kinase ligand Ephrin-A3. J
Biol Chem 2008;283(23):15878-83
96. Lorenzen JM, Kielstein JT, Hafer C, et al.
Circulating miR-210 predicts survival in
critically ill patients with acute kidney
injury. Clin J Am Soc Nephrol 2011;6(7):
1540-6
97. Scian MJ, Maluf DG, David KG, et al.
MicroRNA profiles in allograft tissues and
paired urines associate with chronic allograft
dysfunction with IF/TA. Am J Transplant
2011;11(10):2110-22
Review Papadopoulos, Belliere, Bascands, Neau, Klein & Schanstra
doi: 10.1586/14737159.2015.1009449 Expert Rev. Mol. Diagn.
Ex
pe
rt 
Re
vi
ew
 o
f M
ol
ec
ul
ar
 D
ia
gn
os
tic
s D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
N
yu
 M
ed
ic
al
 C
en
te
r o
n 
02
/1
6/
15
Fo
r p
er
so
na
l u
se
 o
nl
y.
98. Maluf DG, Dumur CI, Suh JL, et al. The
urine microRNA profile may help monitor
post-transplant renal graft function. Kidney
Int 2014;85(2):439-49
99. Malumbres R, Sarosiek KA, Cubedo E,
et al. Differentiation stage-specific
expression of microRNAs in B lymphocytes
and diffuse large B-cell lymphomas. Blood
2009;113(16):3754-64
100. Chaudhuri AA, So AY, Sinha N, et al.
MicroRNA-125b potentiates macrophage
activation. J Immunol 2011;187(10):5062-8
101. Medrano S, Monteagudo MC,
Sequeira-Lopez ML, et al. Two microRNAs,
miR-330 and miR-125b-5p, mark the
juxtaglomerular cell and balance its smooth
muscle phenotype. Am J Physiol Renal
Physiol 2012;302(1):F29-37
102. Primo MN, Bak RO, Schibler B,
Mikkelsen JG. Regulation of
pro-inflammatory cytokines TNFalpha and
IL24 by microRNA-203 in primary
keratinocytes. Cytokine 2012;60(3):741-8
103. Sonda N, Simonato F, Peranzoni E, et al.
miR-142-3p prevents macrophage
differentiation during cancer-induced
myelopoiesis. Immunity 2013;38(6):
1236-49
104. Huang B, Zhao J, Lei Z, et al. miR-142-3p
restricts cAMP production in CD4+CD25-
T cells and CD4+CD25+ TREG cells by
targeting AC9 mRNA. EMBO Rep 2009;
10(2):180-5
105. Cheng AM, Byrom MW, Shelton J,
Ford LP. Antisense inhibition of human
miRNAs and indications for an involvement
of miRNA in cell growth and apoptosis.
Nucleic Acids Res 2005;33(4):1290-7
106. Harvey SJ, Jarad G, Cunningham J, et al.
Podocyte-specific deletion of dicer alters
cytoskeletal dynamics and causes glomerular
disease. J Am Soc Nephrol 2008;19(11):
2150-8
107. Rewa O, Bagshaw SM. Acute kidney
injury-epidemiology, outcomes and
economics. Nat Rev Nephrol 2014;10(4):
193-207
108. Saikumar J, Hoffmann D, Kim TM, et al.
Expression, circulation, and excretion profile
of microRNA-21, -155, and -18a following
acute kidney injury. Toxicol Sci 2012;
129(2):256-67
109. Ramachandran K, Saikumar J, Bijol V,
et al. Human miRNome profiling identifies
microRNAs differentially present in the
urine after kidney injury. Clin Chem 2013;
59(12):1742-52
110. Li YF, Jing Y, Hao J, et al.
MicroRNA-21 in the pathogenesis of acute
kidney injury. Protein Cell 2013;4(11):
813-19
111. Lindsay MA. microRNAs and the immune
response. Trends Immunol 2008;29(7):
343-51
112. Godwin JG, Ge X, Stephan K, et al.
Identification of a microRNA signature of
renal ischemia reperfusion injury. Proc Natl
Acad Sci USA 2010;107(32):14339-44
113. Lan YF, Chen HH, Lai PF, et al.
MicroRNA-494 reduces ATF3 expression
and promotes AKI. J Am Soc Nephrol
2012;23(12):2012-23
114. Li Y, Fang X, Li QZ. Biomarker profiling
for lupus nephritis. Genomics Proteomics
Bioinformatics 2013;11(3):158-65
115. Altorok N, Sawalha AH. Epigenetics in the
pathogenesis of systemic lupus
erythematosus. Curr Opin Rheumatol 2013;
25(5):569-76
116. Stagakis E, Bertsias G, Verginis P, et al.
Identification of novel microRNA signatures
linked to human lupus disease activity and
pathogenesis: miR-21 regulates aberrant T
cell responses through regulation of
PDCD4 expression. Ann Rheum Dis 2011;
70(8):1496-506
117. Dai Y, Huang YS, Tang M, et al.
Microarray analysis of microRNA expression
in peripheral blood cells of systemic lupus
erythematosus patients. Lupus 2007;16(12):
939-46
118. Dai Y, Sui W, Lan H, et al. Comprehensive
analysis of microRNA expression patterns in
renal biopsies of lupus nephritis patients.
Rheumatol Int 2009;29(7):749-54
119. Wang G, Tam LS, Li EK, et al. Serum and
urinary cell-free MiR-146a and MiR-155 in
patients with systemic lupus erythematosus.
J Rheumatol 2010;37(12):2516-22
120. Wang G, Tam LS, Kwan BC, et al.
Expression of miR-146a and miR-155 in
the urinary sediment of systemic lupus
erythematosus. Clin Rheumatol 2012;31(3):
435-40
121. Williams AE, Perry MM, Moschos SA,
et al. Role of miRNA-146a in the
regulation of the innate immune response
and cancer. Biochem Soc Trans 2008;
36(Pt 6):1211-15
122. Pedersen I, David M. MicroRNAs in the
immune response. Cytokine 2008;43(3):
391-4
123. Tang Y, Luo X, Cui H, et al.
MicroRNA-146A contributes to abnormal
activation of the type I interferon pathway
in human lupus by targeting the key
signaling proteins. Arthritis Rheum 2009;
60(4):1065-75
124. Xiao C, Rajewsky K. MicroRNA control in
the immune system: basic principles. Cell
2009;136(1):26-36
125. Borchers AT, Leibushor N, Naguwa SM,
et al. Lupus nephritis: a critical review.
Autoimmun Rev 2012;12(2):174-94
126. Tan YC, Blumenfeld J, Rennert H.
Autosomal dominant polycystic kidney
disease: genetics, mutations and
microRNAs. Biochim Biophys Acta 2011;
1812(10):1202-12
127. Norman J. Fibrosis and progression of
autosomal dominant polycystic kidney
disease (ADPKD). Biochim Biophys Acta
2011;1812(10):1327-36
128. Schieren G, Rumberger B, Klein M, et al.
Gene profiling of polycystic kidneys.
Nephrol Dial Transplant 2006;21(7):
1816-24
129. Ben-Dov IZ, Tan YC, Morozov P, et al.
Urine microRNA as potential biomarkers of
autosomal dominant polycystic kidney
disease progression: description of
miRNA profiles at baseline. PLoS One
2014;9(1):e86856
130. Kawakami K, Enokida H, Chiyomaru T,
et al. The functional significance of
miR-1 and miR-133a in renal cell
carcinoma. Eur J Cancer 2012;48(6):827-36
131. Karihaloo A, Koraishy F, Huen SC, et al.
Macrophages promote cyst growth in
polycystic kidney disease. J Am Soc Nephrol
2011;22(10):1809-14
132. Swenson-Fields KI, Vivian CJ, Salah SM,
et al. Macrophages promote polycystic
kidney disease progression. Kidney Int
2013;83(5):855-64
133. Ta MH, Harris DC, Rangan GK. Role of
interstitial inflammation in the pathogenesis
of polycystic kidney disease. Nephrology
(Carlton) 2013;18(5):317-30
134. Lechuga S, Baranwal S, Li C, et al. Loss of
gamma-cytoplasmic actin triggers
myofibroblast transition of human epithelial
cells. Mol Biol Cell 2014;25(20):3133-46
135. Available from: www.qiagen.com/ingenuity
136. Shen B, Liu X, Fan Y, Qiu J. Macrophages
regulate renal fibrosis through modulating
TGFbeta superfamily signaling.
Inflammation 2014;37(6):2076-84
137. Di J, Jiang L, Zhou Y, et al. Ets-1 targeted
by microRNA-221 regulates angiotensin
II-induced renal fibroblast activation and
fibrosis. Cell Physiol Biochem 2014;34(4):
1063-74
miRNAs in urine Review
informahealthcare.com doi: 10.1586/14737159.2015.1009449
Ex
pe
rt 
Re
vi
ew
 o
f M
ol
ec
ul
ar
 D
ia
gn
os
tic
s D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
N
yu
 M
ed
ic
al
 C
en
te
r o
n 
02
/1
6/
15
Fo
r p
er
so
na
l u
se
 o
nl
y.
138. Correa-Costa M, Braga TT, Felizardo RJ,
et al. Macrophage trafficking as key
mediator of adenine-induced kidney injury.
Mediators Inflamm 2014;2014:291024
139. Akao Y, Iio A, Itoh T, et al.
Microvesicle-mediated RNA molecule
delivery system using monocytes/
macrophages. Mol Ther 2011;19(2):395-9
140. Wang JY, Gao YB, Zhang N, et al.
miR-21 overexpression enhances
TGF-beta1-induced epithelial-to-
mesenchymal transition by target smad7 and
aggravates renal damage in diabetic
nephropathy. Mol Cell Endocrinol 2014;
392(1-2):163-72
141. Du R, Xia L, Ning X, et al.
Hypoxia-induced Bmi1 promotes renal
tubular epithelial cell-mesenchymal
transition and renal fibrosis via PI3K/Akt
signal. Mol Biol Cell 2014;25(17):2650-9
142. Chawla LS, Kimmel PL. Acute kidney
injury and chronic kidney disease:
an integrated clinical syndrome. Kidney Int
2012;82(5):516-24
143. Billeter AT, Hellmann J, Roberts H, et al.
MicroRNA-155 potentiates the
inflammatory response in hypothermia by
suppressing IL-10 production. FASEB J
2014;28(12):5322-36
144. Santra M, Zhang ZG, Yang J, et al.
Thymosin beta4 up-regulation of
microRNA-146a promotes oligodendrocyte
differentiation and suppression of the
Toll-like proinflammatory pathway. J Biol
Chem 2014;289(28):19508-18
145. Lyn-Cook BD, Xie C, Oates J, et al.
Increased expression of Toll-like receptors
(TLRs) 7 and 9 and other cytokines in
systemic lupus erythematosus (SLE)
patients: ethnic differences and potential
new targets for therapeutic drugs. Mol
Immunol 2014;61(1):38-43
146. Ichii O, Otsuka S, Sasaki N, et al. Altered
expression of microRNA miR-146a
correlates with the development of chronic
renal inflammation. Kidney Int 2012;81(3):
280-92
147. Salama A, Fichou N, Allard M, et al.
MicroRNA-29b modulates innate and
antigen-specific immune responses in mouse
models of autoimmunity. PLoS One 2014;
9(9):e106153
148. Gomez-Guerrero C, Lopez-Franco O,
Sanjuan G, et al. Suppressors of cytokine
signaling regulate Fc receptor signaling and
cell activation during immune renal injury.
J Immunol 2004;172(11):6969-77
149. Kim MK, Maeng YI, Sung WJ, et al. The
differential expression of TGF-beta1, ILK
and wnt signaling inducing epithelial to
mesenchymal transition in human renal
fibrogenesis: an immunohistochemical study.
Int J Clin Exp Pathol 2013;6(9):1747-58
150. Jiang BH, Liu LZ. PI3K/PTEN signaling in
angiogenesis and tumorigenesis. Adv Cancer
Res 2009;102:19-65
151. Kato M, Putta S, Wang M, et al. TGF-beta
activates Akt kinase through a
microRNA-dependent amplifying circuit
targeting PTEN. Nat Cell Biol 2009;11(7):
881-9
152. Friedlander MR, Lizano E, Houben AJ,
et al. Evidence for the biogenesis of more
than 1,000 novel human microRNAs.
Genome Biol 2014;15(4):R57
153. Calin GA, Croce CM.
MicroRNA signatures in human cancers.
Nat Rev Cancer 2006;6(11):857-66
154. Danborg PB, Simonsen AH, Waldemar G,
Heegaard NH. The potential of microRNAs
as biofluid markers of neurodegenerative
diseases - a systematic review. Biomarkers
2014;19(4):259-68
155. Menghini R, Stohr R, Federici M.
MicroRNAs in vascular aging and
atherosclerosis. Ageing Res Rev 2014;17:
68-78
156. Pogue AI, Hill JM, Lukiw WJ.
MicroRNA (miRNA); sequence and
stability, viroid-like properties, and disease
association in the CNS. Brain Res
2014;1584:73-9
157. Filip S, Pontillo C, Peter Schanstra J, et al.
Urinary proteomics and molecular
determinants of chronic kidney disease:
possible link to proteases. Expert Rev
Proteomics 2014;11(5):535-48
158. Li Z, Hassan MQ, Jafferji M, et al.
Biological functions of miR-29b contribute
to positive regulation of osteoblast
differentiation. J Biol Chem 2009;284(23):
15676-84
159. Zhao J, Tang N, Wu K, et al.
MiR-21 simultaneously regulates
ERK1 signaling in HSC activation and
hepatocyte EMT in hepatic fibrosis. PLoS
One 2014;9(10):e108005
160. Amara S, Lopez K, Banan B, et al.
Synergistic effect of pro-inflammatory
TNFalpha and IL-17 in periostin mediated
collagen deposition: potential role in liver
fibrosis. Mol Immunol 2015;64(1):26-35
161. Raamsteeboers AJ, Bogaard HJ,
Vonk Noordegraaf A. Pulmonary arterial
hypertension preceding idiopathic
pulmonary fibrosis in a BMPR2 mutation
positive patient. Eur Respir Rev 2014;
23(131):147-9
162. Gao X, Cao Y, Staloch DA, et al. Bone
morphogenetic protein signaling protects
against cerulein-induced pancreatic fibrosis.
PLoS One 2014;9(2):e89114
163. Konta T, Ichikawa K, Suzuki K, et al.
A microarray analysis of urinary microRNAs
in renal diseases. Clin Exp Nephrol 2014;
18(5):711-17
164. Mischak H, Allmaier G, Apweiler R, et al.
Recommendations for biomarker
identification and qualification in clinical
proteomics. Sci Transl Med 2010;2(46):
46ps42
Review Papadopoulos, Belliere, Bascands, Neau, Klein & Schanstra
doi: 10.1586/14737159.2015.1009449 Expert Rev. Mol. Diagn.
Ex
pe
rt 
Re
vi
ew
 o
f M
ol
ec
ul
ar
 D
ia
gn
os
tic
s D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
N
yu
 M
ed
ic
al
 C
en
te
r o
n 
02
/1
6/
15
Fo
r p
er
so
na
l u
se
 o
nl
y.
